Hormone and transcription factor regulation of cytokines in the mammary gland by Atashgaran, Vahid
 
 
HORMONE AND TRANSCRIPTION FACTOR REGULATION 











DISCIPLINE OF SURGERY 
SCHOOL OF MEDICINE 
FACULTY OF HEALTH SCIENCES 
THE UNIVERSITY OF ADELAIDE 
 
15TH OCTOBER 2018 
 
A thesis submitted to the University of Adelaide in fulfilment of the requirements for 




ASSOCIATE PROFESSOR WENDY INGMAN 
DR PALLAVE DASARI 
ASSOCIATE PROFESSOR SIMON BARRY 
 
TABLE OF CONTENTS 
 
. 
ABSTRACT …………………………………………………………………..……. i 
DECLARATION.……………………………………………………………..…... iii 
ACKNOWLEDGEMENTS…………………………………………………..……iv 




LITERATURE REVIEW  
1.1. INTRODUCTION ………………………………………………………. 1 
1.2. OVERVIEW OF MAMMARY GLAND DEVELOPMENT ………… 1 
1.3. MAMMARY GLAND DEVELOPMENT …………………………….. 5 
1.4. THE MENSTRUAL CYCLE AND MAMMARY GLAND………….. 7 
1.4.1. The Menstrual Cycle ....................................................................................... 7 
1.4.2. Changes in Mammary Epithelial Cells during the Menstrual Cycle ......... ...10 
1.5. THE IMMUNE MICROENVIRONMENT IN THE MAMMARY GLAND
 ...................................................................................................................13 
1.5.1. Macrophages ................................................................................................ 13 
1.5.2. T lymphocytes ............................................................................................... 15 
1.5.3. Regulatory T cells (Tregs) ............................................................................ 16 
1.5.4. Mast cells and Eosinophils ........................................................................... 17 
1.6. KEY TRANSCRIPTIONAL REGULATORS OF MAMMARY GLAND 
DEVELOPMENT AND FUNCTION.........................................................18 
1.6.1. Role of ELF5 in Mammary Gland Development and Breast Cancer ........... 19 
1.6.2. Role of FoxP3 in Mammary Gland Development ......................................... 21 
 
1.7. CYTOKINE NETWORKS IN MAMMARY GLAND IMMUNE 
MICROENVIRONMENT .........................................................................23 
1.8. CONCLUSION ...................................................................................25 
1.9. HYPOTHESIS AND AIMS ................................................................26 
1.10. RESEARCH PLAN ...........................................................................26 
 
CHAPTER TWO 
MATERIALS AND METHODS 
2.1. HUMAN BREAST TISSUE COLLECTION: .....................................29 
2.2. PROCESSING OF BREAST TISSUE FOR HISTOLOGY, EPITHELIAL 
ORGANOIDS AND EXPLANTS...............................................................29 
2.2.1. Isolation of Human Mammary Epithelial Organoids ................................... 29 
2.2.2. Dissection and Culture of Breast Tissue into Explants ................................ 30 
2.3. CELL CULTURE ...............................................................................32 
2.3.1. Culture of Human Mammary Epithelial Organoids in Matrigel .................. 32 
2.3.2. Human Mammary Epithelial Cell lines ........................................................ 32 
2.4. CRYOPRESERVATION AND THAWING ........................................33 
2.5. HORMONE TREATMENTS IN CELL AND TISSUE CULTURES ..33 
2.6. BUFFERS AND SOLUTIONS ............................................................34 
2.6.1. siRNA Solutions ............................................................................................ 34 
2.6.2. Phosphate Buffered Saline ............................................................................ 34 
2.7. TRANSFECTION OF HUMAN MAMMARY EPITHELIAL CELLS35 
2.7.1. ELF5 siRNA Transfection of Cell Lines ....................................................... 35 
2.7.2. Production of Lentiviral Vectors .................................................................. 35 
2.7.3. Lentiviral Transduction of Mammary Epithelial Organoids ........................ 38 
2.8. HISTOLOGY AND IMMUNOHISTOCHEMISTRY .........................38 
2.8.1. Tissue Embedding and Sectioning ................................................................ 38 
 
2.8.2. Haematoxylin and Eosin Staining ................................................................. 38 
2.8.3. S100A8 Immunostaining on Human Breast Explants ................................... 39 
2.9. PROTEIN ANALYSIS .......................................................................40 
2.9.1. Western Blot .................................................................................................. 40 
2.10. ANIMALS AND SURGERIES .........................................................40 
2.10.1. Mice ............................................................................................................ 40 
2.10.2. Blood Collection ......................................................................................... 41 
2.10.3. Estrous Cycle Tracking ............................................................................... 42 
2.10.4. Mammary Gland Whole-Mount Preparation ............................................. 44 
2.10.5. Ductal Branching Analysis ......................................................................... 44 
2.11. NUCLEOTIDE ANALYSIS ..............................................................45 
2.11.1. DNA Extraction ........................................................................................... 45 
2.11.2. Genotyping Mice ......................................................................................... 45 
2.11.3. Total RNA Extraction.................................................................................. 49 
2.11.4. Complementary DNA (cDNA) Synthesis ..................................................... 50 
2.11.5. Quantitative Real Time-PCR ...................................................................... 50 
2.12. STATISTICAL ANALYSIS: ............................................................52 
 
CHAPTER THREE 
HORMONAL REGULATION OF MAMMARY EPITHELIAL CELLS 
3.1. INTRODUCTION ..............................................................................53 
3.2. RESULTS ...........................................................................................56 
3.2.1. Messenger RNA Expression of Cytokines in the Hormone-Treated Mammary 
Epithelial Cell Organoids ....................................................................................... 56 
3.2.2. Messenger RNA Expression of Genes in the Hormone-Treated Mammary 
Epithelial Cell Lines ............................................................................................... 58 
3.2.3. Gene Regulations in Mice Mammary Gland during the Estrous Cycle ....... 69 
 
3.3. DISCUSSION .....................................................................................73 
3.3.1. Hormonal Regulation of TGFB1 Expression in the Mammary Gland ......... 73 
3.3.2. Signal Transducer and Activator of Transcription (STAT 3 and STAT5): ... 75 
3.3.3. Hormone Regulation of Pro-Inflammatory Cytokines in the Mammary Gland: 
  ................................................................................................................ 77 
3.3.4. Limitations: ................................................................................................... 78 
3.4. CONCLUSION ...................................................................................79 
 
CHAPTER FOUR 
THE ROLE OF ELF5 IN HORMONE REGULATED CYTOKINE EXPRESSION 
4.1. INTRODUCTION ..............................................................................81 
4.2. RESULTS ...........................................................................................84 
4.2.1. Messenger RNA Expression of Cytokines in Hormone-Treated Organoids: 84 
4.2.2. Messenger RNA Expression of Cytokines in Human Mammary Epithelial Cancer 
Cell lines: ................................................................................................................ 86 
4.2.3. Messenger RNA Expression of Cytokines in the Mouse Mammary Gland during 
the Estrous Cycle .................................................................................................... 96 
4.2.4. The Effect of Progesterone on Cytokine Expression in T47D cells .............. 98 
4.2.5. siRNA Transfection of T47D Cell Line ....................................................... 100 
4.2.6. Protein Expression of S100A8 in Hormone-Treated Human Breast Explants .  
  .............................................................................................................. 103 
4.3. DISCUSSION ................................................................................... 105 
4.3.1. Hormone Regulation of ELF5 And Its Downstream Cytokines .................. 105 
4.3.2. The Role of ELF5 in Hormone-Regulated Cytokine Expression ................ 107 




THE ROLE OF FOXP3 IN MAMMARY GLAND DEVELOPMENT 
5.1. INTRODUCTION ............................................................................ 111 
5.2. RESULTS ......................................................................................... 114 
5.2.1. The Effects of FoxP3 Heterozygosity on Mammary Gland Morphogenesis at 
Puberty  .............................................................................................................. 114 
5.2.2. The Effect of FoxP3 Heterozygosity on Estrous Cycling ............................ 118 
5.2.3. The Effects of FoxP3 Heterozygosity on Mammary Gland Morphogenesis during 
the Ovarian Cycle ................................................................................................. 120 
5.2.4. Messenger RNA expression of FoxP3 in the Mammary Gland during the Estrous 
Cycle  .............................................................................................................. 122 
5.2.5. Messenger RNA Expression of Cytokines in Hormone-Treated Human Mammary 
Epithelial Organoids ............................................................................................. 124 
5.2.6. Messenger RNA Expression of Cytokines in Human Mammary Epithelial Cancer 
Cell Lines .............................................................................................................. 125 
5.2.7. FoxP3 Overexpression in Human Mammary Epithelial Organoids .......... 130 
5.3. DISCUSSION ................................................................................... 133 
5.3.1. FoxP3 Heterozygosity Does Not Affect Mammary Gland Development in Mice 
  .............................................................................................................. 133 
5.3.2. Hormone Regulation of FoxP3 in Mammary Epithelial Cells and its Effect on Zeb1
  .............................................................................................................. 135 
5.3.3. FoxP3 Overexpression in Human Mammary Epithelial Organoids: ......... 136 
5.4. CONCLUSION ………………………………………………………… 139 
 
CHAPTER SIX 
GENERAL DISCUSSION  
6.1. INTRODUCTION …………………………………………………….. 140 
 
6.2. CURRENT KNOWLEDGE ON THE CELLULAR AND MOLECULAR 
CHANGES IN THE BREAST DURING THE MENSTRUAL CYCLE ..141 
6.3. HORMONAL REGULATION OF IMMUNE-RELATED CYTOKINES IN 
THE MAMMARY GLAND ……………………………………………….. 144 
6.4. LIMITATIONS OF THIS STUDY ………………………………….. 147 
6.5. FUTURE RESEARCH DIRECTIONS ……………………………… 149 










Increased number of menstrual cycles is associated with an increased lifetime risk for breast 
cancer, however the biological basis for this increased risk is not well understood. Previous 
research in mouse models suggest the immune microenvironment is critically regulated by 
fluctuations in circulating estrogen and progesterone across the menstrual cycle, which may 
affect breast cancer susceptibility. The work in this thesis aims to investigate hormonal 
regulation of transcription factors and cytokines that affect cells of the immune system in the 
mammary gland, using an array of approaches including primary human mammary epithelial 
organoid structures (n=6), human mammary epithelial cell lines (MCF7, T47D and ZR751), 
and mouse mammary gland tissues.  
 
Firstly, primary mammary epithelial organoid cultures were treated with combinations of 17-
beta estradiol and progesterone for 72 hours, and the abundance of messenger RNA encoding 
cytokines transforming growth factor beta 1 (TGFB1), tumour necrosis factor alpha (TNFA), 
signal transducer and activator of transcription 3 (STAT3), STAT5, interleukin-12 (IL12), E74-
like factor 5 (ELF5), C-X-C motif chemokine ligand 12 (CXCL12), S100 calcium binding 
protein A8 (S100A8), S100A9, Forkhead box P3 (FOXP3), and Zinc Finger E-Box Binding 
Homeobox 1 (ZEB1) were analysed using real-time PCR. Moreover, lentiviral vectors were 
used to investigate the effects of FOXP3 overexpression on downstream cytokines in the human 
mammary epithelial organoids. In the second approach, human mammary epithelial cell lines 
were treated with combinations of 17-beta estradiol and progesterone at different time courses 
and the abundance of mRNA encoding the cytokines of interest was analysed using real-time 
PCR. Further, the expression of ELF5, a mammary epithelial morphogenesis transcription 
factor, was transiently silenced by small interfering RNA oligos in T47D mammary epithelial 
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cell lines to investigate the role of ELF5 in progesterone-mediated cytokine expression. Lastly, 
to investigate the effects of Foxp3 heterozygosity on mammary ductal morphogenesis, C57BL6 
wildtype and Foxp3 heterozygous female mice were tracked over a period of 28 days by 
histological analysis of vaginal smears. The 4th pair of the mammary glands from each mouse 
was collected at each of the four stages of the cycle for cytokine expression studies and whole-
mount analysis.  
 
In primary organoid cultures, there was high variability in cytokine expression between 
patients; the only consistent result was that combined estradiol and progesterone treatment 
significantly attenuated TGFB1 mRNA expression (p<0.05). Also, overexpression of FOXP3 
in these cells resulted in an insignificant increase in the mRNA expression of ZEB1. Hormone 
treatments of cell lines at different time courses resulted in different expression of mRNA 
encoding the cytokines of interest. However, silencing of the ELF5 gene in T47D cells resulted 
in induced mRNA expression of S100A9 and CXCL12 by 50% compared to non-silenced cells 
(p<0.05). Finally, analysis of whole-mount images revealed that mammary ductal 
morphogenesis in Foxp3 heterozygous mice was similar to that of wildtype mice.  
 
These results suggest that estrogen and progesterone variably regulate the cytokine synthesis 
by mammary epithelial cells, depending on the hormone receptor profile of the cells. In this 
case, ELF5 transcription factor might moderate the effects of progesterone on pro-inflammatory 
cytokines. Moreover, it seems that Foxp3 heterozygosity does not have any significant effect 
on mammary glands morphogenesis in mice.  
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1.1.   INTRODUCTION 
Breast cancer is a complex disease characterized by abnormal growth of cells, leading to 
invasion into the surrounding tissue, metastasis to distant sites in the body and, at times, death. 
It is the most common cancer diagnosed in females; in Australia, 1 in 8 women will be 
diagnosed with breast cancer before the age of 85 (1). A number of risk factors are associated 
with breast cancer, including family history of breast cancer, increasing age, high breast density, 
and increased number of years of menstrual cycling (1-3). In the past, breast cancer was known 
as “The Nun’s Disease” because Catholic nuns had more prevalence and higher death rates 
from it compared to ordinary women (4). This observation was initially linked to the marital 
status and the presence or absence of sexual and reproductive factors. However, significant 
number of epidemiological studies have found strong correlations between cumulative number 
of menstrual cycles and the development of breast cancer in women (1, 5, 6). For example, for 
each year younger a girl commences menstrual cycling, there is a 5% increase in lifetime risk 
of breast cancer. Similarly, for each year older at the time of menopause, there is a 3.5% 
increased breast cancer risk (6). This indicates that fluctuations in ovarian hormones associated 
with menstrual cycling affect breast cancer susceptibility. However, the biological basis for this 
increased risk is not well understood.
 
1.2.   OVERVIEW OF MAMMARY GLAND DEVELOPMENT 
The mammary glands are bilateral organs present in females of all mammalian species which 
produce milk essential for the nourishment of infants. It is a unique organ, in which the vast 
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majority of mammary gland development occurs postnatally, during puberty, pregnancy, and 
the postpartum period. This development is regulated through complex interactions between 
hormones, growth factors, and cytokines. 
 
The mammary gland is composed of a number of different cell types that together form complex 
interactive networks required for the normal development and function of the tissue (7). 
Morphologically, there are numerous lobules connected to the nipple through a series of 
branched ducts (2) (Figure 1.1). The lobules contain epithelial structures surrounded by 
mammary stroma that provide physical support for the overall architecture of the ductal 
epithelium. At the histological level, the epithelial structures are comprised of two types of 
mammary epithelial cells: myoepithelial cells found as a thin layer above the basement 
membrane, and luminal epithelial cells that produce milk during lactation. These different types 
of mammary epithelial cells are organised together to form the ductal structures of the 
mammary gland. It is important to note that the majority of breast carcinomas originate from 
mammary epithelial cells (8). The stroma of the mammary gland supports epithelial cell 
morphogenesis and function and is comprised of an extracellular matrix containing an 
abundance of collagen fibres, as well as fibroblasts, endothelial cells, macrophages, T 
lymphocytes and other immune cells (7) (Figure 1.2). 
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Figure 1.1: Diagrammatic representation of the main architectural parts of normal mammary gland 
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Figure 1.2: Schematic of normal mammary duct and lobule supported by their stroma (7). 
Myoepithelial cells in the duct are located as a complete layer around the luminal epithelial cells, 
whereas they form a more fenestrated layer in the alveoli. The yellow arrows represent potential 
interactions between the different cell types and/or their surrounding matrix, important to support 
mammary gland morphogenesis. 
  
 
Figure 1: Schematic of normal mammary duct and lobule supported by their stroma. 
it li l cells in the duct are located as a complete layer around the luminal pithelial 
cells, whereas they form a more fenestrated layer in the alveoli. The yellow arrows represent 
potenti l interacti ns between the different cell types and/or their surrounding matrix, important 
to support mammary gland morphogenesis (6) 
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1.3.   MAMMARY GLAND DEVELOPMENT  
At birth, the structure of the mammary gland is a simple rudimentary epithelial duct present in 
both female and male infants. With the onset of puberty, the surge of estrogen in females drives 
the primary epithelial ducts to proliferate and develop into club-shaped structures known as 
terminal end buds (TEBs) (2). Further proliferation of these structures gives rise to smaller 
projections called alveolar buds that form bundles eventually becoming organized into a sphere-
like structure termed a lobule. This process of pubertal development occurs slowly, with lobules 
developed over the course of two or more years.  
 
During adulthood, the lobules can further differentiate into four types; type I and II lobules are 
branching primary and secondary ducts with minimal alveolar budding, type III lobules have 
greater abundance of alveolar buds sprouted into tertiary structures, and type IV lobules which 
form during pregnancy, and have the highest intensity of budding and lobule formation. By the 
end of pregnancy, the breast tissue is considered fully developed, enabling commencement of 
lactation. Upon weaning of the infant, the mammary epithelial cells undergo programmed cell 
death (i.e. apoptosis) causing the mammary gland to remodel back to its basic architecture 
(Figure 1.3) (2, 10). 
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Figure 1.3: Schematic representation of mammary gland development during different stages (11). 
The structure of mammary gland is a simple rudimentary epithelial duct observed at birth, which 
proliferates and undergoes dramatic morphological changes during different stages of life. 
  
 
Figure 1: Schematic representation of mamm ry gland development during different 
stages (12). 
The structure of mam ary gland is a simple rudimentary epithelial duct observed at birth, 
which proliferates and undergoes dramatic morphological changes during different stages of 
life.  
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1.4.   THE MENSTRUAL CYCLE AND MAMMARY GLAND 
While there has been much interest in the cellular and molecular interactions directing 
mammary gland development during pregnancy, surprisingly little is understood of the 
biological mechanisms that promote development during the menstrual cycle. Although the 
developmental changes that occur during the menstrual cycle are less dramatic than those 
during pregnancy, understanding the mechanisms that regulate these developmental processes 
will shed light on the increased breast cancer risk associated with increased number of years of 
menstrual cycling. It is suggested that ovarian hormone-regulated proliferation of mammary 
epithelial cells with each successive menstrual cycle causes increased likelihood of progressive 
somatic mutations occurring in the cell-lineage, leading to increased risk of breast cancer (12, 
13). However, what is less extensively investigated is the possible hormone-dependent role of 
cell-to-cell interactions between epithelium and the surrounding stroma in affecting DNA 
mutation rate and the DNA damage response. Therefore, understanding the cellular interactions 
that regulate mammary epithelial morphogenesis during the menstrual cycle may reveal new 
strategic directions to treat or prevent breast cancer. 
 
1.4.1.   THE MENSTRUAL CYCLE 
Hormonal fluctuations over the course of the menstrual cycle in women are necessary to prepare 
the mammary gland for pregnancy and lactation. The duration of the menstrual cycle is 28 – 32 
days (14) and can be categorized into three main phases: 
1- The Follicular Phase: Immature oocytes in the ovaries, each within a sac-like structure called 
a follicle, grow as a result of hormonal secretions from the pituitary gland. One of these follicles 
become dominant and continues to mature. 
2- The Ovulatory Phase: The fully developed dominant follicle releases its mature oocyte into 
the fallopian tube. 
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3- The Luteal Phase: Following ovulation of the mature oocyte, inhibitory factors present in the 
follicle dissipate, and the remnant follicle differentiates into a structure known as the corpus 
luteum. This structure produces and secretes progesterone in preparation for implantation (15). 
If pregnancy does not proceed, the corpus luteum begins to break down, and declining 
progesterone secretion initiates menstruation and the next follicular phase. 
 
The phases of the menstrual cycle are driven by interactions between the pituitary gland 
hormones, follicle-stimulating hormone and luteinizing hormone, and the ovarian hormones, 
estrogen and progesterone. During the follicular phase, follicle-stimulating hormone stimulates 
follicle development and oocyte maturation. When the oocyte is nearly matured, the high 
concentration of circulating estrogen produced by the dominant follicle stimulates the pituitary 
to produce luteinizing hormone. This weakens the wall of the mature follicle and causes it to 
release the mature oocyte into the fallopian tubes (15). 
 
Clinical studies on premenopausal women indicate that the concentration of circulating 
estrogen increases during the follicular phase and is reduced during the luteal phase until 
menstruation, where the lowest serum level of estrogen is observed (16, 17). During the 
follicular phase, circulating progesterone concentration is low, and begin to rise following 
ovulation. In the luteal phase, the corpus luteum secretes progesterone and the circulating 
concentration of progesterone continues to rise, peaking in the mid-luteal phase. If implantation 
does not occur, progesterone decreases gradually towards the end of the luteal phase. 
Circulating concentration of estrogen and progesterone are at a minimum during menstruation 
(16, 18). Figure 1.4 illustrates the hormonal changes during different stages of the menstrual 
cycle and categorizes the events occurring in the breast, ovaries, and uterus. 
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Figure 1.4: Serum hormone fluctuations during a typical menstrual cycle along with changes in the 
breast and uterus (16). 
Fluctuations in the ovarian hormones, estrogen and progesterone across the menstrual cycle are 
associated with morphological changes in the breast tissue. Note that, the proliferative phase on the 
uterine cycle is considered as the time the endometrium builds up before ovulation. However, in the 
breast, cell proliferation occurs post ovulation and during luteal phase of the menstrual cycle. 
  
 
Figure 1: Serum hormone fluctuations during a typical menstrual cycle along with 
changes in the breast and uterus (18). 
Fluctuations in th ovarian hormones, oestrogen and progesteron across the menstrual cycle 
are associated with morphological changes in the breast tissue. Note that, the proliferative 
phase on the uterine cycle is considered as the time the endometrium builds up before 
ovulation. However, in the breast, cell proliferations occurs post ovulation and during luteal 
phase of the menstrual cycle.  
Menses
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1.4.2.   CHANGES IN MAMMARY EPITHELIAL CELLS DURING THE 
MENSTRUAL CYCLE 
Fluctuations in circulating estrogen and progesterone during the menstrual cycle affect 
mammary gland epithelial cell morphology. Mammary epithelial cell proliferation is mediated 
by estrogen and progesterone in the early to mid-luteal phase, whilst declining progesterone 
drives epithelial cell apoptosis and mammary gland regression in the late luteal phase (12). 
Progesterone is the key hormone likely to promote mammary gland development, as a murine 
study conducted by Fata, Chaudhary (19) demonstrates that epithelial cell proliferation has a 
positive correlation with the serum concentration of progesterone, but not estrogen. Similarly,  
Chua, Hodson (20) demonstrated that during the ovarian cycle there is a positive correlation 
between the percentage of alveolar epithelial ducts in the mammary gland and the concentration 
of serum progesterone, but not with serum estradiol. 
 
Analysis into the effect of the different stages of the estrous cycle on development of alveolar 
epithelial cells in the mammary glands of mice found that the highest percentage of alveolar 
epithelium were observed during the diestrus phase, where the concentration of serum 
progesterone is maximal (Figure 1.5). Furthermore, a progesterone receptor knockout mouse 
model suggested that progesterone receptor expressed by mammary epithelial cells is necessary 
for epithelial cell proliferation (21). The role of estrogen in the mammary gland during the 
menstrual cycle appears primarily to be to upregulate expression of the progesterone receptor 
(18). Conversely, epithelial cell apoptosis is greatest during the menstrual phase with rapidly 
decreasing estrogen and progesterone levels (18). 
 
Several histological studies have demonstrated differences in breast tissue morphology during 
different stages of the menstrual cycle in women (22-24). In a study of 30 women with healthy 
breast tissue, the epithelial and myoepithelial layers were observed as two moderately separate 
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layers during the follicular phase, whereas in the luteal phase there was a prominent distinction 
between epithelial and myoepithelial layers; this suggests that the architecture of the breast 
tissue was more developed during the luteal phase (23). This study also reported that the highest 
level of mitotic and apoptotic activity in mammary epithelial cells occurred during the luteal 
phase of the cycle. However, not all literature is consistent with this observation. Vogel, 
Georgiade (25) reported that the highest level of mitotic and apoptotic activity was observed 
during the follicular phase (days 8-14), while there were high levels of apocrine secretions 
during the luteal phase (days 15-20). 
 
Fluctuations in hormones and mammary gland morphology associated with menstrual cycling 
are indeed cyclical in nature, and occur continuously, such that each cycle merges into the next. 
There are also degrees of variability between different women. This makes it difficult to match 
the morphological stage with the exact date or phase of the menstrual cycle (23). Consequently, 
the literature offers some conflicting results about the correlation of mammary gland 
histological characteristics with the different stages of the menstrual cycle. However, the 
majority of the literature on menstrual cycle-associated changes in women is consistent with 
mouse literature, and suggests that the main proliferative phase is the early luteal phase of the 
menstrual cycle, during which time circulating progesterone and estrogen are both high, and 
epithelial alveolar buds begin to form. The high level of mitotic activity in this phase suggests 
progesterone is associated with a proliferative action (22). Conversely, the late luteal phase or 
the menstruation phase could be considered as the regression phase of mammary gland 
epithelium. During this time, the concentration of circulating ovarian hormones decrease 
significantly and the newly formed alveolar buds undergo apoptosis and the breast tissue reverts 
to its basic architecture (20). 
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Figure 1.5: The percentage of development of alveolar epithelial cells in the mouse mammary 
gland during estrous cycle (20). 
The percentage of alveolar epithelial cells fluctuates across the course of estrous cycle and it is 
correlated positively with serum progesterone levels. The highest levels of alveolar epithelial cells are 
found at diestrus compared to other phases of the cycle (E, estrus; M, metestrus; D, diestrus; P, 
proestrus). 
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1.5.   THE IMMUNE MICROENVIRONMENT IN THE MAMMARY 
GLAND 
It is well established that mammary gland development and function is dependent on the 
dynamic interactions between hormonally responsive mammary gland epithelium and the 
immune microenvironment in the stroma. Immune cells localise to different sites during the 
various stages of mammary gland development and contribute to multiple effector functions  
(26) and may also affect cancer risk and development. According to Hanahan and Weinberg 
(27), there are ten hallmarks, or vital biological processes, required for cancer to be established 
and metastasize into other tissues. Two hallmarks are related to the immune system; they are 1) 
evading the immune detection and destruction and 2) promotion of tumour growth by 
inflammation (28). Indeed, the failure of immune cells in recognition and elimination of 
transformed cells throughout life can lead to cancer development. In the mammary gland, the 
immune cells primarily present are macrophages, mast cells, eosinophils, and T cells, which 
together have essential roles in hormonally-driven mammary gland development (29), and may 
also promote or protect the breasts against cancer (30). Considering their roles in the immune 
evasion of the tumour in the breast (31) and their crosstalk with mammary epithelial cells, it is 
possible that these cells affect menstrual cycle-associated breast cancer risk. 
 
1.5.1.   MACROPHAGES 
Macrophages are immune cells involved in the generation and execution of immune responses. 
However, over the past 20 years, new roles for macrophages in developmental processes have 
been discovered. These functions in development appear to be particularly significant in 
reproductive tract tissues, which undergo considerable morphological changes over the course 
of adult life (32). In the mammary gland, macrophages are a significant component of the 
stroma and have diverse roles in cell proliferation, phagocytosis, and tissue remodelling (20). 
There is high plasticity in macrophage phenotypes to accomplish specific immunological and 
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developmental requirements in different tissues. Activated macrophages are classified into 
classically activated macrophages and alternatively activated macrophages, each of which 
respond to and produce specific cytokines and have particular functions within the tissue (32). 
Classically activated macrophages function as part of cell-mediated immune system responses, 
which are involved in host defense against intracellular pathogens and produce pro-
inflammatory cytokines. Alternatively activated macrophages produce anti-inflammatory 
cytokines and have roles in tissue repair, immune tolerance, and wound healing (33). 
 
Due to their high plasticity, macrophages can change from one class to another class dependent 
on certain signals within the microenvironment (34). Previously it was thought that 
macrophages only protect the tissues from cancer by phagocytosing the apoptotic cell debris or 
presenting tumour-associated antigens to T cells. However, more recent studies suggest that 
these cells can also be involved in breast tumorigenesis, progression and metastasis, depending 
on their functional phenotype (35, 36). 
 
Macrophages are required for normal ductal epithelial development, and they have been found 
to be in direct contact with ductal and alveolar mammary epithelium, suggesting that there is a 
paracrine singling network between these cell types (20, 37-39). Also, the number of 
macrophages fluctuates over the course of the estrous cycle in mice; increasing at metestrus, 
peaking at diestrus, and decreasing rapidly at proestrus (20, 40). As mammary gland 
macrophages are physically associated with hormonally responsive mammary epithelial cells, 
ovarian hormones are likely to indirectly affect the function of macrophages through the 
production of cytokines by mammary epithelial cells. Therefore, it is important to understand 
the cytokine microenvironment that directs macrophage function within the mammary gland. 
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1.5.2.   T LYMPHOCYTES 
T lymphocytes are another class of immune cell that play central roles in cell-mediated 
immunity through cytokine signals and cell-to-cell interactions, and mediate humoral and 
immunoregulatory immune responses. T cells express unique receptors (known as TCRs) on 
their surface and are subdivided into different groups based on their lineage markers and 
functional activities (41). A major T cell lineage includes T helper cells (i.e., identified by 
surface cluster of differentiation CD4), which can differentiate into various effector subsets 
such as Th1, Th2, Th17 and regulatory T cells (Tregs), based on the signals that they receive 
from particular cytokines. The different subsets of Th cells have very different functions, they 
can promote or inhibit inflammation, or dampen the immune response. Recent studies illustrate 
the importance of T cells and their mediators in various stages of mammary gland development 
(42, 43); however, studies into their function in the mammary gland are limited. 
 
Cytokines usually associated with different T cell responses appear to be involved in mammary 
development associated with lactation. Induction of mammary epithelial cell differentiation to 
milk-secreting cells is accompanied by a switch from production of Th1 cytokines (such as 
TNFA, IFNG, and IL12) to Th2 cytokine (such as IL4, IL10, and IL13) by mammary epithelial 
cells (42). Interestingly, progesterone has been shown to regulate Th1/Th2 phenotypes in the 
mammary gland (44). Th1 cytokines are more effective in producing antitumor immunity and 
tumour rejection, whereas Th2 cytokines are mostly produced by tumours and they are involved 
in increasing humoral protumouringenic responses (45, 46). Therefore, an imbalance of normal 
Th1/Th2 ratios in the mammary gland microenvironment could cause a major dysfunction in 
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1.5.3.   REGULATORY T CELLS (TREGS) 
Tregs play critical roles in the prevention of autoimmunity, dampen excessive inflammation, 
downregulate the amplitude of an immune response, and regulate immunological tolerance (41, 
47, 48). Naturally arising Tregs develop in the thymus and account for 1-2% of peripheral CD4+ 
T cells in healthy humans (49). However, these cells are also present in non-lymphoid organs, 
and they are postulated to mediate suppressive mechanisms during mammary gland 
development. 
 
It has been suggested that estrogen and progesterone promote immune suppression via Tregs 
and cytokines (50, 51), which may assist incipient tumours evade immune detection. Exogenous 
estradiol promotes proliferation of T cell receptor-activated Tregs isolated from healthy 
individuals and enhances their suppressive function in vitro (50). Moreover, progesterone 
induces naïve T cells to differentiate into immune suppressive FOXP3+ Tregs and promotes 
immune tolerance in foetal cord blood (52). However, Tregs require activation before hormones 
can enhance their suppressive functions (50, 53). It is far from clear what stimuli activate Tregs 
during the menstrual cycle; however, infections or altered cell signalling pathways may play a 
role. 
 
In 2007, Arruvito, Sanz (53) stated that Treg abundance in the peripheral blood of healthy 
women increases during the follicular phase of the menstrual cycle, correlates with serum 
estrogen concentration, and decreases dramatically during the luteal phase. Therefore, 
fluctuations of the ovarian hormones over the course of the menstrual cycle could affect the 
modulation of tolerance by Tregs and impose immunosuppressive effects in the mammary 
gland microenvironment, increasing the risk of breast cancer development. 
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1.5.4.   MAST CELLS AND EOSINOPHILS 
Other type of immune cells that contribute to mammary gland development and homeostasis 
are eosinophils and mast cells (29). Eosinophils are phagocytic leukocytes implicated in 
combating multicellular parasites, helminth infections, and allergic reactions (54). Mice 
genetically deficient in eosinophils exhibit mammary gland retardation, and have altered 
estrous cyclicity (55). In the rat uterus, the abundance of eosinophils fluctuates across the 
estrous cycle with the lowest abundance observed during diestrus, and the greatest abundance 
during the estrus phase (56). 
 
Mast cells are tissue-resident leukocytes that play roles in allergic reactions, wound healing, 
inflammatory disorders, and immune tolerance (57). These cells are present in mouse mammary 
stroma at all stages of mammary gland development, regulate mammary epithelial ductal 
branching during puberty, and are localized around the ductal epithelium and the TEBs (58). 
An increase in the number of mast cells is linked to mammary epithelial lobule regression 
during estrous cycling and involution (59). Like eosinophils, the abundance of lobule-
associated mast cells is also hormone-dependent and fluctuates in cycling rats (59). 
 
Although eosinophils and mast cells are required for expansion of mammary epithelial cells in 
rodents, there is little known about their roles in the human breast. Moreover, both of these cell 
types are capable of producing inflammatory cytokines and chemokines that contribute to the 
metastatic potential of tumours. Therefore, it would be of interest to understand the associations 
of eosinophils and mast cells in human mammary gland during the menstrual cycle, and whether 
they are linked to breast cancer risk during this period. 
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1.6.   KEY TRANSCRIPTIONAL REGULATORS OF MAMMARY 
GLAND DEVELOPMENT AND FUNCTION 
The mammary gland has adopted a number of coactivators, transcription factors, and signalling 
pathways for its development and function. Through experimental mouse genetics and 
mammary gland transplantation techniques, researchers have identified some of the key 
signalling molecules that function along with the ovarian hormones to promote and regulate 
mammary epithelial cell proliferation, differentiation and regression (60). Of particular 
significance are the signal transducer and activator of transcription (STAT) family of proteins 
which play a wide range of functions in mammary gland development and activate diverse 
genetic programs (61, 62). STATs usually reside in the cytoplasm where they can be activated 
by tyrosine phosphorylation, dimerize and then translocate to the nucleaus. In the nucleus, they 
act as transcription factors by binding to DNA in order to regulate gene transcription (63). Two 
highly homologous STAT family members, STAT5 and STAT3 are essential for mammary 
alveolar development and tissue remodelling (64). Conditional knockout studies in mice 
showed that STAT5 is essential for proliferation and differentiation of mammary epithelium, 
and that its loss in differentiated alveolar cells causes rapid cell death (64, 65). On the other 
hand, STAT3 plays a pivotal role in mammary gland involution by inducing mammary 
epithelial cell death, removing the apoptotic cells, and regulating the immune cell 
microenvironment within the mammary gland (62, 66, 67). 
 
STAT3 and STAT5 are activated by estrogen and progesterone and they are often 
inappropriately activated in a variety of human malignancies, including breast cancer (68-70). 
These proteins are progesterone-dependent as their expression has been found to be induced by 
progesterone in human and mouse breast cancer cells in a PR-dependent manner (69, 70). 
Proietti, Salatino (71) noted that transcriptional activation of STAT3 is essential for progestin-
stimulated breast cancer growth in vitro and in vivo. However, estrogen is known to have 
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inhibitory effects on IL-6 induced STAT3 activation in breast cancer cells, an effect that is 
reversible with ER antagonist, Tamoxifen (72). Considering their essential roles in mammary 
epithelial cell proliferation and regression as well as in breast cancer, they are ideal candidates 
for studying the effects of estrogen and progesterone on mammary epithelial cell function. 
Nonetheless, the activity of these transcription factors is not only regulated by hormones, but 
other transcription factors and cofactors could also be involved. For example, the activity of 
STAT5 in governing the mammary alveolar differentiation program is suggested to be mediated 
by E74-like factor 5 (ELF5) transcription factor (73). 
 
Recent studies suggest that transcription factors are critical elements in controlling the function 
of immune cell signalling and they may affect complex interactions between immune cells and 
the hormonally-regulated network of epithelial cells in the breast (74). It is not clear how 
transcription factors contribute to epithelial-stromal crosstalk in the breast and affect menstrual 
cycle-associated breast cancer risk. However, it is likely that alterations of any cellular events 
in the mammary gland affect the proliferation rate of mammary epithelial cells which might 
increase DNA mutations and consequently lead to breast cancer in women. In the current study, 
we will utilise a variety of approaches in vitro and in vivo to investigate the expression of 
specific transcription factors in the mammary epithelium to investigate whether they are 
hormonally regulated and their relationship with the immune microenvironment. 
 
1.6.1.   ROLE OF ELF5 IN MAMMARY GLAND DEVELOPMENT AND 
BREAST CANCER 
ELF5 (also known as ESE-2) is an epithelial cell-specific member of ELF subfamily of Ets 
transcription factors, found in the lung, kidney, placenta, and most prominently in the mammary 
gland (75, 76). In the mammary gland, ELF5 has roles in mammary epithelial cell proliferation 
and promotes transcription of genes involved in alveolar morphogenesis (77). ELF5 specifies 
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alveolar cell fate and is mainly expressed by the luminal progenitor cells in the mammary gland 
(78). Studies in Elf5 null mutant mouse models demonstrate that these animals are either unable 
to lactate due to failed alveolar development, or exhibit impaired functional secretory units due 
to improper differentiation of alveoli. This indicates that ELF5 is a crucial transcriptional 
mediator required for structural and functional morphogenesis of lobuloalveoli (77). 
 
The role of ELF5 in breast cancer is controversial. It has been suggested to be either a tumour 
suppressor gene (79, 80), suppressor of epithelial-to-mesenchymal transition (EMT) and breast 
cancer metastasis (81), or even a mediator of mammary tumour’s metastasis into the lungs in 
mouse models (82). The chromosome on which ELF5 is located (human chromosome 11p 13-
15) is known to have a loss of heterozygosity in some breast cancer cases (83). Moreover, high 
expression of ELF5 correlates with more aggressive basal cancers and resistance to anti-
estrogen cancer therapies (84). 
 
ELF5 is a direct transcriptional target of the progesterone receptor, and its expression is 
increased by progestin treatment in vivo in mice and in vitro in T47D human breast cancer cell 
lines (85). Little is known of the role of this transcription factor in directing epithelial cell-
specific cytokine secretion. However, ELF5 is essential for progesterone-mediated RANK 
ligand production (75). RANK ligand is a tumour necrosis factor-like cytokine that promotes 
alveolar development during the ovarian cycle and pregnancy and is responsible for progestin-
mediated mammary cancer risk in a mouse model (86). Hence, ELF5 can be considered an 
essential mediator of progesterone-regulated mammary epithelial cell proliferation and 
differentiation and might affect cancer susceptibility through the production of cytokines that 
affect interactions between the mammary epithelium and surrounding immune cell populations. 
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1.6.2.   ROLE OF FOXP3 IN MAMMARY GLAND DEVELOPMENT  
The Forkhead box 3 (FOXP3) gene is located at the short arm of the X chromosome, region 
11.23 and contains 11 coding exons and three non-coding exons (87). FOXP3 is a member of 
forkhead/winged family of transcription factors and functions as an essential regulator of 
CD4+CD25+ Tregs development (88). Thymic CD4+CD25+ T cells express FOXP3 and 
become Tregs in order to temper immune responses (47, 48). Null mutation in FOXP3 in 
humans leads to a deficiency in the population of CD4+CD25+ Tregs, which leads to severe 
inflammation. This manifests as an X-recessive autoimmune disease called 
immunodysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome (IPEX) in 
males (89). These patients develop enteropathy, dermatitis, thyroiditis, and nail dystrophy, and 
usually die in the first 1-2 years of life due to severe infections (90). An analogous disease 
develops in male scurfy mice (Foxp3sf/Y) which are characterised by scaly and ruffled skin, 
reddened eyes, enlarged spleen and lymph nodes, and these mice die approximately 3-4 weeks 
after birth (91, 92). 
 
FOXP3 is predominantly expressed in the thymus and the spleen from where Tregs are derived. 
However, some reports have shown its expression in the epithelial cells of specific tissues such 
as the breast, lung, and prostate (93, 94). The expression of FOXP3 in the epithelium suggests 
that it may play a broad function outside of Tregs. Although epithelial-intrinsic function of 
FOXP3 has not been well-investigated, most studies suggest that FOXP3 acts as a tumour 
suppressor gene in breast cancer (94-96). As a transcription factor, it can bind to approximately 
700 genes (97) and act as either a transcriptional repressor (e.g. by directly repressing the S-
phase kinase-associated protein 2 (SKP2) and HER2 oncogenes (95, 98), or a transcriptional 
activator (e.g. by maintaining the expression of the p21 tumour suppressor in the mammary 
epithelium) (99). 
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In 2007, Zuo, Wang (94) analysed the expression of FOXP3 in normal and cancerous tissues 
and noted its expression to be present in only 20% of human breast cancer samples (mostly the 
HER2− or ER+ phenotype), whereas 80% of normal breast tissues expressed this protein. These 
researchers also found that Foxp3 heterozygous female mice develop mammary carcinomas 
spontaneously at a high rate as they age (94). In addition, when Foxp3 heterozygous female 
mice were challenged with the chemical carcinogen DMBA in conjunction with progesterone, 
a significant increase in the susceptibility to mammary cancer development was observed (94). 
Further studies in human breast cancer samples showed that a high rate of FOXP3 somatic 
mutations in breast tumours (100, 101), suggesting that FOXP3 defects play a role in breast 
cancer susceptibility. 
 
The biological function of FOXP3 in the mammary gland and whether it is regulated by 
estrogen and progesterone is not well-investigated. However, in vivo and in vitro studies on 
mouse models showed that estrogen at physiological doses expands the number of 
CD4+CD25+ T cells in different lymphoid tissues in estradiol-treated ovariectomised mice and 
that it induces the expression of FoxP3 gene (102). Therefore, it is possible that hormone 
regulation of FOXP3 expression in the mammary gland is associated with breast cancer risk. 
 
In the study by Zuo, Wang (94), 40% of aged Foxp3 heterozygous mice with breast cancer 
developed lung metastasis, suggesting that Foxp3 is involved in metastatic mechanisms (94, 
103). Also, using human and mouse breast cancer cells, Zhang, Zhang (103) found that FOXP3 
regulates the transcriptional activity of mircroRNA (miR)-200s, which are promising 
biomarkers of breast tumour progression and metastasis. On the other hand, transcription factor 
Zinc Finger E-Box Binding Homeobox 1 (ZEB1), which promotes the EMT in various human 
tumours (104, 105), has been shown to inhibit the transcription of miR-200 clusters (105, 106). 
Since FOXP3 and ZEB1 are linked together through the regulation of miR-200, we hypothesise 
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that regulation of FOXP3 by ovarian hormones could influence the expression of ZEB1in the 
mammary epithelial cells. 
 
1.7.   CYTOKINE NETWORKS IN MAMMARY GLAND IMMUNE 
MICROENVIRONMENT  
The events involved in mammary gland development require not only steroid hormones but 
also signalling by an array of other proteins, including cytokines (107). Cytokines are a group 
of small proteins (5-20 kDa) that are involved in cell signalling processes, cell fate 
determination, and act as intercellular mediators in generating immune responses. These 
molecules are usually secreted transiently and locally and exert their effects in a paracrine or 
autocrine manner (108). In the mammary gland, cytokines are produced and secreted by a broad 
range of cells, including epithelial cells, fibroblasts, adipocytes, macrophages or other immune 
cells (74). More importantly, some of these cytokines have been ascribed to be involved directly 
in mammary gland development and tissue remodelling during different stages of development 
(55, 74, 109). 
 
The cytokine microenvironment in the mammary gland can be affected by estrogen and 
progesterone during different stages of development (39). The function of these cytokines can 
be pro-inflammatory, anti-inflammatory, tissue growth promoting, or immunoregulatory. Pro-
inflammatory cytokines promote systemic inflammation, while anti-inflammatory cytokines are 
immunoregulatory proteins that limit pro-inflammatory cytokine responses (110). In a study on 
ovariectomised mice, Dasari and colleagues reported that the concentration of specific pro-
inflammatory cytokines fluctuates in the mammary gland across the estrous cycle and is 
hormonally regulated. They observed that estradiol induces cytokine production in the 
mammary gland during the estrus phase, which is actively suppressed by progesterone during 
the other phases of the cycle (111). They suggested that fluctuations in the cytokine 
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microenvironment in the mammary gland regulates the phenotypes of resident leukocytes and 
affect mammary gland tumour susceptibility (111). 
 
In order to assess the effect of menstrual cycle hormones on the immune microenvironment and 
breast cancer risk, we have identified leading cytokine candidates to investigate in in vitro and 
in vivo studies. These candidate cytokines are expressed by mammary epithelial cells and have 
known roles in breast cancer development and progression. These cytokines are: Transforming 
Growth Factor Beta 1 (TGFB1), Tumour Necrosis Factor Alpha (TNFA), Interleukin 12 (IL-
12), Chemokine C-C receptor ligand 12 (CXCL12), S100A8 and S100A9. 
 
TGFB1 is an important multifunctional cytokine that has roles in a diverse range of processes 
including mammary epithelial cell proliferation, differentiation, apoptosis, and immune system 
responses and affects local mammary macrophage population (112, 113). TNFA is a pro-
inflammatory cytokine produced by many cell types including mammary epithelial cells and is 
proposed to play a role in mammary ductal branching morphogenesis (114, 115). The serum 
levels of IL12, which is the main regulator of Th1 differentiation is higher in breast cancer 
samples and correlates with tumour progression (116). CXCL12 is a homeostatic chemokine 
for lymphocytes and monocytes and has roles in breast cancer progression (117, 118). It is 
primarily expressed in hormone receptor-positive luminal cells (119) and its expression is 
strongly upregulated in estrogen-treated MCF7 breast cancer cell lines (120). The calcium-
binding proteins S100A8 and S100A9 are expressed by neutrophils, macrophages, and 
activated monocytes (121) and their expression is associated with estrogen receptor loss in 
breast cancer cell lines (122). S100A8 and S100A9 are overexpressed in breast cancer and 
regulate inflammatory responses, suggesting that they might play a potential role in 
tumorigenesis (123). Although these inflammatory cytokines have roles in breast cancer, the 
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molecular mechanisms through which they are involved in tumorigenesis in the mammary 
gland is not well understood. 
 
1.8.   CONCLUSION 
The cumulative effects of fluctuating ovarian hormones on mammary epithelial cell 
proliferation, differentiation and apoptosis are considered as a highly significant factor leading 
to increased risk of breast cancer (124). Furthermore, early age at menarche, late age at 
menopause, and short cycle length are all factors that increase lifetime risk of breast cancer, 
and contribute to prolonged exposure to ovarian hormones (6, 125). Hence, it is important to 
study the precise cellular and hormonal mechanisms involved in regulating mammary gland 
development during the menstrual cycle. 
 
From the literature, it is clear that estrogen and progesterone promote mammary gland 
development through direct effects on epithelial cells and indirect effects through macrophages, 
T cells and other immune cells in the mammary stroma. Although the mechanisms through 
which estrogen and progesterone direct these functions is not known, it is likely to involve 
crosstalk with the hormonally responsive mammary epithelium. Mammary epithelial cells 
secrete a variety of cytokines, and mouse models suggest these epithelial cell-derived cytokines 
affect the surrounding microenvironment. However, the crosstalk between mammary epithelial 
cells and the immune microenvironment has not been previously investigated in human breast. 
In this context, ELF5 and FOXP3 may be key mediators of hormone-regulated cytokines 
produced by human mammary epithelium. Dissecting the interaction between hormonally 
responsive mammary epithelial cells and their cytokine expression in the breast will shed light 
on how fluctuations in ovarian hormones during the menstrual cycle affect breast cancer risk. 
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1.9.   HYPOTHESIS AND AIMS 
The experiments described in this thesis aim to address the following hypotheses:  
 Estrogen and progesterone regulate the expression of specific immune-related 
mammary epithelial cytokines in different human cell culture models.  
 Transcription factors ELF5 and FOXP3 are key regulators of hormone-induced cytokine 
production by human mammary epithelial cells.  
 Foxp3 heterozygosity affects the ovarian cycle regularity and mammary gland 
development in pubertal and adult mice. 
 
These experiments will address the following aims: 
 To explore the effects of estrogen and progesterone in the regulation of gene expression 
in different human cell culture models. 
 To explore the role of estrogen and progesterone in the regulation of ELF5 and 
downstream cytokine production by mammary epithelial cells. 
 To explore the role of estrogen and progesterone in the regulation of FOXP3 and 
downstream cytokine production by mammary epithelial cells. 
 To investigate the physiological role of Foxp3 in regulating mammary gland 
development using Foxp3 heterozygous mice. 
 
1.10.   RESEARCH PLAN 
To investigate the role of estrogen and progesterone in regulating the cytokine expression in 
the mammary gland, healthy non-neoplastic mammary epithelial organoids, human breast 
tissue explants, human breast cancer cell lines, and mouse mammary glands will be utilised.  
 
When primary mammary epithelial cells are cultured in single cell 2 dimensional (2D) 
monolayers, they lose their responsiveness to estrogen and progesterone (126). Therefore, these 
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studies seek to utilise new approaches to cell culture using mammary epithelial cells obtained 
from women at surgery that retain their cell-to-cell associations. Organoids are fragments of 
mammary alveolar epithelial structures which retain some of their in situ 3 dimensional (3D) 
structure, and can provide understanding of hormonal regulation of normal breast structure and 
development (127). To investigate the role of estrogen and progesterone on human mammary 
epithelial cytokine production, primary human organoids were cultured in Matrigel in a 3D 
model before being treated with hormones. This in vitro culture model, recently developed and 
described by Graham, Mote (126), can preserve the proliferative capacity and progenitor cell 
complement of normal breast tissue and retain the hormone responsiveness of mammary 
epithelial cells up to 14 days; hence it is suitable for studies related to hormone action in the 
normal breast (126). Moreover, it does not favour the growth of a specific epithelial cell type 
over the other, unlike most primary culture models (128). Indeed, when primary cells are 
embedded into 3D Matrigel cultures, both luminal and myoepithelial cells grow in the culture 
in a balanced manner. In contrast, when these cells are cultured in a 2D monolayer, bipotent 
epithelial progenitors lose their complex inter-relationships, their ability to give rise to both 
luminal or myoepithelial cells, and their hormone responsiveness within three days of culture 
(126). Nevertheless, this 3D model recapitulates the effects of estrogen and progesterone on 
human mammary epithelium, thus providing a reliable model system to represent the in vivo 
actions of these hormones on cytokine production. 
 
To determine the effects of estrogen and progesterone on epithelial cell cytokine expression in 
ex vivo human breast tissue explants, small fragments of human breast tissue are cultured. This 
model enables investigation of the mammary epithelium in the context of its natural 
microenvironment, as each tissue fragment is composed of the mammary epithelium embedded 
within the breast extracellular matrix and surrounded by stromal cells including fibroblasts and 
macrophages. Studies from our laboratory demonstrate that breast explant cultures undergo a 
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process of cellular rearrangement when first cultured, with the orientation of epithelial and 
stromal tissue compartments re-established within the first 7 days (Dasari et al., in preparation). 
Importantly, the epithelial cells maintain estrogen and progesterone responsiveness, and the 
cellular components of stroma are observed directly adjacent to epithelial cells in these cultures, 
remaining stable for at least 7 days following the initial 7-day establishment phase. Therefore, 
this model is an ideal approach to investigate the paracrine signalling between hormonally 
responsive mammary epithelial cells and the surrounding microenvironment. 
 
To complement studies on human primary mammary cells, which are obtained at the time of 
surgery and are therefore greatly limited in abundance, studies on human breast cancer cell lines 
were also conducted as part of this work. Cell lines are cost-effective, valuable in vitro tools 
which can compensate for experimental problems with primary mammary epithelial cells, and 
have advanced our understanding of breast biology. For this study, ATCC human mammary 
epithelial cell lines T47D, ZR751, and MCF7 were used as each of these express receptors for 
estrogen and progesterone (129, 130) and they have retained the luminal epithelial phenotype 
of breast cells (131). It should be noted that we are focusing on the overall actions of hormones 
on cytokine production by mammary epithelial cells in different conditions, and we do not 
translate the findings from breast cancer cell lines into a context of normal cycling mammary 
gland. Moreover, to reflect our gene expression studies in the context of naturally occurring 
cycling mice, and validate our results from the in vitro human cell culture models, mouse 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
 
2.1.   HUMAN BREAST TISSUE COLLECTION: 
Healthy non-neoplastic breast tissues were collected from women undergoing surgery for breast 
cancer, prophylactic mastectomy or reduction mammoplasty at The Queen Elizabeth Hospital. 
Human ethics committee approval was obtained from The Queen Elizabeth Hospital (TQEH 
Ethics Approval# 2011120) and informed consent was obtained from patients. In patients with 
a past or present history of breast cancer, breast tissues were taken to the pathology laboratory 
at the Queen Elizabeth Hospital to confirm the tissues are clear of malignancy. Inclusion and 
exclusion criteria for this study are as follows: 
Inclusion criteria: 
• Women attending TQEH for breast surgery 
• Between 18 and 75 years of age 
• Capable of giving informed consent 
Exclusion criteria:  
• Pregnancy  
• Patients highly dependent on medical care who may be unable to give consent. 
 
2.2.   PROCESSING OF BREAST TISSUE FOR HISTOLOGY, 
EPITHELIAL ORGANOIDS AND EXPLANTS 
2.2.1.   ISOLATION OF HUMAN MAMMARY EPITHELIAL ORGANOIDS  
Breast tissue was dissected with scalpel blades into small pieces, discarding excess fat and 
digested with 100U/ml of Hyaluronidase (Sigma Aldrich, St Louis, USA; Cat# H3506) and 
480U/ml of Collagenase (Sigma Aldrich; Cat# C0130) in Advanced DMEM/F12 medium (Life 
Materials and Methods   
~ 30 ~ 
Technologies, Australia; Cat# 12491015); supplemented with 2.5mg/ml Fungizone (Life 
Technologies; Cat# 15290018), 1X Penicillin/Streptomycin (Life Technologies; Cat# 
15240062), 10mM HEPES buffer (Life Technologies; Cat# 15630080), and 1X L-Glutamine 
(Life Technologies; Cat# 25030081). The digestion flask was placed in a 37ºC shaking water 
bath for 16 hours to dissociate the stromal and epithelial components of the tissue. It was then 
centrifuged at 180 x g for 10 minutes to separate undigested tissue fragments from the lipid 
layer. Advanced DMEM/F12 media was added to the pellet, mixed and gravity settled for 2 
hours. Fragments of mammary alveolar epithelial structures, known as organoids, were isolated 
from the supernatant through gravity settling. Media was removed and the cells were digested 
again with collagenase (300U/ml) for 2 hours and centrifuged at 480 x g for 5 minutes. The 
organoid pellet was treated with red blood cell lysis buffer (BD Bioscience, USA; Cat# 555899) 
(4ml for 15 minutes) to remove red blood cells. Organoids were then filtered through 100µm 
and 40µm cell strainers (Sigma-Aldrich; Cat# CLS431750) and collected in a Falcon tube. Cells 
were centrifuged at 480 x g for 5 minutes, resuspended in Advanced DMEM/F12 medium and 
stored in liquid nitrogen until required (refer to section 2.4. for freezing and thawing protocol). 
 
2.2.2.   DISSECTION AND CULTURE OF BREAST TISSUE INTO EXPLANTS 
Breast tissue was dissected into small tissue fragments (approximately 5mm) using scalpel 
blades. Tissue fragments were cultured on dental sponges (Ferrosan, Denmark; Cat# MS0005) 
as explants, maintained in 500μl RPMI1640 phenol red-free media (Life Technologies; Cat# 
32404014) (supplemented with 10% low-hormone Foetal Calf Serum (FCS) (Thermo Fisher 
Scientific, USA; Cat# 10099141), 1X Penicillin/Streptomycin, 10μg/ml Hydrocortisone 
(Sigma-Aldrich; Cat# H4001), and 10μg/ml insulin (Sigma Aldrich; Cat# I6634). Explant 
cultures were incubated at 37°C CO2 incubator for one week to allow tissue to recover before 
they are treated with combinations of hormones for one week. Figure 2.1 summarises the tissue 
processing protocol used to obtain human mammary epithelial organoids and explants.  
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Figure 2.1:  Human breast tissue processing protocol. 
Human breast tissues were collected from patients and prepared for culture as organoids or explants: 
1) A large portion of breast tissue was digested with enzymes for 16 hours in shaking water bath. 
Through several steps of gravity settling, the mammary epithelial organoids were obtained. 2) 
Fragments of the breast were cut into small pieces and cultured on top of dental sponges as explants. 
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2.3.   CELL CULTURE 
2.3.1.   CULTURE OF HUMAN MAMMARY EPITHELIAL ORGANOIDS IN 
MATRIGEL 
Organoids were thawed and split evenly into four Eppendorf tubes to be cultured into the central 
wells of 8-well tissue culture chamber slide (Sarstedt, Germany; Cat# 94.6140.802). Medium 
171 (Life Technologies; Cat# M171500) was supplemented with 1X Mammary Epithelial 
Growth Supplement (MEGS) (Life Technologies; Cat# S-015-5) for culturing the cells. 
Working quickly on ice, organoids (resuspended in approximately 40μl of the complete 
Medium 171, mixed with 160μl of Matrigel) were transferred into one of the centre wells of the 
8-well chamber slide. After 5 minutes incubating at room temperature, chamber slide was 
transferred to the 37ºC incubator for 20-30 min to allow for complete solidification of the 
Matrigel. Once the Matrigel was solidified, it was overlaid with 400µl of complete medium. 
The cultures were returned to the incubator, and the media was replaced every 2-3 days. Cells 
were cultured for 5 days to allow organoids to stabilise and grow prior to hormonal treatments.  
 
2.3.2.   HUMAN MAMMARY EPITHELIAL CELL LINES 
Human malignant mammary epithelial cell lines (MCF7, T47D, and ZR751) were purchased 
from the American Type Culture Collection (ATCC, Manassas, VA, USA). These cell line were 
utilised as they express receptors for estrogen and progesterone (132), making them useful for 
analysing hormonal effects on mediating cytokine synthesis by mammary epithelial cells. 
However, hormone responsiveness is known to vary between mammary epithelial cell lines. 
T47D cell lines have naturally high levels of progesterone receptor and are highly responsive 
to progesterone, whereas MCF7 cells are mainly estrogen responsive, as they contain high 
affinity specific receptors of estrogen (133). On the other hand, ZR751 cells respond to both of 
these hormones effectively (134). All cells were grown in 6-well culture plates at the density of 
2x105 cells/well in complete RPMI-1640 (ATCC; Cat# 30-2001) (supplemented with 1X 
Penicillin/Streptomycin, 0.2 Units/ml bovine insulin (Sigma-Aldrich; Cat# I5500), 10mM 
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HEPES buffer and 10% FCS). The cells were incubated at standard culture conditions at 37°C 
in 5% CO2 and 95% humidity. 
 
2.4.   CRYOPRESERVATION AND THAWING 
To preserve mammary cells for later culture, human mammary epithelial organoids and ATCC 
mammary epithelial cell lines were resuspended in 50% FCS /Advanced DMEM/F12 medium, 
and 6% dimethyl sulfoxide (Sigma-Aldrich; Cat# D5879) and aliquoted into 1ml cryovials and 
stored in liquid nitrogen in storage facility at the Basil Hetzel Institute at The Queen Elizabeth 
Hospital.  
 
To thaw, organoids and cell lines were collected from liquid nitrogen storage facility and 
thawed initially in a 37ºC water bath. The contents were then transferred to a Falcon tube where 
appropriate media was added to them drop-wise. Cells were then centrifuged at 300 x g for 5 
minutes, and the pellet was resuspended in 1ml of appropriate media. The media used for 
thawing are as follows: 
• Organoids: Medium 171 (Life Technologies; Cat# M171500) supplemented 1 in 100 
(v/v) with 1 X Mammary Epithelial Growth Supplement (MEGS) (Life Technologies; Cat# 
S0155), 1X Penicillin/Streptomycin, and Fungizone at 1/1000 dilution.  
• Cell lines: RPMI 1640 supplemented with 1X Penicillin/Streptomycin, 0.2 Units/ml 
bovine insulin, 10mM HEPES buffer and 10% FCS. 
 
2.5.   HORMONE TREATMENTS IN CELL AND TISSUE 
CULTURES 
For hormone treatments of in vitro culture of organoids, cell lines and explants, stock hormones 
in ethanol of 10mM 17β-estradiol (Sigma-Aldrich; Cat# 491187) and 20mM progesterone 
(Sigma-Aldrich; Cat# P0130) were diluted in appropriate culture medium containing charcoal-
stripped FCS. For hormone treatment of in vitro cultures, existing media was replaced with 
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media containing either ethanol control or the hormones (dissolved in ethanol 1/1000 dilution). 
Hormone treatments were performed every 24 hours using fresh media. The hormone treatment 
protocol was as following: 
• Organoids and cell line cultures: 10nM estradiol and/or 100nM progesterone were 
diluted in 400µl of Medium 171 or in 2ml RPMI 1640 media, and the cultures were treated with 
hormones for 72 hours. These concentrations reflect the physiological serum hormone levels in 
women using combined oral contraceptives (135) and they have minimal toxicity effects on the 
cells in vitro.  
• Explant cultures: 10nM estradiol and/or 10µM progesterone were diluted in 500µl of 
RPMI1640 media, and the cultures were treated with hormones for 72 hours.  
• 0.1% ethanol diluted in sterile water was mixed into appropriate media and used as the 
control for all three models. 
72 hours hormone treatment was chosen to follow the previous established protocols and also 
to be consistent with our cell line studies which showed that 72 hours hormone treatments 
results in higher hormone responses compared to 24 hours treatment. 
 
2.6.   BUFFERS AND SOLUTIONS  
2.6.1.   SIRNA SOLUTIONS 
For transfection of cell lines, 20µM stock siRNA solutions were diluted in 1X siRNA buffer 
(Thermo Fisher Scientific; Cat# 13-002000-UB-100) to prepare 10µM working solutions. 
  
2.6.2.   PHOSPHATE BUFFERED SALINE 
Commercial, sterile, 1X Dulbecco’s phosphate buffered saline (PBS) (Thermo Fisher 
Scientific; Cat# 10010023) was used in all cell culture and immunostaining protocols. 
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2.7.   TRANSFECTION OF HUMAN MAMMARY EPITHELIAL 
CELLS 
2.7.1.   ELF5 SIRNA TRANSFECTION OF CELL LINES 
T47D cells were grown in T75 culture flasks until optimal density (i.e., 60-80% confluent); 
they were treated with 1ml trypsin and washed twice in antibiotic-free complete RPMI1640 
medium (supplemented with 10% FCS). Cells were counted using Countess automated cell 
counter (Invitrogen, Australia), and diluted to 2.5 x 105 cells/ml for transfection in each well of 
a 6-well culture plate. 25pmol of SMARTpool human ELF5 siRNA (Dharmacon, Lafayette, 
USA, Cat# L-011265-02-0005) and non-targeting siRNA (Dharmacon, Cat# D-001810-01-05) 
solutions (at 10µM) were mixed with Lipofectamine RNAiMax transfection reagent (Life 
Technologies; Cat# 13778030) in 1:3 ratios for 5 minutes prior to transfection. Opti-MEM 
reduced-serum medium (Life Technologies; Cat# 31985062) was used as the transfection 
medium for initial dilution of ELF5 siRNA, non-targeting siRNA, and Lipofectamine 
RNAiMax. Next, cells were mixed with siRNA-transfection lipid mix. Transfected cells were 
then seeded into each well of a 6-well culture plate and 2ml antibiotic-free complete RPMI1640 
media was added. Cells were incubated at 37°C in 5% CO2 for 24 hours before hormone 
treatments. 
 
2.7.2.   PRODUCTION OF LENTIVIRAL VECTORS 
To investigate the roles of FOXP3 and downstream cytokine production by mammary epithelial 
organoids, lentiviral vectors plvEIG-FOXP3 (previously described in (136)) were purchased 
from the Gene Silencing and Expression Facility (GSEx) at the University of Adelaide. These 
vectors had been generated by transient transfection of Human Embryonic Kidney cells (HEK 
293T) with transfer vector (plvEIG) and packaging vectors pCMV-VSV-G (VSV-G), pMDL-
g/p-PRE (gag/pol) and pRSV-REV (REV) in the presence of transfection reagent 
Lipofectamine 2000 (Invitrogen; Cat# 11668027) and Opti-MEM reduced serum medium. The 
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supernatant was harvested 72 hours post-transfection and the virus was concentrated to 25X 
using ultracentrifugation (22,000 rpm for 90min at 4°C).  
 
Figure 2.2 illustrates the elements used for production of the lentiviral vectors. The construct, 
plvEIG, contains an expression cassette encoding the (EF)-1 alpha promoter, where FOXP3 has 
been inserted downstream followed by an internal ribosome entry site (IRES) which controls 
the reporter gene GFP. The vector is self-inactivating with a deletion in the 3’LTR. It also 
includes a Rev-Responsive Elemebt (RRE), Post-transcriptional Regulatory Element, Rous 
Sarcoma Virus promoter (RSV) and the central Polypurine Tract (cPPT) which enhances the 
transduction efficiency (136). These lentiviral vectors are capable of integrating into human 
mammary epithelial cells and subsequently overexpress FOXP3 in the cells. Also, pLVEIG-
GFP lentiviral constructs which contain an additional GFP gene in place of FOXP3, were used 
as the control.  
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Figure 2.2: The vectors required for the production of the pLVEIG lentivirus.  
The pLVEIG lentiviral vectors contain either GFP (A) or full-length FOXP3 (B), driven by the EF1α 
promoter. An EMCV IRES allows the expression of the GFP reporter downstream. It also includes a Rev-
Responsive Elemebt (RRE), Post-transcriptional Regulatory Element, Rous Sarcoma Virus promoter 






RSV RRE cPPT GFP EMCV IRES PRE ∆U3LTR
(A)n
dGFPEF1α
RSV RRE cPPT FoxP3 EMCV IRES PRE ∆U3LTR
(A)n
dGFPEF1α
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2.7.3.   LENTIVIRAL TRANSDUCTION OF MAMMARY EPITHELIAL 
ORGANOIDS 
Human mammary epithelial organoids were thawed as described earlier (section 2.4). 
Organoids were resuspended in complete Medium 171 containing 8μg/ml polybrene (Sigma-
Aldrich; Cat# H9268) and transduced with 5µl of lentiviral particle solution at multiplicity of 
infection (MOI) of 10 at 37°C, 5% CO2 incubator for 6 hours. Transduced cells were then 
centrifuged at 300 x g for 5 minutes, and the pellet was mixed with 160μl of Matrigel and 
cultured in 8-well chamber slides for 5 days. Transduction efficiency was then assessed 
qualitatively and quantitatively using confocal microscopy and RT-PCR. To confirm the 
efficiency, the intensity of GFP as well as the expression of mRNA encoding FOXP3 were 
measured in FOXP3-GFP-transduced cells and compared with the control cells. 
 
2.8.   HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
2.8.1.   TISSUE EMBEDDING AND SECTIONING 
Breast explant tissues were fixed in 4% paraformaldehyde (PFA) (Sigma-Aldrich; Cat# P6148), 
for 24 hours at 4°C, washed with 1X PBS overnight, and kept in 70% ethanol solution until 
tissue processing. Tissue was processed, and paraffin embedded using Excelsior tissue 
processor (Thermo Fisher Scientific) which involved the following incubation protocol: 1 
minute 75% ethanol, 1 minute 90% ethanol, 1 minute 95% ethanol, 3 x 1 minute absolute 
ethanol, 3 x 1 minute xylene, 3 x 1 minute paraffin wax at 62°C. Blocks and sections were 
stored at room temperature prior to staining. 
 
2.8.2.   HAEMATOXYLIN AND EOSIN STAINING 
5μm serial sections were cut using a Microtome (Leica Biosystems, Australia) and four sections 
per slide were mounted on adhesive glass slides (HD Scientific, NSW, Australia). Sections were 
dewaxed through three changes of xylene (Merck Millipore, Darmstadt, Germany; Cat# 
108298) and treated with 100%, 95%, 70%, and 50% ethanol gradually to rehydrate. The 5th 
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and 15th slide were then stained with haematoxylin (Sigma-Aldrich; Cat# HHS16) and 
counterstained with eosin (Sigma-Aldrich; Cat# 318906) before dehydrating and mounting with 
microscopy Entallen (Proscitech, Australia; Cat# IM022). H&E stained sections were then used 
to identify the slides containing alveolar epithelium (i.e. clusters of epithelial structures 
containing alveolar lumens) for immunohistochemical staining. 
  
2.8.3.   S100A8 IMMUNOSTAINING ON HUMAN BREAST EXPLANTS 
To investigate the effects of estrogen and progesterone on S100A8 expression, paraffin-
embedded sections were heated at 60°C for 1 hour before cooling to room temperature for 20 
minutes. Sections were then dewaxed twice with xylene for 5 minutes and rehydrated gradually 
with 100%, 90%, 70% and 50% ethanol, and H2O. The slides were incubated in citrate buffer 
(pH=6) for 30min at 95°C in a water bath. The slides were then removed from the water bath 
and allowed to cool, in the citrate buffer, for 20 minutes. Slides were then washed with envision 
wash buffer (Dako, USA; Cat# K8007) before incubating with 2µg/ml mouse anti-human 
S100A8 monoclonal antibody (Thermo Fisher Scientific; Cat# RG2231245) (1:100 dilution in 
antibody diluent (Dako; Cat# S0809); 1 hour at room temperature). Any unbound primary 
antibody was removed through three washes in Envision wash buffer and secondary antibody 
was applied (Envision Flex/HRP (RTU) (Dako; Cat# DM842) for 30 minutes at room 
temperature. After washing, the sections were incubated with 3,3′-Diaminobenzidine (DAB) 
(Dako; Cat# K3468) for 10 minutes at room temperature. Sections were then counterstained 
with hematoxylin and dehydrated with 90% and 100% ethanol (each for 3 minutes) and xylene 
(2X for 5 minutes), and coverslipped with microscopy Entallen. The negative controls had no 
application of primary antibody. Stained sections were then visualized using a Nanozoomer 
digital scanner (Hamamatsu photonics, Japan) and the images were acquired at 40X 
magnification using the Nanozoomer software for further analysis. 
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2.9.   PROTEIN ANALYSIS 
2.9.1.   WESTERN BLOT 
Protein was extracted from the cells using 200µl of RIPA buffer (Sigma-Aldrich; Cat#R0278) 
containing 1% β-mercaptoethanol (Sigma-Aldrich; Cat# M6250). Protein samples were 
quantified using Bradford Protein Assay (Bio-Rad, USA; Cat# 5000002) as according to the 
manufacturer’s instructions and 20µg from each sample was used for western blot analysis. 
Western blots were performed as per the Bio-Rad protocol for western blotting. Briefly, 
samples were separated on 12% precast polyacrylamide gel (Bio-Rad; Cat# 4568044) at 200V 
for 30 minutes. Proteins were then transferred onto a nitrocellulose membrane using Trans-Blot 
Turbo Transfer Packs (Bio-Rad; Cat# 1704156) in a Trans-Blot Turbo Transfer chamber system 
(Bio-Rad; Cat# 17001919). The membrane was blocked with 5% skim milk for 1 hour at room 
temperature prior to incubation with 20ng/ml of primary antibody overnight at 4°C. It was then 
incubated with 0.5µg/ml of appropriate secondary antibody conjugated to Horse Radish 
Peroxidase (HRP) for 1 hour at room temperature and washed 5X with TBST solution 
(containing 50mM Tris, 150mM NaCl, and 0.1% Tween 20). The membrane was incubated 
with the Clarity Western ECL substrate reagent mix (Bio-Rad; Cat# 170-5060) for 5 minutes 
to visualise the proteins using ChemiDoc Touch Imaging System (Bio-Rad; Cat# 17001402). 
To re-probe the membrane, it was stripped in 1X antibody stripping solution for 15 minutes at 
room temperature as per manual for western blot recycling kit (Alpha Diagnostics, TX USA), 
blocked with 1X Blocking Buffer and subsequently re-probed with primary antibodies as 
described above. 
 
2.10.   ANIMALS AND SURGERIES   
2.10.1.   MICE 
All animals in this study were approved by the University of Adelaide Animal Ethics 
Committee (Ethics# M-2015-268) and were conducted according to the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes (137). All mice were 
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maintained under specific pathogen-free conditions with controlled light (12hr light, 12hr dark 
cycle) and temperature at the Laboratory Animal Services Medical School South facility. 
 
2.10.1.1.   FOXP3 HETEROZYGOUS MICE (FOXP3SF/+) 
The scurfy mouse genotype developed spontaneously from a multiple recessive stock of seven 
mutations, at the Oak Ridge National Laboratory in 1949 (138). This mutation is characterised 
by insertion of two adenosine residues into exon 8, leaving scurfy mice with a truncated Foxp3 
protein that lacks the carboxy terminal-forkhead domain. Homozygous scurfy male mice 
(known as Foxp3Sf/Y) develop T cell tolerance leading to an X-linked lymphoproliferative 
disease, and generally die by 16-25 days of age. Phenotypes associated with scurfy mice include 
runting, scaly skin on the ears, eyes and tails, squinted eyes, dermal thickening, swelling of the 
genital papilla, and small testicles retained in the abdominal cavity (91, 92). 
 
In this project, all the experiments used Foxp3Sf/+ heterozygous female mice on a C57BL/6J 
background. Foxp3Sf/+ were bred with the wildtype C57BL/6J mice and the breeding pairs 
produced progeny that were homozygous for a targeted mutation in the Foxp3 gene (Foxp3Sf/Y), 
heterozygous (Foxp3Sf/+), or homozygous wild-type (Foxp3+/+). Wild-type C57BL/6J mice 
from Jackson Laboratory (Maine, USA) were used as controls for the heterozygous scurfy mice. 
Mice were weaned at three weeks and 5mm of their tail tips were cut for genotyping (protocol 
described in section 2.11.2). Homozygous scurfy male mice were culled as soon as they 
developed the disease to prevent them from suffering.  
 
2.10.2.   BLOOD COLLECTION 
Cardiac puncture was used to collect blood (up to 1ml) from mice while they were deeply 
anaesthetised with 0.4-0.5 ml 2% Avertin (Sigma-Aldrich; Cat# T48402) using a 20 g needle. 
It was incubated at room temperature for 30 minutes, then centrifuged for 8 minutes at 14,000 
rpm. Serum was collected and stored at -80 °C. 
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2.10.3.   ESTROUS CYCLE TRACKING 
Vaginal smear analysis was used to determine the estrous cycle stage as described by (139, 
140). Daily vaginal smears were conducted between 8:00am–11:00am for at least 28 days. 20µl 
of sterile PBS was used to flush the vagina; the contents were smeared on a glass slide and 
covered with a cover slip. The cellular contents were examined using a phase contrast 
microscope. Each stage of the cycle was determined based on the relative proportion of each 
cell type (i.e. nucleated epithelial cells, cornified epithelial cells, or leukocytes) (Table 2.1). 
Representative images of these cell types in the vaginal smears are shown in Figure 2.3. 
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Table 2.1: Determining the estrous cycle stages by vaginal smears.  
Estrous cycle stage Cytology of the cells in vaginal smears 
Proestrus E or EC 
Estrus EC+ or C+ 
Metestrus C++ clumps or C+L+ 
Diestrus L++ 




Figure 2.3: Representative images of vaginal cytology at each stage of the estrous cycle. Images are 
derived from (139).  
Three different cell types identified in vaginal smears of mice at each stages of the estrous cycle A) 
proestrus, B) estrus, C) metestrus, and D) diestrus. 
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2.10.4.   MAMMARY GLAND WHOLE-MOUNT PREPARATION 
For mammary gland whole-mount preparation, the 4th left inguinal mammary gland was 
excised and spread on a glass slide. The slides were fixed for a minimum of 4 hours in Carnoy’s 
solution (60% ethanol, 30% chloroform, and 10% glacial acetic acid). The fixed mammary 
glands were washed in 70% ethanol for 15 minutes and then rinsed in MQ water for 5 minutes. 
Tissues were stained with carmine alum [2% carmine (Sigma-Aldrich; Cat# C1022), 5% 
aluminium potassium (Sigma Aldrich; Cat# 237086) overnight at 4°C]. The slides were washed 
in 70% ethanol, followed by 95% and 100% ethanol (15 minutes each). Finally, the slides were 
cleared in xylene for one week and mounted on the slide with a cover slip using DPX (Merck). 
Mammary whole-mounts were photographed using an Olympus SZ61 stereo microscope 
(Olympus, Japan) and a SC50 camera (Olympus). 
 
2.10.5.   DUCTAL BRANCHING ANALYSIS 
The number of branch points per millimetre length of epithelial ducts was counted using Image 
J software. The three longest ducts from each mammary gland were selected, and the number 
of branch points on each duct was counted manually (assessor was blinded to mouse genotype). 
A mean value of three ducts per mammary gland was calculated and expressed as branch 
points/mm to give a single value for each animal. 
 
The number of TEBs and the ductal length was also quantified in the mammary gland whole-
mounts. TEBs projected out from the distal end of the ducts were counted manually across the 
widest portion of the mammary gland. Only terminal end buds greater than 100μm were 
counted. The length of ductal epithelial growth in the mammary gland was measured using 
Image J software, from the nipple to the furthest TEB. 
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2.11.   NUCLEOTIDE ANALYSIS 
2.11.1.   DNA EXTRACTION: 
Mouse tail tips were digested in 250µl digestion buffer containing 17mM tris, 17mM EDTA, 
170mM sodium chloride, 0.85% SDS (PH 7.8) with 0.1mg proteinase K (all from Sigma-
Aldrich) at 55°C for 4 hours. To precipitate out the proteins and cellular debris, 250µl of 4M 
ammonium acetate was added to each sample and incubated for 25 minutes at room temperature 
with regular mixing. Samples were then centrifuged at 12,000 rpm for 10 minutes and the clear 
supernatant was transferred onto a new tube. 800µl of 100% Ethanol was added to each sample 
and centrifuged at 12,000 rpm for 8 minutes to pellet the DNA. The pellet was washed with 
70% ethanol and air dried on a heat block for 15-20 minutes. Next, 50µl of RNase-free water 
was added to break down the DNA pellet. DNA concentration was measured using 
spectrophotometer ND 1000 Nanodrop (Thermo Fisher Scientific). DNA was stored at 20°C 
prior to genotyping. 
 
2.11.2.   GENOTYPING MICE: 
TaqMan genotyping assay was used to determine the genotypes of mice. DNA from tail 
biopsies were analysed for the expression of intact or mutant Foxp3 gene. 
 
2.11.2.1.   PCR PRIMERS AND CONDITIONS: 
The primers and conditions used to determine the genotype of mice in respect to FoxP3 
mutation were followed based on the method recommended by JAX genotyping Resources 
(Jackson Laboratory). The mutant (MUT) probe has two adenosine residues inserted into exon 
8 in the reading frame. This reading frameshift is predicted to produce a truncated non-
functional protein lacking the carboxy-terminal forkhead domain. Table 2.2 specifies the 
sequence Foxp3 primer along with wild-type (WT) and MUT probes labelled with specific 
fluorophore dyes.  
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Table 2.2: The protocol TaqMan assay used for genotyping mice. 
Primer Type 5' Label Sequence 5' --> 3' 3' Label 
Forward --- GGC TAC AAT GAA ATG ACA AGC --- 
Reverse --- GAC TCC ACT GAC CTG GGA AG --- 
WT Probe VIC CAA TGG ACA AGA GCT CTT GC QSY quencher 
MUT Probe 6-FAM CAA TGG ACA AAA GAG CTC TTG C QSY quencher 
 
2.11.2.2.   TAQMAN ASSAY: 
To determine the genotype of mice, TaqMan gene expression assays were performed using 
ViiA7 Real Time PCR system (Applied Biosystem) based on the expression of Foxp3 variants 
in the DNA. Reactions were prepared separately for each variant (i.e. FoxP3 WT or MUT 
probe) in a total volume of 20µl containing 1µl of the probe, 10µl of TaqMan Fast Advanced 
Master Mix (Applied Biosystem, Cat# 4444557), 7μl of nuclease-free water and 2μl of DNA. 
A no template control (nuclease-free water) was used to confirm the absence of DNA 
contamination. Tables 2.3 and 2.4 summarise the reaction set up and PCR conditions for 
genotyping the mice.  
 
Table 2.3: The reaction set up for genotyping mice using WT and MUT probes. 
Reaction Component Final Concentration Volume/reaction (µl) 
Probe (WT/MUT) 15 µM 1 
ddH2O - --- 7 
TaqMan Fast Advanced Master Mix 1X 10 
DNA 100ng 2 
Total --- 20 
 
Table 2.4: PCR conditions for genotyping mice.  
Step # Temperature °C Time Note 
1 95 3min --- 
2 95 5sec --- 
3 60 30sec --- 
4 --- --- Repeat steps 2-3 for 40 cycles 
5 4 --- ∞ 
 
Genotypes were determined based on the presence or absence of WT or MUT alleles as 
following: WT DNA only expressed the Foxp3 WT allele; scurfy DNA only expressed the 
Foxp3 MUT allele; and heterozygous mice expressed both WT and MUT alleles in their DNA 
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(Table 2.5). Examples of amplification plot for three mice with different genotypes are shown 
in Figure 2.4. 
 
Table 2.5: The summary of End Point Analysis outcomes for each Foxp3 genotype.  
Mouse Genotype WT MUT 
Homozygous Mutants (Foxp3Sf/Y)   
Homozygous Wild-type (Foxp3+/+)   
Heterozygous (Foxp3Sf/+)   
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Figure 2.4: Amplification plots for mouse genotyping using TaqMan assay. 
Examples of the amplification plots for mice with different genotypes is shown: A) DNA from wildtype 
homozygous mouse expressing only the wildtype allele of FoxP3, B) DNA from Foxp3Sf/+ heterozygous 
mouse expressing both wildtype and mutant alleles of Foxp3, C) DNA from Foxp3Sf/Y homozygous 
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2.11.3.   TOTAL RNA EXTRACTION 
Third pair mammary glands and the lymph nodes (pooled sample of Mesenteric, Lumbar, and 
Axillary lymph nodes) were collected from all female mice to quantify the expression of mRNA 
encoding the genes of interest. Tissues were dissected under RNase Free conditions, snap frozen 
in liquid nitrogen and stored at -80°C until processing. Total RNA was isolated from tissues 
using 1ml of TRIZOL reagent (Invitrogen, Cat# 15596026) for each sample. Tissues were 
transferred into tubes containing 0.6g of 1.4mm ceramic beads (QIAGEN, Victoria, Australia, 
Cat# 13113-325) and were homogenised with the Powerlyzer 24 Bench Top Bead Based 
Homogenizer (MoBio, USA) (30Hz, 5 minutes). After 5 minutes incubating at room 
temperature, 200µl of Chloroform (Sigma Aldrich; Cat# 288306-1L) was added to the tubes. 
Samples were vigorously mixed by manual shaking and centrifuged at 12000 x g for 15 min at 
4°C. Approximately 400µl of the top aqueous phase (containing RNA) was transferred into a 
fresh tube and 500µl of Isopropanol (Sigma-Aldrich; Cat# 563935) was added to the tubes. 
Samples were centrifuged at 12000 x g for 10 minutes at 4°C. The pellet was washed with 1ml 
of 75% ethanol and centrifuged at 7500 x g for 5 minutes at 4°C. The pellet was air dried for 
10 minutes before being resuspended in 50µl of RNase-free water. Extracted RNA was 
quantified using spectrophotometer ND 1000 Nanodrop. 10µg RNA from each sample was 
treated with DNase to remove genomic DNA contamination using DNA-free kit (Life 
Technologies; Cat# AM1906) according to the manufacturer’s instructions. 5µl of 10X DNase 
I buffer and 1µl of DNase I was added to each sample and incubated for 30 minutes at 37°C. 
Next, 5µl of DNase Inactivating Reagent was added to each sample and incubated for 2 minutes 
at room temperature. Samples were then centrifuged at 10,000 x g for 2 minutes at room 
temperature, and the RNA-containing supernatant was transferred to a clean tube. DNase-
treated RNA was quantified using the Nanodrop Spectrophotometer. 
 
To isolate RNA from the organoids and the cell lines, an RNeasy Mini Plus kit (QIAGEN; Cat# 
74104) was used according to the manufacturer’s instructions, and treated with RNase-free 
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DNase (QIAGEN; Cat# 79254) to remove any trace of genomic DNA. RNA yield was 
measured using 2µl of each sample on the Nanodrop Spectrophotometer. 
 
2.11.4.   COMPLEMENTARY DNA (CDNA) SYNTHESIS 
An iScript cDNA synthesis kit (Bio-Rad; Cat# 1708890) was used to reverse-transcribe 
messenger RNA into cDNA. All cDNA synthesis reactions were set up using appropriate 
amounts of RNA, 4µl of 5 x iScript reaction mix (containing dNTPs, MgCl2, and buffer), 1µl 
of iScript reverse transcriptase and nuclease-free water in a total volume of 20µl. Reaction set 
up conditions were as follows: 
• The amount of RNA used in the reaction set up was 500ng from the organoids, 1µg 
from the cell lines, and 2µg from mice tissues.   
• Samples were incubated on the PTC-100 programmable thermal controller (MJ 
Research, USA) for 5 minutes at 25°C to anneal primers, 30 minutes at 42°C for reverse 
transcription, and 5 min at 85°C to terminate the reaction. 
• Synthesized cDNA was diluted 1:10 in nuclease-free water (giving a final concentration 
of 3ng/µl for the organoids, 10ng/µl for the cell lines, and 20ng/µl for mice) in a total volume 
of 200µl. It was then stored at -20°C freezer until required. 
 
2.11.5.   QUANTITATIVE REAL TIME-PCR 
2.11.5.1.   SYBR GREEN-BASED DETECTION 
To assess abundance of cDNA, quantitative real time PCR (qRT-PCR) was performed using a 
CFX96 Real Time Detection System running CFX Manager 3.0 software (Bio-Rad). Reactions 
were performed in a total volume of 10µl containing 5µl master-mix of SYBR green (Bio-Rad), 
0.4µl of each primer set (i.e. reverse and forward primer), 2.2µl of nuclease-free water and 2µl 
of diluted cDNA. Reactions were then incubated on the thermocycler, which was set based on 
the following conditions: 
- 3 minutes at 95°C  
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- 40 amplification cycles at 95°C for 15 seconds, 
- 15 seconds at 60°C, and 
- 30 seconds at 72°C.  
All samples were run in triplicates and a no template control (nuclease-free water) was used for 
each PCR plate. Quantitative RT-PCR data was analysed by the comparative Ct method (i.e. 2-
(ΔΔCT) method) (141), relative to expression of the housekeeping gene. The results were 
normalized to this gene so that the average of the control samples was 1. All primers were 
purchased from Geneworks (Adelaide, Australia). The sequence of all primers are provided in 
Table I in the appendix. 
 
2.11.5.2.   SELECTION OF HOUSEKEEPING GENES: 
Housekeeping genes are constitutive genes typically involved in basic cellular functions and 
are expressed in most cells of an organism under normal conditions. However, the expression 
of some housekeeping genes may vary depending on the experimental conditions. 
Housekeeping genes that exhibit minimal variation in messenger RNA quantity in response to 
different hormone treatments provide valuable controls for relative quantification of data (142). 
Overall, housekeeping genes are expected to be expressed at constant levels in all cells and 
conditions. This is because these genes are involved in maintaining basic cellular functions that 
are essential for cell life (143). Three housekeeping genes, MPRL19, PPIA and GAPDH were 
assessed to determine a suitable housekeeper gene for these studies. The expression of GAPDH 
and PPIA was highly correlated with many of the target genes and it was altered by hormone 
treatments in the cultures. As a result, GAPDH and PPIA were not used as the endogenous 
control gene for normalisation of the qRT-PCR data. Quantitative RT-PCR results showed that 
the housekeeping gene MPRL19 has an invariable expression in response to all hormone 
treatments; thus, it was used as the endogenous control gene.  
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2.12.   STATISTICAL ANALYSIS:  
For statistical analysis of RT-PCR data from human mammary epithelial organoids, the “R 
software” (144) and the lme4 library (145) were used, which enabled us to analyse multiple 
genes on the same sample. This method of statistical analysis was specifically chosen for this 
dataset to account for within sample correlations that might lead to an underestimate of the 
“true” standard deviation, which would increase the risk of type I error.  
 
For statistical analysis of RT-PCR data from human mammary epithelial cell lines and mice, 
data were assessed using SPSS Statistics Version 24 (IBM Corporation, Armonk, NY, USA). 
Relative expression of genes was analysed by one-way ANOVA, followed by post-hoc Tukey 
test to assess the associations between two variables and comparisons between groups. Data are 
presented as the mean ± SEM (standard error of mean). The difference between groups was 
considered statistically significant if p<0.05. An asterisk (*) identifies a treatment that differs 
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CHAPTER THREE 
HORMONAL REGULATION OF MAMMARY EPITHELIAL CELLS 
 
 
3.1.   INTRODUCTION 
Fluctuations in circulating estrogen and progesterone during the menstrual cycle affect 
mammary gland morphology. Mammary epithelial cells proliferate in the early luteal phase 
when the concentration of circulating estrogen and progesterone is high. However, when the 
concentration of progesterone declines during the late luteal and menstrual phase, mammary 
epithelial cells undergo apoptosis and the breast tissue reverts to its basic architecture (18). The 
cumulative effects of fluctuating ovarian hormones on mammary epithelial proliferation, 
differentiation and apoptosis over successive menstrual cycles are considered a highly 
significant factor leading to increased risk of breast cancer (124). Hence, it is important to study 
the precise cellular and hormonal mechanisms that regulate mammary gland development over 
the course of the menstrual cycle. 
 
The mammary gland is composed of a number of different cell types including epithelial, 
adipose, and stromal cells, which together form complex interactive networks required for the 
normal development and function of this tissue (146). Although the majority of breast 
carcinomas originate from mammary epithelial cells (8), immune cells in the mammary gland 
stroma have been implicated as paracrine regulators affecting breast cancer susceptibility, 
development and progression (30). Previous studies by our group have shown that macrophages 
play important roles in mammary epithelial cell proliferation, phagocytosis, and tissue 
remodelling (20). In the adult mammary gland, macrophages are in direct contact with the 
epithelial cells and their abundance fluctuates over the course of the estrous cycle in mice (20, 
40). As mammary gland macrophages are physically located in close proximity with the 
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hormonally responsive mammary gland epithelium, ovarian hormones may indirectly affect the 
function of macrophages through production of cytokines by mammary epithelial cells (113). 
 
Mammary epithelial cells and immune cells both produce a number of cytokines including 
TGFB1, TNFA, and IL12, which mediate different aspects of mammary gland development 
and affect other stromal cells including the phenotype and activity of local macrophage 
populations (113, 147). The signal transducer and activator of transcription (STAT) family of 
transcription factors also play a wide range of functions in mammary gland development and 
cytokine signal transduction, and are associated with T cell lineages (62, 107, 148). In 
particular, STAT5 and STAT3 are of great interest as they are essential for alveolar 
development during pregnancy and tissue remodelling during mammary gland involution (64). 
In this study, we will investigate the expression of some of these cytokines in the mammary 
epithelium to understand how they are hormonally regulated. 
 
It has been suggested that the cytokine signature of mammary epithelial cells is specific and 
depends on differentiation status (42). The function of cytokines can be pro-inflammatory, anti-
inflammatory, tissue growth promoting, or immunoregulatory. Since breast cancer is an 
inflammation-linked disease and the tumour microenvironment is enriched with inflammatory 
components (149), these inflammatory mediators may play essential roles in increasing breast 
cancer risk.  
 
To confirm the efficacy of estradiol and progesterone in our in vitro experiments on human 
mammary epithelial cells, we analysed the mRNA expression of genes encoding PGR and 
FKBP51. Estrogen activates the expression of the gene encoding PGR which is followed by the 
expression of PGR protein (150) and thus PGR can be used to assess estradiol responsiveness 
in cell culture. It has also been observed that estrogen induces expression of PGR in female 
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reproductive tissues as well as in normal and malignant mammary epithelial cells (151, 152). 
On the other hand, FKBP51 is expressed abundantly in a number of tissues, and its expression 
is strongly enhanced by progesterone (153, 154). 
 
The experiments described in this chapter were devised to investigate the hormonal regulation 
of cytokines in mammary epithelial cells using three different models. Firstly, we used 3D 
culture of human primary mammary epithelial organoids obtained from human breast of women 
undergoing surgery. 3D organoids maintain their paracrine signalling relationships between 
adjacent epithelial cells which are essential for primary cells to retain their estrogen and 
progesterone responsiveness in culture. This 3D culture protocol was specifically developed by 
Graham, Mote (126) to investigate the effects of estrogen and progesterone in mammary 
epithelial cells in culture, and this approach is superior to alternative approaches utilising 2D 
primary epithelial cell cultures. Secondly, hormone-sensitive human mammary epithelial cell 
lines, which have more defined hormone receptor profile than primary cells, were used to 
explore the cytokine expression in the epithelial cells. Lastly, to investigate physiological 
fluctuations in ovarian hormones in the mammary gland, the cytokine profile during the estrous 
cycle in vivo using adult female virgin mice was assessed. We found there was a large degree 
of variation in estradiol and progesterone regulation of the expression of mRNA encoding 
cytokines, depending on the hormone receptor profile of the mammary epithelial cells.   
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3    
3.2.   RESULTS 
3.2.1.   MESSENGER RNA EXPRESSION OF CYTOKINES IN THE 
HORMONE-TREATED MAMMARY EPITHELIAL CELL ORGANOIDS 
To investigate the effects of estrogen and progesterone on mammary epithelial cell cytokine 
production, primary human mammary epithelial organoids (n=6) were embedded in Matrigel 
and treated with combinations of estradiol (10nM) and progesterone (100nM) for 72 hours. 
Messenger RNA expression of genes PGR, FKBP51, TGFB1, TNFA, STAT3, STAT5, and IL12 
were examined from hormone-treated human mammary epithelial organoids. The comparative 
Ct method (i.e. 2-(ΔΔCT) method) was used to analyse quantitative real-time PCR data, relative 
to the mean of expression of housekeeping gene MPRL19 from the same patient. 
 
The expression of mRNA encoding TGFB1 was significantly attenuated by the combination of 
estradiol and progesterone treatment (Figure 3.1.C; p<0.05). However, there was a large extent 
of variability in production of all other genes in the primary organoid cultures between different 
women, and no other significant relationship with hormone treatments was observed (Figure 
3.1). 
  





Figure 3.1: Hormonal regulation of mRNA encoding cytokines in 3D organoid cultures.  
Box plots represent the mean variation in the expression of genes A) PGR, B) FKBP51, C) TGFB1, D) 
TNFA E) STAT3, F) STAT5 and G) IL12 from Matrigel-embedded human epithelial organoids upon 
treatment with combinations of estradiol (E2) and/or progesterone (P4) for 72 hours (n=6). Data are 
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3.2.2.   MESSENGER RNA EXPRESSION OF GENES IN THE HORMONE-
TREATED MAMMARY EPITHELIAL CELL LINES:  
To assess the efficacy of hormone treatments, and to provide cell line comparisons with the 
results obtained from the 3D organoid model, human mammary epithelial cell lines were 
analysed over different time courses. Messenger RNA expression of cytokines FKBP51, PGR, 
TGFB1, TNFA, STAT3, STAT5, and IL12 were examined from MCF7, T47D, and ZR751 
human mammary epithelial cell lines treated with combinations of estradiol and progesterone 
for i) 24 hours and ii) 72 hours. The comparative Ct method (i.e. 2-(ΔΔCT) method) was used 
to analyse quantitative real-time PCR data, relative to expression of housekeeper gene MPRL19 
in each treatment group. The results were normalised so that the average of the control samples 
was 1. 
 
MCF7 cells are exquisitely responsive to estradiol and less responsive to progesterone, as they 
contain high affinity specific receptors of estrogen (133, 155). T47D cell lines have naturally 
high levels of progesterone receptor and are highly responsive to progesterone (133) while 
being less responsive to estradiol. ZR751 cells respond to both estrogen and progesterone, 
although these cells mainly express the estrogen receptors (156). Our results show that the 
maximal PGR mRNA expression was observed in MCF7 cells treated with estradiol for 72 
hours (Figure 3.5A), while the highest expression of mRNA encoding FKBP51 was in T47D 
cells treated with progesterone for 72 hours (Figure 3.6B). Also, the expression of both PGR 
and FKBP51 genes was induced in ZR751 cells treated with estradiol and progesterone 
respectively, confirming the dual hormone responsiveness of this particular cell line (Figure 3.4 
and 3.7). Progesterone treatment was effective in down-regulating expression of its own 
receptor in all three cell lines. These results support the previous studies that describe the 
differential effects of estradiol and progesterone on T47D, MCF7, and ZR751 cells, and confirm 
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that estradiol and progesterone were effective in stimulating epithelial cells, as reported 
previously. 
 
In MCF7 cells treated with hormones for 24 hours, the expression of mRNA encoding TNFA 
was increased by 60% upon treatment with estradiol compared to the control-treated cells 
(p<0.05). On the other hand, the expression of mRNA encoding STAT5 and IL12 genes were 
significantly attenuated by 50% and 30% respectively (p<0.05 for both genes) upon treatment 
with the combination of estradiol and progesterone (Figure 3.2F and 3.2G). Hormone treatment 
of these cells for 24 hours did not have any significant effect on the mRNA expression of 
FKBP51, TGFB1 and STAT3 (Figure 3.2). 
 
Hormone treatments of T47D cells for 24 hours resulted in more dramatic changes in the 
expression of genes encoding cytokines. Abundance of mRNA encoding TGFB1 and TNFA 
was significantly attenuated upon treatment with progesterone or a combination of estradiol and 
progesterone by more than 60%, compared to estradiol-treated and control-treated cells (p<0.01 
for both cytokines) (Figure 3.3C and 3.3D). However, the same treatments significantly 
increased the expression of mRNA encoding STAT5 by approximately 12-fold (p<0.01) 
compared to estradiol-treated and control-treated cells. There was a trend of increased mRNA 
expression of this gene by approximately 6-fold upon treatment with the combination of 
estradiol and progesterone; however, the results were not significant (Figure 3.3F). 
Furthermore, treatment with the combination of hormones significantly increased the 
expression of mRNA encoding STAT3 by 4-fold, compared to the control-treated cells (Figure 
3.3E). There was no significant effect observed in the expression of IL12 upon hormone 
treatment in T47D cells (Figure 3.3G). 
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In ZR751 mammary epithelial cell lines, the combination of estradiol and progesterone 
treatment for 24 hours significantly increased the expression of mRNA encoding STAT5 by 
approximately 5-fold, compared to estradiol-treated and control-treated cells (p<0.01) (Figure 
3.4F). Furthermore, estradiol treatment of these cells significantly increased the expression of 
mRNA encoding TGFB1 by 50%, compared to all other treatments (p<0.01 for P4; p<0.05 for 
control and E2+P4). However, the expression of STAT3 and IL12 were not significantly affected 
by hormone treatments in ZR751 cells (Figure 3.4E and 3.4G). 
  




Figure 3.2: Cytokine gene profile in MCF7 mammary epithelial cell lines after 24 hours treatment 
with hormones. 
Graphs represent the variation in the expression of genes A) PGR, B) FKBP51, C) TFGB1, D) TNFA, E) 
STAT3, F) STAT5, and G) IL12 in human mammary epithelial cell lines (MCF7) upon treatment with 
combinations of estradiol (E2) and/or progesterone (P4) for 24 hours (n=3 experiments, each in 
triplicate). Results were normalised to the housekeeper gene MPRL19 so that the average of the 
control samples was 1. Data are mean + SEM and were analysed by one-way ANOVA, followed by post-














































































































Figure 3.3: Cytokine gene profile in T47D mammary epithelial cell lines after 24 hours treatment 
with hormones. 
Graphs represent the variation in the expression of genes A) PGR, B) FKBP51, C) TFGB1, D) TNFA, E) 
STAT3, F) STAT5, and G) IL12 in human mammary epithelial cell lines (T47D) upon treatment with 
combinations of estradiol (E2) and/or progesterone (P4) for 24 hours (n=3 experiments, each in 
triplicate). Results were normalised to the housekeeper gene MPRL19 so that the average of the 
control samples was 1. Data are mean + SEM and were analysed by one-way ANOVA, followed by post-
































































































































Figure 3.4: Cytokine gene profile in ZR751 mammary epithelial cell lines after 24 hours treatment 
with hormones. 
Graphs represent the variation in the expression of genes A) PGR, B) FKBP51, C) TFGB1, D) TNFA, E) 
STAT3, F) STAT5, and G) IL12 in human mammary epithelial cell lines (ZR751) upon treatment with 
combinations of estradiol (E2) and/or progesterone (P4) for 24 hours (n=3 experiments, each in 
triplicate). Results were normalised to the housekeeper gene MPRL19 so that the average of the 
control samples was 1. Data are mean + SEM and were analysed by one-way ANOVA, followed by post-
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In MCF7 mammary epithelial cell lines treated with hormones for 72 hours, the expression of 
mRNA encoding TGFB1 was attenuated by approximately 90% in response to progesterone 
alone or in combination with estradiol, compared to the other treatments (p<0.01) (Figure 
3.5C). The same hormone treatments dramatically reduced the expression of mRNA encoding 
STAT3 and STAT5 genes by more than 100-fold compared to the control-treated cells (p<0.05) 
(Figure 3.5E and 3.5F). Expression of mRNA encoding TNFA was significantly downregulated 
upon progesterone treatment by approximately 60% (p<0.05) compared to estradiol-treated and 
control-treated cells. The mRNA expression of this cytokine was also reduced by 40% when 
MCF7 cells were treated with the combination of estradiol and progesterone (non-significant) 
(Figure 3.5D). Hormone treatments tended to reduce the expression of mRNA encoding IL12 
in MCF7 cells, however, the results were not statistically significant (Figure 3.5G). 
 
In T47D cells, 72 hours treatment with progesterone resulted in induced expression of mRNA 
encoding STAT3 and TNFA by approximately 100% (p<0.05 for STAT3; and p<0.01 for 
TNFA) (Figure 3.6E and 3.6D). The expression of mRNA encoding STAT5 gene was 
dramatically upregulated by approximately 35-fold upon progesterone treatment, compared to 
all other treatments. However, when estradiol and progesterone were combined, the expression 
of this gene tended to be increased by only 7-fold compared to control-treated cells, however, 
this finding was not significant (Figure 3.6F). There was also a tendency for estradiol and 
progesterone to reduce the expression of mRNA encoding IL12 in T7D cells, however, the 
results were not significant (Figure 3.6G). 
 
In ZR751 cells, the expression of mRNA encoding TGFB1 was significantly upregulated by 
100% upon treatment with estradiol compared to progesterone-treated cells (p<0.05) (Figure 
3.7C). Moreover, there was a tendency for estradiol to reduce the expression of mRNA 
encoding STAT3 and STAT5 genes in ZR751 cells, however, the results were not significant. 
Hormonal Regulation of Mammary Epithelial Cells   
65 
 
The expression of mRNA encoding TNFA and IL12 was not significantly affected upon 
treatment with the hormones (Figures 3.7D and 3.7G).  




Figure 3.5: Cytokine gene profile in MCF7 mammary epithelial cell lines after 72 hours treatment 
with hormones. 
Graphs represent the variation in the expression of genes A) PGR, B) FKBP51, C) TFGB1, D) TNFA, E) 
STAT3, F) STAT5, and G) IL12 in human mammary epithelial cell lines (MCF7) upon treatment with 
combinations of estradiol (E2) and/or progesterone (P4) for 72 hours (n=1 experiment in triplicate). 
Results were normalised to the housekeeper gene MPRL19 so that the average of the control samples 
was 1. Data are mean + SEM and were analysed by one-way ANOVA, followed by post-hoc Tukey test 


























































































































Figure 3.6: Cytokine gene profile in T47D mammary epithelial cell lines after 72 hours treatment 
with hormones. 
Graphs represent the variation in the expression of genes A) PGR, B) FKBP51, C) TFGB1, D) TNFA, E) 
STAT3, F) STAT5, and G) IL12 in human mammary epithelial cell lines (T47D) upon treatment with 
combinations of estradiol (E2) and/or progesterone (P4) for 72 hours (n=1 experiment in triplicate). 
Results were normalised to the housekeeper gene MPRL19 so that the average of the control samples 
was 1. Data are mean + SEM and were analysed by one-way ANOVA, followed by post-hoc Tukey test 






























































































































Figure 3.7: Cytokine gene profile in ZR751 mammary epithelial cell lines after 72 hours treatment 
with hormones. 
Graphs represent the variation in the expression of genes A) PGR, B) FKBP51, C) TFGB1, D) TNFA, E) 
STAT3, F) STAT5, and G) IL12 in human mammary epithelial cell lines (ZR751) upon treatment with 
combinations of estradiol (E2) and/or progesterone (P4) for 72 hours (n=1 experiment in triplicate). 
Results were normalised to the housekeeper gene MPRL19 so that the average of the control samples 
was 1. Data are mean + SEM and were analysed by one-way ANOVA, followed by post-hoc Tukey test 
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3.2.3.   GENE REGULATIONS IN MICE MAMMARY GLAND DURING THE 
ESTROUS CYCLE: 
To confirm that adult female C57BL6 mice in these experiments were undergoing regular 
estrous cycles, cycles were tracked for a period of 28 days by histological analysis of vaginal 
smears from 8 weeks of age (n=37 mice in total). The average cycle length was assessed over 
28 days in mice, and a single complete cycle was defined as the first day of estrus through to 
the first day of the next estrus. Furthermore, to verify that estrous cycling was changing the 
morphology of the mammary gland in C57BL6 mice, as has been previously described in (19, 
20), the 4th pair of the mammary glands from each mouse was collected at each of the four 
stages of the cycle and whole-mounts were stained with carmine alum. Examples of mammary 
gland whole-mounts at each phase of the cycle are shown in Figure 3.8. 
 
Vaginal cytology analysis revealed that all mice underwent normal estrous cycling with an 
average cycle length of 6.0 ± 0.2 days. Ductal branching analysis on mammary gland whole-
mounts showed that there were approximately 2.0 ± 0.2 branch points/mm during the estrus 
phase (n=8). Similarly, mice had 2.0 ± 0.1 branch points/mm in their mammary fat pad during 
the metestrus phase (n=10). However, the highest number of mammary ductal branch points 
could be observed at the diestrus phase with 2.3 ± 0.1 branch points/mm (n=10). This was 
significantly higher (20%) than the branch points quantified at the proestrus phase with 1.8 ± 
0.1 branch points/mm (n=9; p<0.05) (Figure 3.8). These studies confirmed that the mice in this 
experimental cohort were undergoing regular ovarian cycling that was affecting mammary 
gland morphology as previously described (19, 20). 
  




Figure 3.8: Ductal branch point analysis in virgin adult mice during the estrous cycle. 
Mammary gland whole-mounts of virgin adult C57BL6 mice were stained with carmine alum at estrus 
(n=8), metestrus (n=10), diestrus (n=10) and proestrus (n=9). A-D) Representative images of mammary 
gland whole-mounts during all stages of the estrous cycle. E) The number of branch points per 
millimetre was calculated. Data are mean + SEM and were analysed by one-way ANOVA followed by 
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To investigate the expression of mRNA encoding cytokines in mice during the estrous cycle, 
third pair mammary glands were collected at each of the four stages of the cycle from female 
adult mice. The comparative Ct method (i.e., 2-(ΔΔCT) method) was used to analyse 
quantitative real-time PCR data, relative to expression of housekeeper gene Rpl13a in each 
mouse. The results were normalised to the average expression of each gene in the estrus phase 
so that the average of mRNA expression at this stage is 1 (n=8-10 per stage). 
 
RT-PCR results showed that there was a high degree of variability in the expression of mRNA 
encoding all genes during the estrous cycle and none of the results were significant (Figure 3.9). 
  




Figure 3.9: Cytokine gene profile in C57BL/6 mice’s mammary glands at different stages of the 
estrous cycle.  
RNA was extracted from the third mammary gland of female adult mice. Using RT-PCR, the messenger 
RNA expression of Pgr, Fkbp51, Tgfb1, Tnfa, Stat3, Stat5, and Il12 was analysed in the mammary gland 
at all stages of the estrous cycle. The average expression of these genes in mice was normalized to the 
average expression in estrus stage so that the average of mRNA expression in this stage is 1 (n=8-10 
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3.3.   DISCUSSION 
The mechanisms by which estrogen and progesterone act in vivo are difficult to disentangle due 
to the complex interactions of endocrine hormones at the cellular, tissue and organismal levels 
(16). Moreover, estrogen and progesterone do not necessarily act directly on the target cells that 
express their receptors, but often they exert their effects on the mammary epithelium indirectly 
via paracrine signalling and stromal-epithelial interactions. Therefore, a variety of experimental 
approaches including cell lines, primary organoids and mouse models were used in this study 
to investigate the effects of ovarian hormones on cytokine expression by human mammary 
epithelial cells. The experiments described in this chapter have clearly demonstrated that 
estradiol and progesterone play a significant role in regulating the expression of transcription 
factors and inflammatory cytokines in mammary epithelial cells. 
 
3.3.1.   HORMONAL REGULATION OF TGFB1 EXPRESSION IN THE 
MAMMARY GLAND 
Expression of TGFB1 in human mammary epithelial cell lines suggests that progesterone alone 
or combined with estradiol has inhibitory effects on TGFB1 production by mammary epithelial 
cells. Similarly, mRNA expression of this cytokine was significantly attenuated in primary 
human mammary epithelial organoids treated with the combination of estradiol and 
progesterone. In the mouse mammary gland, Tgfb1 mRNA expression was variable. However, 
there is a tendency for this gene to be lower during estrus compared to other phases of the cycle. 
According to the literature, the highest expression of latent Tgfb1 is observed at the diestrus 
phase of the ovarian cycle, when circulating progesterone peaks (157). This is associated with 
the increased proliferation and apoptosis rate in response to high levels of progesterone during 
the diestrus phase compared to estrus (19). Conversely, Ewan, Shyamala (157) observed that 
overabundance of Tgfb1 in the mammary gland reduced proliferation of terminal end bud 
epithelium and eventually caused regression of these structures. Furthermore, reduced 
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expression of this cytokine resulted in induced epithelial cell proliferation and ductal extension 
in Tgfb1 knockout mouse models (157).  
 
Epithelial cell-derived Tgfb1 exerts strong inhibitory effects on mammary epithelial cell 
proliferation, demonstrated in a mammary transplant mouse model, where Tgfb1 deficient 
epithelium was transplanted in a Tgfb1 replete host, resulting in increased proliferation of 
mammary epithelial cells in the mammary gland (113). Previous studies highlight that TGFB1 
plays important roles in mediating the complex processes involved in mammary gland 
development (158, 159). Robinson, Silberstein (160) have shown that mammary epithelial cells 
express the gene encoding Tgfb1 at high levels in pubertal and virgin adult mice, whereas it is 
lowly expressed during pregnancy-induced alveolar development, with diminished expression 
in the lactating gland. Therefore, the reduction in TGFB1 mRNA expression in the 
progesterone-stimulated breast cancer cell lines in our studies may suggest the removal of an 
inhibitory signal, and enabling proliferation of mammary epithelial cells, which occurs during 
the luteal phase of cycle. 
 
Sun, Robertson (113) reported that epithelial cell-derived Tgfb1 acts through macrophages and 
other stromal cells during the ovarian cycle and inhibits macrophage activation and immune 
surveillance by suppressing Inducible Nitric Oxide Synthase (iNOS) expression. In turn, these 
stromal actions of epithelial cell-derived TGFB1 might exert feedback effects on the 
epithelium, and affect further expression of TGFB1. In addition, basal TGFB1 expression is 
known to be affected by polymorphism in the TGFB1 gene. The L10P gene polymorphism in 
particular causes elevated TGFB1 at the cellular level and in serum (161). This polymorphism 
is also associated with a significant increase in breast cancer risk in a large international 
consortium study (161). 
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Overall, the roles of TGFB1 in mammary gland development and tumorigenesis are critical. 
TGFB1 suppresses development of breast tumours by inhibiting cell proliferation, inhibiting 
production of growth factors, cytokines and chemokines or by inducing apoptosis. However, 
high expression of this cytokine can promote tumour invasion and metastasis by impairing 
immune surveillance and increasing angiogenesis (162). Also, elevated TGFB1 expression has 
been found in many breast cancer patients and strong correlations between TGFB1 
polymorphism and breast cancer risk are reported, as highlighted above. Our findings in this 
experiment suggest that TGFB1 expression in the mammary epithelial cells is inhibited by 
progesterone. It appears that expression of this cytokine varies widely between women and 
fluctuates according to altered ovarian hormone signalling throughout the different phases of 
the ovarian cycle. However, the exact mechanisms through which the ovarian hormones affect 
TGFB1 expression are still unclear. Further research is required to investigate the roles of this 
cytokine in the mammary gland during the menstrual cycle and its link to breast cancer 
development. 
 
3.3.2.   SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 
(STAT 3 AND STAT5): 
Our results derived from the cell lines and mouse mammary gland suggest that STAT3 is 
positively regulated by progesterone. Messenger RNA expression of STAT3 was significantly 
increased in progesterone-responsive T47D and ZR751 cells upon treatment with progesterone. 
There was also a tendency for the expression of this gene to be increased during the 
progesterone-dominant diestrus phase in mice. On the contrary, hormone treatments of the 
estrogen-responsive MCF7 cells for 72 hours resulted in a dramatic reduction of STAT3. 
Previous studies have demonstrated that induced expression of STAT3 can be a death signal 
for activating mammary epithelial cell apoptosis and returning the mammary gland to its basic 
structure. This might affect the function and phenotype of immune cells such as macrophages 
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and mast cells since STAT3 regulates the influx of these cells during involution and drives a 
polarisation of macrophages towards an alternatively activated (M2) phenotype (163). On the 
other hand, a lack of STAT3 in the mammary epithelium is associated with a significant 
increase in the abundance of iNOS, suggesting the existence of classically activated 
macrophages (163). In addition, STAT3 regulates the expression of genes associated with 
innate immunity during involution and mediates tissue remodelling by balancing the 
inflammatory and anti-inflammatory signalling (62). Thus, it is likely that dysregulation of 
STAT3 by ovarian hormones influences the function of immune cells and promotes an 
inflammatory environment in the mammary gland which has pro-tumorigenic potential (164). 
 
Similar results were obtained for STAT5 upon treatment with estradiol and progesterone in the 
cell lines. However, transcriptional changes observed in STAT5 seem to be more significant 
than the changes observed in STAT3, suggesting that hormone signalling strongly activates this 
gene in the mammary gland. It is worth pointing out that despite their high homology, STAT3 
and STAT5 have opposing roles in mammary gland development as well as in breast cancer 
(165). Overexpression of Stat5 in the mouse mammary gland resulted in induced mammary 
epithelial proliferation and differentiation and delayed involution by preventing Stat3 
activation, and also contributed to mammary tumorigenesis (166). In breast cancer, these 
transcription factors regulate a subset of target genes (such as BCL6) in an opposite fashion 
such that the inhibitory effects of STAT5 on gene expression is dominant over the stimulatory 
effects of STAT3 (63). Given that STAT5 is essential for mammary epithelial cell survival and 
maintenance (167), it is likely that dysregulation of this gene by ovarian hormones may alter 
cell proliferation and differentiation rate, and increase the risk of DNA damage in the mammary 
epithelium. Although the roles of STAT3 and STAT5 in mammary gland development and 
tumorigenesis are known, the importance of these transcription factors in the mammary gland 
during the menstrual cycle is not well-understood. Given the roles they play in breast cancer, 
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their impaired activity during the menstrual cycle could represent a genuine risk factor for this 
disease. 
 
3.3.3.   HORMONE REGULATION OF PRO-INFLAMMATORY CYTOKINES 
IN THE MAMMARY GLAND: 
Our mouse studies show that the mRNA expression of Tnfa was highly variable; however, there 
is a trend for this cytokine to be induced during the estrus phase of the cycle. This is in parallel 
with the observations by Dasari, Sharkey (111) who showed using multiplex assay that the 
protein concentration of Tnfa is increased in the mammary gland during the estrus compared 
with other phases. These observations suggest that estradiol has stimulatory effects on Tnfa 
expression in the mammary gland. This is supported by our findings in MCF7 cells treated with 
estradiol (for 24 hours) which resulted in a 50% increase in TNFA mRNA expression. TNFA 
can either induce tumour necrosis and apoptosis or promote tumour development (168). 
Stimulation of T47D cells with TNFA in the presence of estradiol resulted in an enhanced breast 
cancer proliferation in vitro (169). However, our results along with previous observations by 
Dasari, Sharkey (111) show that progesterone has significant inhibitory effects on the 
expression of TNFA. Thus, an increase in the expression of this cytokine during the estrus phase 
may promote a pro-inflammatory and tumorigenic environment in the mammary gland, which 
may get dampened by progesterone at other phases of the cycle. 
 
On the other hand, the expression of IL12 was not noticeably affected by hormone treatments. 
It is important to note that pro-inflammatory cytokines are not constitutively expressed by 
normal cells in the tissue. Indeed, they require inflammatory insults, such as infection or 
necrosis, in order to be highly expressed and promote inflammatory responses (170). The 
variability in regulation of the cytokines reported in the literature and in our study, suggest that 
other stromal components rather than epithelial cells might affect their expression in the 
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mammary gland. As mentioned earlier, many different cell types such as adipocytes, fibroblasts, 
macrophages and mast cells can produce these cytokines. Therefore, to fully understand the 
mechanisms involved in the hormonally regulated cytokine production in the mammary gland, 
the cell sources for each cytokine should be identified. 
 
3.3.4.   LIMITATIONS:  
Each model used in this study possesses limitations which might have affected the results. 
Analysis of RT-PCR results obtained from primary organoids and mouse mammary glands 
demonstrates enormous variability in mRNA expression between different samples, which 
makes it very difficult to derive any conclusion from the data. However, this was not surprising, 
as inter-individual variability is expected due to many genetic and potentially epigenetic factors. 
This heterogeneity truly represents the nature of primary tissues. Another important factor that 
might explain this variability is that the organoids growing in this model recapitulate estrogen 
or progesterone receptor expression observed in vivo. Between 10 and 25% of epithelial cells 
from human breast tissue express estrogen or progesterone receptors in vivo (126). Hence, only 
a low proportion of cells respond to estrogen and progesterone; demonstrating that hormone 
regulation in some samples of primary mammary epithelium can be quite challenging to detect. 
To validate the hormone responsiveness of our models, we analysed the expression of mRNA 
encoding the estrogen-responsive gene encoding PGR and the progesterone-responsive gene 
encoding FKBP51, however, the results were highly variable amongst the samples. Future 
studies could investigate whether higher concentrations of hormones for the organoid cultures, 
and pre-treatment of these cells with estradiol to induce progesterone receptor expression, could 
result in a less variable response. It is also noteworthy that freezing the primary mammary 
epithelial organoids prior to culture might have affected their responsiveness to estrogen and 
progesterone. Future studies should investigate this.  
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Furthermore, studies in the cell lines revealed that the time course of hormone treatments can 
significantly affect the gene expression. Although all cell lines showed great responsiveness to 
estradiol and progesterone, the extent of hormonal response varied in some cells depending on 
the treatment time course. For instance, progesterone treatment of T47D cells for 24 hours 
increased the expression of mRNA encoding FKBP51 up to 4-fold, while 72 hours treatment 
of these cells resulted in a 10-fold increased expression of this gene. This suggests that longer 
exposure to hormones would activate a higher number of receptors, leading to a larger effect 
on gene expression, possibly through an indirect pathway. A similar effect could be observed 
in the mRNA expression of our genes of interest. For instance, hormone treatments of MCF7 
cell lines for 24 hours did not have any effect on the expression of mRNA encoding STAT3 
and STAT5; however, 72 hours treatment of these cells with estradiol and progesterone resulted 
in a significant reduction in the expression of these genes. Such effects could also be due to the 
half-life of the specific mRNA, which is an important factor in determining how long it takes 
to detect a change in the mRNA level of a specific gene (171). Nonetheless, the results obtained 
from these experiments suggest that treating cells with hormones at different time points 
produces different results, most of which can depend on the hormone receptor profile of the 
cells.  
 
3.4.   CONCLUSION 
Using three different cell culture settings, we showed that hormone regulation of cytokines in 
the mammary epithelium is dependent on the hormone receptor responsiveness of the cells, as 
well as the exposure time to the ovarian hormones. However, there are inconsistent results from 
different mouse and cell line studies, and primary organoid cultures exhibit too much variability 
to significantly confirm hormonal regulation. On the other hand, most of the cytokines have 
paradoxical activities in regulation of mammary gland development and breast tumorigenesis. 
Clearly, hormonal regulation of immune-associated cytokines is complex and it is likely that 
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the expression of these cytokines is affected by a number of factors such as infection, genetics, 
and interactions with immune cells and other components of the microenvironment. Therefore, 
further experiments are required to understand the precise roles and effects of these cytokines 
in mammary gland development and breast cancer risk. Studies in the following chapters will 
investigate the role of other important transcription factors in regulating cytokine expression in 






THE ROLE OF ELF5 IN HORMONE REGULATED CYTOKINE 
EXPRESSION BY MAMMARY EPITHELIAL CELLS 
 
 
4.1.   INTRODUCTION 
The previous chapter demonstrated that estradiol and progesterone regulate the mRNA 
expression of specific transcription factors and inflammatory cytokines in mammary epithelial 
cells. However, the precise molecular mechanisms through which these hormones regulate 
cytokine expression in epithelial cells is not well-defined. To address this, we focused on an 
important epithelial cell-specific transcription factor, and analysed its role in hormone regulated 
cytokine secretion by mammary epithelial cells.  
 
E74-like factor 5 (ELF5, also known as ESE-2) is an epithelial cell-specific member of the large 
family of Ets transcription factors, found in the lung, kidney, placenta, and most prominently 
in mammary glands (75, 76). ELF5 plays roles in mammary epithelial cell proliferation and 
differentiation (77). It specifies the mammary secretory cell lineage and is mainly expressed by 
the luminal progenitor cells in the mammary gland (78). Studies in Elf5 null mutant mouse 
models demonstrate that these animals are either unable to lactate due to failed alveolar 
development, or exhibit impaired functional secretory units due to improper differentiation of 
alveoli. This indicates that ELF5 is a crucial transcriptional mediator required for structural and 
functional morphogenesis of lobuloalveoli (77).




The expression of ELF5 is altered in various cancers (172) and implicated in breast cancer as a 
critical regulator of tumour subtypes. ELF5 is involved in mammary tumour metastasis in the 
luminal A breast cancer subtype, by recruiting particular cells of the innate immune system 
such as myeloid-derived suppressor cells (82). Furthermore, high expression of ELF5 correlates 
with more aggressive basal cancers and resistance to anti-estrogen cancer therapies (84). ELF5 
is a direct transcriptional target of the progesterone receptor, and its expression is increased by 
progestin treatment in vivo in mice and in vitro in T47D human breast cancer cell lines (85). 
ELF5 can be considered an essential mediator of progesterone-regulated mammary epithelial 
cell proliferation and differentiation. It might affect cancer susceptibility through the production 
of cytokines that affect interactions between the mammary epithelium and surrounding immune 
cell populations. Little is known of the role of this transcription factor in directing epithelial 
cell-specific cytokine secretion and its association with immune cells. However, using 
chromatin immunoprecipitation sequencing (ChIP-Seq), Ormandy and his colleagues found 
that ELF5 binding sites are located near the promoter region of specific immune-related 
cytokines such as CXCL12, S100A8, and S100A9, suggesting these to be key targets of ELF5 
function in the mammary gland and in breast cancer (Unpublished observations). 
 
CXCL12 is a homeostatic chemokine for lymphocytes and monocytes and has roles in breast 
cancer progression (117, 118). It is primarily expressed in hormone receptor-positive luminal 
cells (119), and its expression is strongly upregulated in estrogen-treated MCF7 breast cancer 
cells (120). The calcium-binding proteins S100A8 and S100A9, expressed by neutrophils, 
macrophages, and activated monocytes (121), are damage-associated molecular pattern 
(DAMP) molecules that are overexpressed in inflammation and breast cancer suggesting that 
they might have a potential role in inflammation-associated tumorigenesis (123). Also, their 
expression is associated with estrogen receptor loss in breast cancer cell lines (122). 
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Nonetheless, the molecular mechanisms through which these cytokines are involved in breast 
cancer is not well understood. Considering the role of hormone-regulated ELF5 in breast 
cancer, it is possible that it regulates the expression of immune-related cytokines to either 
promote immune tolerance or dampen immune surveillance in the breast, subsequently 
increasing the risk of cancer. The experiments described in this chapter were devised to 
investigate the role of ELF5 transcription factor in regulating immune cell-associated cytokines 
by mammary epithelial cells, to better understand the role of ELF5 in the mammary gland.  
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4   
4.2.   RESULTS: 
4.2.1.   MESSENGER RNA EXPRESSION OF CYTOKINES IN HORMONE-
TREATED ORGANOIDS: 
To investigate the effects of estrogen and progesterone on mammary epithelial cell cytokine 
production, primary human mammary epithelial organoids (n=6) were embedded in Matrigel 
and treated with combinations of estradiol (10nM) and progesterone (100nM) for 72 hours. The 
abundance of mRNA encoding cytokines ELF5, CXCL12, S100A8, and S100A9 were 
examined from hormone-treated human epithelial organoids. The comparative Ct method (i.e. 
2-(ΔΔCT) method) was used to analyse quantitative real-time PCR data, relative to the mean 
of expression of housekeeping genes MPRL19 from the same sample. 
 
The expression of all cytokines was highly variable amongst patients with no trend, and no 
statistically significant result was obtained (Figure 4.1). 
  





Figure 4.1: Hormonal regulation of mRNA encoding cytokines in 3D organoid cultures. 
Box plots represent the mean variation in the expression of genes A) ELF5, B) CXCL12, C) S100A8, and 
D) S100A9 from Matrigel-embedded human epithelial organoids upon treatment with combinations 
of estradiol (E2) and progesterone (P4) for 72 hours (n=6). Data are Mean ± SEM; normalized to the 
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4.2.2.   MESSENGER RNA EXPRESSION OF CYTOKINES IN HUMAN 
MAMMARY EPITHELIAL CANCER CELL LINES:  
To investigate the effects of estrogen and progesterone on cytokine production by mammary 
epithelial cells, human mammary epithelial cancer cell lines cultured at optimal density were 
treated with estradiol (10nM) and progesterone (100nM). Messenger RNA encoding cytokines 
ELF5, CXCL12, S100A8, and S100A9 was quantified in MCF7, T47D, and ZR751 human 
mammary epithelial cell lines treated with various combinations of estradiol and progesterone 
for i) 24 hours and ii) 72 hours. The comparative Ct method (i.e., 2-(ΔΔCT) method) was used 
to analyse quantitative real-time PCR data, relative to expression of housekeeper gene MPRL19 
in each sample. The results were normalised to this gene so that the average of the control 
samples was 1. 
 
In MCF7 cell lines treated with hormones for 24 hours, progesterone increased abundance of 
ELF5 mRNA by 50% (p<0.05) compared to ethanol-treated control cells (Figure 4.2A). 
However, the same effect was not observed when both estradiol and progesterone were 
combined as a treatment. Although the expression of all other cytokines was variable, there was 
a trend for CXCL12 to be upregulated by about 50% upon treatment with either estradiol or a 
combination of hormones (non-significant) (Figure 4.2B). 
  
In T47D cells, 24 hours treatment with estradiol or a combination of hormones had inhibitory 
effects on the expression of mRNA encoding ELF5 which was downregulated by 
approximately 50% compared with the controls (p<0.01) (Figure 4.3A). Moreover, 
progesterone alone or combined with estradiol significantly attenuated CXCL12 mRNA by 
more than 90% (p<0.01) compared to estradiol-treated and control cells (Figure 4.3B). The 
expression of mRNA encoding S100A8 was significantly increased by 50% upon treatment 
with progesterone, compared with estradiol-treated cells (p<0.05). However, no changes were 
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observed in the expression of mRNA encoding S100A9 in cells treated with estradiol and 
progesterone either alone or in combination (Figure 4.3D). 
  
In ZR751 cell lines, progesterone treatment for 24 hours resulted in a significant increase (by 
approximately 50%) in the expression of mRNA encoding ELF5 and S100A9, compared with 
estradiol-treated and control cells (p<0.05 for both genes) (Figure 4.4A and 4.4D). Treatment 
of these cells with estradiol dramatically elevated the expression of mRNA encoding CXCL12 
by 35-fold (p<0.01), an effect which was dampened by approximately 10-fold when 
progesterone and estradiol were combined (p<0.01) (Figure 4.4B). 
  




Figure 4.2: Cytokine gene profile in MCF7 mammary epithelial cell lines after 24 hours treatment 
with hormones.  
Graphs represent the variation in the expression of genes A) ELF5, B) CXCL12, C) S100A8, and D) S100A9 
in human mammary epithelial cell lines (MCF7) upon treatment with combinations of estradiol (E2) 
and progesterone (P4) for 24 hours (n=3 experiments, each in triplicate). Results were normalised to 
the housekeeper gene MPRL19 so that the average of the control samples was 1. Data are mean + SEM 









































































Figure 4.3: Cytokine gene profile in T47D mammary epithelial cell lines after 24 hours treatment 
with hormones.  
Graphs represent the variation in the expression of genes A) ELF5, B) CXCL12, C) S100A8, and D) S100A9 
in human mammary epithelial cell lines (T47D) upon treatment with combinations of estradiol (E2) and 
progesterone (P4) for 24 hours (n=3 experiments, each in triplicate). Results were normalised to the 
housekeeper gene MPRL19 so that the average of the control samples was 1. Data are mean + SEM 













































































Figure 4.4: Cytokine gene profile in ZR751 mammary epithelial cell lines after 24 hours treatment 
with hormones. 
Graphs represent the variation in the expression of genes A) ELF5, B) CXCL12, C) S100A8, and D) S100A9 
in human mammary epithelial cell lines (ZR751) upon treatment with combinations of estradiol (E2) 
and progesterone (P4) for 24 hours (n=3 experiments, each in triplicate). Results were normalised to 
the housekeeper gene MPRL19 so that the average of the control samples was 1. Data are mean + SEM 
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Although it was statistically non-significant, the expression of mRNA encoding ELF5 tended 
to be dampened by about 50% upon hormone treatments of MCF7 cell lines (Figure 4.5A). 
Progesterone treatment alone and in combination with estradiol tended to reduce CXCL12 
mRNA expression by more than 80% in these cells (non-significant results). The expression of 
mRNA encoding S100A8 was significantly upregulated by 6-fold upon treatment with the 
combination of estradiol and progesterone compared to all other cells (p<0.01) (Figure 4.5C). 
Estradiol treatment induced the expression of mRNA encoding S100A9 by approximately 3-
fold compared to all other treatments (p<0.01) (Figure 4.5D). 
 
The most dramatic and consistent results were obtained from T47D cells treated with hormones 
for 72 hours. Progesterone alone and in combination with estradiol increased the expression of 
mRNA encoding ELF5 by approximately 200% and 100%, respectively (p<0.01) (Figure 
4.6A). The mRNA expression of CXCL12 was significantly attenuated in the cells treated with 
either progesterone alone (by approximately 80%; p<0.01) or the combination of estradiol and 
progesterone (by approximately 90%; p<0.01), compared to estradiol-treated and control-
treated cells (Figure 4.6B). Also, progesterone treatment significantly increased the mRNA 
expression of genes encoding S100A8 and S100A9 by 30- and 15-fold, compared to estradiol-
treated and control-treated cells (p<0.01). These effects were dampened by 60% when estradiol 
and progesterone were combined (p<0.01) (Figure 4.6C and 4.6D). 
 
72 hours treatment of ZR751 cells with estradiol resulted in a significant upregulation of 
CXCL12 cytokine (by approximately 20-fold), compared to progesterone-treated and control-
treated cells (p<0.01). Also, the combination of hormones tended to increase CXCL12 mRNA 
expression by approximately 10-fold; however, this result was not statistically significant 
(Figure 4.7B). None of the other results obtained from hormone-treated ZR751 cells were 
statistically significant. However, progesterone tended to decrease the expression of mRNA 
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encoding ELF5 by approximately 50% compared to control cells (Figure 4.7A). The expression 
of S100A8 and S100A9 was not affected by hormone treatments (Figure 4.7C and 4.7D). 
  




Figure 4.5: Cytokine gene profile in MCF7 mammary epithelial cell lines after 72 hours treatment 
with hormones. 
Graphs represent the variation in the expression of genes A) ELF5, B) CXCL12, C) S100A8, and D) S100A9 
in human mammary epithelial cell lines (MCF7) upon treatment with combinations of estradiol (E2) 
and progesterone (P4) for 72 hours (n=1 experiment in triplicate). Results were normalised to the 
housekeeper gene MPRL19 so that the average of the control samples was 1. Data are mean + SEM 











































































Figure 4.6: Cytokine gene profile in T47D mammary epithelial cell lines after 72 hours treatment 
with hormones.  
Graphs represent the variation in the expression of genes A) ELF5, B) CXCL12, C) S100A8, and D) S100A9 
in human mammary epithelial cell lines (T47D) upon treatment with combinations of estradiol (E2) and 
progesterone (P4) for 72 hours (n=1 experiment in triplicate). Results were normalised to the 
housekeeper gene MPRL19 so that the average of the control samples was 1. Data are mean + SEM 
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Figure 4.7: Cytokine gene profile in ZR751 mammary epithelial cell lines after 72 hours treatment 
with hormones. 
Graphs represent the variation in the expression of genes A) ELF5, B) CXCL12, C) S100A8, and D) S100A9 
in human mammary epithelial cell lines (ZR751) upon treatment with combinations of estradiol (E2) 
and progesterone (P4) for 72 hours (n=1 experiment in triplicate). Results were normalised to the 
housekeeper gene MPRL19 so that the average of the control samples was 1. Data are mean + SEM 
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4.2.3.   MESSENGER RNA EXPRESSION OF CYTOKINES IN THE MOUSE 
MAMMARY GLAND DURING THE ESTROUS CYCLE: 
To investigate the effects of ovarian hormones on cytokine expression during the estrous cycle 
in the mammary gland, third pair mammary glands from wildtype C57BL/6 mice were collected 
at each of the four stages of the cycle. Messenger RNA expression of cytokines Elf5, Cxcl12, 
S100a8, and S100a9 were examined from the mammary glands at each stage of the estrous 
cycle. The comparative Ct method (i.e. 2-(ΔΔCT) method) was used to analyse quantitative 
real-time PCR data, relative to the mean of expression of housekeeping gene Rpl13a from the 
same sample. 
 
Although none of the results were statistically significant, the expression of all four cytokines 
tended to change over the course of the estrous cycle. The expression of mRNA encoding Elf5 
was increased by 100% during metestrus and diestrus phases of the cycle compared to the estrus 
phase, while it dropped to baseline during proestrus. Cxcl12 expression was increased during 
metestrus by about 70%; however, it decreased gradually towards the proestrus phase. The 
expression of mRNA encoding S100a8 and S100a9 were also upregulated during diestrus (by 
100 % and 60% respectively) compared to the estrus phase of the cycle (p=0.088 for S100a8 
and p=0.334 for S100a9) (Figure 4.8). 
  




Figure 4.8: Cytokine gene profile in C57BL/6 mice’s mammary glands at different stage of the 
estrous cycle. 
RNA was extracted from the third mammary gland of wildtype mice. Using RT-PCR, the messenger RNA 
expression of Elf5, Cxcl12, S100a8 and S100a9 was analysed in the mammary gland at all stages of the 
estrous cycle. The average expression of these genes in mice was normalized to the average expression 
in estrus stage so that the average of mRNA expression in this stage is 1 (n=8-10 per stage). Data are 
mean + SEM, and were analysed using a one-way ANOVA, followed by Tukey post-hoc test.  
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4.2.4.   THE EFFECT OF PROGESTERONE ON CYTOKINE EXPRESSION IN 
T47D CELLS: 
The most dramatic changes in the expression of mRNA encoding cytokines were observed in 
the T47D cell line treated with progesterone for 72 hours. Hence, further studies were conducted 
using T47D cells in such culture condition. To confirm the efficacy and reproducibility of 
results obtained from the previous section, T47D cells were treated with progesterone alone 
(100nM) for 72 hours. Messenger RNA expression of genes encoding ELF5, CXCL12, 
S100A8, and S100A9 was examined using RT-PCR. The comparative Ct method (i.e., 2-
(ΔΔCT) method) was used to analyse quantitative real-time PCR data, relative to expression of 
housekeeper gene MPRL19 in each treatment group. The results were normalised to this gene 
so that the average of the control samples was 1. 
 
There are dramatic changes in the expression of all cytokines of interest in T47D cells treated 
with progesterone. As it can be seen from Figure 4.9, ELF5 mRNA expression was induced 
significantly by 150% compared to the control cells (p<0.05). This was followed by a 
significant rise in the expression of mRNA encoding S100A8 and S100A9 (20- and 13-fold, 
respectively; p<0.05)). In addition, the expression of CXCL12 was reduced by more than 80% 
(p<0.01) upon treatment with progesterone compared to the control. 
  




Figure 4.9: Cytokine gene profile in T47D mammary epithelial cell lines after 72 hours treatment 
with progesterone. 
Graphs represent the variation in the expression of genes A) ELF5, B) CXCL12, C) S100A8, and D) S100A9 
in human mammary epithelial cell lines (T47D) upon treatment with progesterone (P4) for 72 hours 
(n=6 experiment, each in triplicate). Results were normalised to the housekeeper gene MPRL19 so that 
the average of the control samples was 1. Data are mean + SEM and were analysed by one-way ANOVA, 
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4.2.5.   SIRNA TRANSFECTION OF T47D CELL LINE: 
To investigate the role of ELF5 in the hormonal regulation of cytokine production by mammary 
epithelial cells, the human mammary epithelial cell line T47D was transfected with 
SMARTpool human ELF5 siRNA and/or non-targeting siRNA oligos for 24 hours. Cells were 
then treated with progesterone for 72 hours post-transfection. Messenger RNA expression of 
genes ELF5, CXCL12, S100A8 and S100A9 was examined from the transfected cells. The 
comparative Ct method (i.e. 2-(ΔΔCT) method) was used to analyse quantitative real-time PCR 
data, relative to expression of ELF5 in the cells transfected with the non-targeting siRNA. 
 
ELF5 gene was silenced at the mRNA level with more than 80% efficiency (p<0.05) compared 
to the cells which were transfected with non-targeted siRNA oligos (Figure 4.10A). All 
cytokines were hormonally regulated and followed a similar trend as it was observed in Figure 
4.9. However, when ELF5 was knocked down, the expression of mRNA encoding S100A8 and 
S100A9 genes were increased by about 100% in the cells treated with progesterone (p<0.05 for 
S100A9). On the other hand, CXCL12 mRNA was attenuated by about 50% (p<0.05) in the 
progesterone-treated cells lacking ELF5 compared to the cells which had functional ELF5. 
Moreover, silencing this transcription factor did not affect the expression of any of the cytokines 
in the hormone-free control-treated cells (Figure 4.10). 
 
ELF5 knockdown efficiency was also assessed at the protein level using Western Blot. Protein 
was extracted from transfected cells, and ELF5 was detected in the samples using monoclonal 
ELF5 antibody. Consistent with the results obtained from RT-PCR, the protein expression of 
ELF5 increased with progesterone treatment (approximately 150% compared to the control), 
particularly in the cells transfected with non-targeting siRNA. Although ELF5 protein was not 
reduced in control-treated cells, it was attenuated in progesterone-treated cells. (Figure 4.11).  




Figure 4.10: Progesterone regulation of cytokines in T47D cell line transfected with ELF5 siRNA and 
non-targeting siRNA. 
A) ELF5 mRNA knockdown efficiency in T47D cells was assessed using RT-PCR. Graphs represent the 
variation in the expression of genes B) ELF5, C) CXCL12, D) S100A8, and E) S100A9 in ELF5-transfected 
human mammary epithelial cell lines (T47D) upon treatment with progesterone (P4) for 72 hours (n=4 
experiments, each in triplicate). Results were normalised to the housekeeper gene MPRL19 so that the 
average of the control samples in non-targeting transfected cells was 1. Data are mean + SEM and were 
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Figure 4.11: Western blot for progesterone regulation of ELF5 in T47D cell line transfected with 
ELF5 siRNA and non-targeting siRNA. 
T47D cells were transfected with either ELF5 siRNA or non-targeting siRNA oligos for 24 hours and 
treated with either progesterone (100nM) or ethanol control for 24 hours post transfection. The 
comparative Ct method (i.e. 2-(ΔΔCT) method) was used to analyse quantitative real-time PCR data, 
relative to expression of ELF5 in the cells transfected with the non-targeting siRNA. A) Whole cell lysate 
extracted from T47D cell line was subjected to western blotting with a monoclonal ELF5 antibody. A 
beta actin monoclonal antibody was used as a loading control. B) Bar graph represents the expression 
of ELF5 protein in the cells transfected with ELF5 siRNA, relative to the expression of control-treated 
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4.2.6.   PROTEIN EXPRESSION OF S100A8 IN HORMONE-TREATED 
HUMAN BREAST EXPLANTS: 
To investigate the effects of estrogen and progesterone on protein expression of S100A8, human 
breast tissues were dissected into small pieces and cultured on dental sponges as explants (n=8). 
Explant cultures were then treated with a combination of hormones for 3 days, sectioned, fixed 
and paraffin embedded. The paraffin-embedded sections were incubated with mouse anti-
human S100A8 monoclonal antibody overnight, stained with streptavidin/Alexa Fluor 594, and 
counterstained with DAPI. 
 
The intensity of S100A8 expression (brown regions) in the mammary gland was scored in three 
random clusters of epithelial alveolar buds in each section (Figure 4.12). The scoring system 
was based on the intensity of positive stained cells in each section compared to the negative 
controls in a blinded analysis. Indeed, positive cells were analysed in two ways: epithelial cells 
with visible haematoxylin stained nuclei were included in the ‘epithelial’ analysis, while 
stromal regions with positive staining were scored and categorized into ‘stromal’ analysis. 
  




Figure 4.12: Hormonal regulation of S100A8 in human mammary epithelial explant models (n=8). 
Mammary epithelial explant cultures were treated with ethanol or a combination of estradiol and 
progesterone and the tissue sections were stained with S100A8 monoclonal antibody. Representative 
images of human breast explants stained with S100A8 antibody are shown: A) Negative control for 
control-treated breast tissue explant, B) control-treated explant stained with S100A8 monoclonal 
antibody, C) Negative control for E2+P4 treated explant, D) E2+P4 treated explant stained with S100A8 
antibody. Box plots represent the mean score of S100A8 expression from human ex vivo cultures upon 
treatment with combination of hormones and/or ethanol: E) S100A8 expression in the mammary 
epithelial cells, F) S100A8 expression in the mammary stromal regions. Data are mean ± SEM and were 
statistically analysed using an unpaired t test.  
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4.3.   DISCUSSION: 
From the results there are two main observations. First, ELF5 and its putative downstream 
cytokines were hormonally regulated in mammary epithelial cells. Second, silencing ELF5 at 
the mRNA level resulted in induction of S100A8 and S100A9, and a reduction in the mRNA 
expression of CXCL12 in progesterone-stimulated cells. These results suggest that ELF5 
reduces, but does not eliminate the pro-inflammatory effects of progesterone on these cytokines. 
Indeed, these expression patterns could be related to activation of specific signalling pathways 
governed by ELF5 transcription factor.  
 
4.3.1.   HORMONE REGULATION OF ELF5 AND ITS DOWNSTREAM 
CYTOKINES 
Our results show that estradiol and progesterone regulate the expression of mRNA encoding 
ELF5 and its downstream cytokines in mammary epithelial cells. S100A8 and S100A9 act as 
pro-inflammatory danger signals and are released to the extracellular microenvironment in 
response to inflammation and cell damage (173). Acting as DAMPs, they bind to cell surface 
receptors such as receptor of advanced glycation end product (RAGE) and Toll-like receptors 
(TLRs), as part of the innate immune signalling that recognizes danger signals derived from 
pathogens, cellular stress, or damaged cells, and subsequently mounts intracellular immune 
responses (174, 175). S100A8 and S100A9 also serve as potential markers of tumour invasion 
and metastasis, and their expression is reported to be correlated with tumour progression and a 
poor outcome in breast cancer patients (176). Therefore, it is likely that upregulation of S100A8 
and S100A9 in the mammary gland induces myeloid cell recruitment and exerts inflammatory 
responses which can assist in inflammation-associated tumorigenesis. 
 
The dramatic changes in the mRNA expression of CXCL12 in the cell lines suggest that 
estradiol strongly activates CXCL12, whereas progesterone has inhibitory effects on this 
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chemokine. This is also in line with our mouse studies which illustrated that Cxcl12 mRNA 
expression is higher during the metestrus phase compared to all other stages of the estrous cycle. 
CXCL12 binds to its receptor and activates a wide array of signal transduction pathways which 
mediate the migration and survival of monocytes and lymphocytes. Indeed, neutrophils and 
macrophages express CXCR4 on their surface which allows them to migrate towards CXCL12 
present at the site of inflammation. Moreover, CXCL12 signalling can induce the differentiation 
of monocytes into proangiogenic, immunosuppressive macrophages in the tumour 
microenvironment (177). CXCL12 acts as a direct target for ERA, and estradiol induces its 
secretion in MCF7 cancer cells (120), however, its association with progesterone in the 
mammary epithelium is not well-understood. In 2011, Okada, Okamoto (178) reported that 
progestins attenuate estradiol-induced CXCL12 production in vitro in hormone-responsive 
human endometrial stromal cells. Our results agree with this, showing that progesterone has 
inhibitory effects on the expression of CXCL12 in malignant breast epithelial cells. Although 
downregulation of this chemokine in dermal wound tissues has previously been observed in 
response to inflammation (179), it is still not clear how progesterone affects its function in the 
mammary gland. 
 
Collectively, from these results, it can be suggested that progesterone produces an inflammatory 
signal in the breast epithelium which is associated with an upregulation of S100A8 and S100A9 
and a reduction in the expression of CXCL12. These cytokines play roles in the recruitment of 
inflammatory and resident immune cells; hence, alterations in their expression due to hormonal 
fluctuations may influence the phenotype and function of immune cells in the mammary gland 
microenvironment. It would be of great interest to understand the precise cellular mechanisms 
and signalling pathways that govern these hormonal effects in the mammary gland. In this 
context, it was hypothesised that transcription factor ELF5 has a role in directing the expression 
of these cytokines. 




4.3.2.   THE ROLE OF ELF5 IN HORMONE-REGULATED CYTOKINE 
EXPRESSION: 
Different transcription factors intrinsic to the mammary epithelium have been identified, and 
often involved in both normal mammary gland development and in development of breast 
cancer; however, their target genes are still not well-defined (51). An important candidate 
implicated in mammary gland development and breast cancer risk is ELF5. A few studies have 
already investigated the associations of ELF5 and the ovarian hormones in the mammary gland. 
Using mammary epithelial cell lines, the effect of ELF5 expression on 289 estrogen-induced 
genes was analysed and it was noted that the predominant effect of ELF5 expression is to 
suppress estrogen-induced gene expression (75). Moreover, Hilton, Kalyuga (85) showed that 
ELF5 plays a role in progestin-mediated regulation processes such as cell cycle control, 
adhesion and cell signalling. However, there is still limited information about ELF5 might 
impact on the immune microenvironment through cytokine expression by mammary epithelial 
cells. In our study, T47D cell lines were used to investigate the role of ELF5 in mediating the 
hormonally regulated cytokine expression by mammary epithelial cells in vitro. Silencing ELF5 
gene at the mRNA level resulted in induction of S100A8 and S100A9 by 100%, and a 50% 
reduction in the mRNA expression of CXCL12 in progesterone-stimulated cells. This suggests 
that ELF5 reduces, but does not eliminate the pro-inflammatory effects of progesterone on these 
cytokines. These expression patterns could be related to activation of specific signalling 
pathways governed by ELF5 transcription factor. 
 
Although the importance of ELF5 in regulating normal mammary gland development and 
function is well established, there is much debate on its role in breast tumorigenesis. A few 
studies suggest that this transcription factor contributes to cancer development and metastasis 
(180, 181), while others consider ELF5 as a tumour suppressor gene (79). In 2015, Gallego-
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Ortega, Ledger (82) noted that ELF5 overexpression promotes the recruitment of myeloid 
derived suppressor cells (MDSCs) in luminal breast cancer and drives metastasis into the lungs 
in mice. In contrast, Chakrabarti, Hwang (81) reported that silencing ELF5 in polyoma middle 
T antigen (PyMT) mouse mammary glands and T47D cancer cells induce epithelial to 
mesenchymal transition (EMT) and metastasis (81). MDSCs are a group of myeloid cells 
including myeloid progenitors, immature granulocytes, dendritic cells, and macrophages which 
have critical roles in suppression of immune responses and induction of tolerance in cancer 
(182). Although we did not investigate the role and abundance of these cells, our results suggest 
that ELF5 negatively regulates the expression of S100A8 and S100A9 which have been 
implicated in MDSC’s function. Upregulation of S100A8 and S100A9 impairs differentiation 
of mature myeloid cells such as macrophages and dendritic cells and induces accumulation of 
MDSCs (183). It has also been reported that pro-inflammatory cytokines such as IL6 and IL1 
beta can induce MDSCs and block adaptive immunity which may promote tumour progression 
(184, 185). 
 
To investigate the abundance of ELF5 at the protein level, western blot analysis was performed 
on T47D cells treated with progesterone. ELF5 expression was induced in progesterone-treated 
cells, similar to the results obtained at the mRNA level. The results also suggest that ELF5 was 
knocked down at the protein level, however the protein was stable enough that it was still 
observed in control-treated cells. It is when the cells attempt to increase the expression of ELF5 
that the knockdown effect becomes apparent. There is not much information available about 
the protein stability of ELF5. However, it has been suggested that post-transcriptional 
mechanisms such as protein stability impact the cellular abundance and activity of Ets factors 
(181). Possibly, ELF5 protein has high stability and a long half-life and it does not require 
constant translation from the mRNA; hence the knockdown efficiency using RT-PCR is not 
reflected in western blot analysis. Using short hairpin RNA (ShRNA) knockdown via lentiviral 
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vectors could overcome this issue as it constantly suppresses the mRNA and allows for longer 
period selection. 
 
It is likely that ELF5 acts a modulator of the inflammatory response which dampens the pro-
inflammatory effects of immune cytokines such as S100A8, S100A9 and CXCL12. However, 
these effects do not reflect such cytokines as direct transcriptional targets of ELF5 function. 
The role of ELF5 in the mammary gland remains controversial. What accounts for the different 
effects of ELF5 in different cell culture environments and how it regulates the immune cytokine 
network in the breast is still not clear. However, there might be an optimal level of ELF5 
required in the mammary gland to direct immune responses via cytokine regulation. Thus, 
dysregulation of this transcription factor during the menstrual cycle might be associated with 
mechanisms leading to tumour initiation and progress. 
 
4.4.   CONCLUSION: 
A large number of cytokines may contribute to increased breast cancer risk when regulated by 
hormones or other cellular events. In particular, pro-inflammatory cytokine networks can affect 
cell survival, proliferation, differentiation, and mutation, as well as epithelial-stromal crosstalk 
in the breast. Our results suggest that the activation and infiltration of inflammatory 
macrophages to the mammary gland at the diestrus phase of the mouse ovarian cycle reported 
by others (20, 40) may be the result of progesterone-induced pro-inflammatory cytokine 
production by mammary epithelial cells, a process that might be dampened by ELF5 
transcription factor. In other words, ELF5 appears to function as a gatekeeper to limit the 
inflammatory functions of progesterone during the high progesterone phase of the ovarian 
cycle. Therefore, a reduction of ELF5 in the mammary gland might increase inflammation and 
lead to an increased breast cancer susceptibility. Future experiments will be needed to further 
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CHAPTER FIVE 
THE ROLE OF FOXP3 IN MAMMARY GLAND DEVELOPMENT 
 
 
5.1.   INTRODUCTION 
FOXP3 is a member of forkhead/winged family of transcription factors and functions as an 
essential regulator of CD4+CD25+ Treg development (88). Thymic T cells express FOXP3 and 
become Tregs to prevent inappropriate immune responses (47, 48). The lack of a functional 
FOXP3 gene in lymphoid tissues leads to a deficiency in the population of CD4+ CD25+ Tregs 
which causes a severe autoimmune lesion in males, manifesting as an X-recessive autoimmune 
disease called IPEX (89). An analogous disease develops in male mice lacking functional Foxp3 
gene, known as “scurfy” mice, characterised by scaly and ruffled skin, reddened eyes, and 
enlarged spleen and lymph nodes (91, 92). 
 
FOXP3 is predominantly expressed in the thymus and the spleen, from where Tregs are derived. 
However, a few reports have demonstrated its expression in epithelial cells of specific tissues 
such as the breast, lung, and prostate (93-95). FOXP3 expression in the epithelium suggests 
that it may play a broad function outside of T cells where it can bind and regulate several target 
genes (93). Although the epithelial cell-specific function of FOXP3 has not been well-
investigated, some studies have suggested that FOXP3 acts as a tumour suppressor gene in 
breast cancer. As a transcription factor, FOXP3 can bind to approximately 700 genes (97) and 
act as either a transcriptional repressor (e.g. by directly repressing certain  oncogenes  (95, 96, 
98)), or a transcriptional activator (e.g. by maintaining the expression of the p21 tumour 
suppressor) in the mammary epithelium (99).
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In 2007, Zuo, Wang (94) analysed the expression of FOXP3 in normal and cancerous tissues 
and noted its expression to be present in only 20% of human breast cancer samples (mostly the 
HER2− or ER+ phenotype), whereas 80% of normal breast tissues expressed this protein. These 
researchers also found that Foxp3 heterozygous female mice develop mammary carcinomas 
spontaneously at a high rate as they age (94). In addition, when Foxp3 heterozygous female 
mice were challenged with the chemical carcinogen DMBA in conjunction with progesterone, 
a significant increase in the susceptibility to mammary cancer development was observed (94). 
Further studies in human breast cancer samples showed a high rate of FOXP3 somatic mutations 
in breast tumours (100, 101), suggesting that FOXP3 defects play a role in breast cancer 
susceptibility. 
 
In the study by Zuo, Wang (94), 40% of aged Foxp3 heterozygous mice with breast cancer 
developed lung metastasis, suggesting that Foxp3 is involved in metastatic mechanisms (94, 
103). Also, using human and mouse breast cancer cells, Zhang, Zhang (103) found that FOXP3 
regulates the transcriptional activity of mircroRNA (miR)-200s, which are promising 
biomarkers of breast tumour progression and metastasis. On the other hand, transcription factor 
ZEB1 which promotes the EMT in various human tumours (104, 105), has been shown to 
inhibit the transcription of miR-200 clusters (105, 106). Since FOXP3 and ZEB1 are linked 
together through the regulation of miR-200, we hypothesise that regulation of FOXP3 by 
ovarian hormones could influence the expression of ZEB1 in the mammary epithelial cells. 
 
The biological function and regulation of FOXP3 in the mammary gland is not well understood. 
It has been shown, however, that ovarian hormones regulate the abundance of peripheral Tregs 
(53, 186) which suggests they may also regulate FOXP3 expression in the mammary gland. In 
vitro and in vivo studies in mouse models showed that estrogen at physiological doses expands 
the number of CD4+CD25+ Tregs in different lymphoid tissues in estradiol-treated 
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ovariectomised mice and that it induces the expression of the Foxp3 gene (102). Moreover, 
progesterone at high levels acts as a potent inducer of Th2 type cytokines produced by T cells 
(187). The experiments described in this chapter were devised to investigate the effects of 
Foxp3 heterozygosity on mammary gland development during puberty and the estrous cycle in 
mice. To investigate hormonal regulation of FOXP3 in the human breast, mammary epithelial 
organoids and cell lines were cultured with combinations of estradiol and progesterone. In 
addition, the effect of overexpression of FOXP3 on cytokine production by human mammary 
epithelial cells was investigated.  
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5.2.   RESULTS 
5.2.1.   THE EFFECTS OF FOXP3 HETEROZYGOSITY ON MAMMARY 
GLAND MORPHOGENESIS AT PUBERTY 
To investigate the effects of Foxp3 heterozygosity on mammary gland morphogenesis at 
puberty, the 4th pair of mammary glands from 6 week-old Foxp3 heterozygous (n=12) and 
C57BL6 wildtype (n=9) control females were dissected and whole-mounts were stained with 
carmine alum. The number of branch points per millimetre length of epithelial ducts, the 
number of TEBs, and the length of ductal epithelial growth were measured using Image J 
software. 
 
Puberty is a crucial stage of ductal morphogenesis whereby any changes at this period may have 
critical implications for later patterns of mammary gland development (188). Ductal branch 
point analysis on mammary gland whole-mounts showed that there was no difference in 
mammary ductal branching morphogenesis between Foxp3 heterozygous and wildtype control 
mice. At six weeks of age, both groups of mice exhibited similar number of branches (i.e., 1.6 
± 0.2 branch points per millimetre for Foxp3 heterozygous vs. 1.6 ± 0.1 branch points per 
millimetre for wildtype mice) (Figure 5.2). 
 
Blinded analysis of the whole-mounts showed that the number of TEBs is also very similar 
between the two groups of mice. Foxp3 heterozygous females had approximately 9.0 ± 0.7 
TEBs, while the wildtype mice had 9.2 ± 1.3 TEBs in their mammary fat pad (Figure 5.3A). 
Altered development of TEBs can have lasting consequences on mammary gland development 
(189). However, TEBs in the mammary tissues from Foxp3 heterozygous and wildtype mice 
appeared to be of normal structure and size. 
 
Ductal growth in the wildtype mice was 27.4 ± 0.6 millimetre, while the average of ductal 
growth in the heterozygous animals was 24.5 ± 1.3 millimetre (non-significant results), and 
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there was a high degree of variability within each group of mice (Figure 5.3B). Epithelial ducts 
in the heterozygous mice elongated normally into the mammary fat pad, similar to that of 
wildtype controls. 
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Figure 5.1:  Representative images of mammary gland whole-mounts during puberty. 
Mammary gland whole-mounts of Foxp3 heterozygous (n=12) and wildtype control (n=9) mice were 
stained with carmine alum at six weeks of age. The images are representative of mammary glands from 
A) wildtype and B) Foxp3 heterozygous female mice. Green arrows represent terminal end buds in 




Figure 5.2: The effect of Foxp3 heterozygosity on mammary gland morphogenesis during puberty.  
Mammary gland whole-mounts of Foxp3 heterozygous (n=12) and wildtype control (n=9) were stained 
with carmine alum at six weeks of age. The number of branch points per millimetre was calculated. 
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Figure 5.3: The effect of Foxp3 heterozygosity on pubertal mammary gland development. 
Mammary gland whole-mounts of Foxp3 heterozygous (n=12) and wildtype control (n=9) were stained 
with carmine alum at six weeks of age. A) The number of terminal end buds in each mammary gland 
was counted. Terminal end buds, defined as club-like structures projected out from the distal end of 
the ducts, were counted in mammary glands. B) Ductal epithelial length was measured from both 
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5.2.2.   THE EFFECT OF FOXP3 HETEROZYGOSITY ON ESTROUS 
CYCLING 
To investigate the effect of Foxp3 heterozygosity on the regularity of the estrous cycle in mice, 
cycles were tracked for 28 days by histological analysis of vaginal smears in eight-week old 
adult virgin females (n=8-10 mice per group). The average cycle length and number were 
analysed over 28 days in Foxp3 heterozygous and wildtype mice, while a single complete cycle 
was defined as the day of estrus through to the day of the next estrus. Also, the percentage of 
the time spent in each of the four stages of the estrous cycle was analysed between the two 
groups. Data are presented as mean ± SEM and were analysed by an unpaired t-test. 
 
Estrous cycle length was not affected by mouse genotype as both groups had a similar cycle 
length of approximately six days on average (Figure 5.4). Both groups of mice had similar 
number of cycles (Table 5.1). Moreover, there was no significant difference in the percentage 
of the time spent in each stage of the estrous cycle between the two groups. However, Foxp3 
heterozygous mice spent slightly more time in metestrus phase (32%) compared to the wildtype 
mice which were in that phase for about 27% of the time. Both groups of mice spent more time 
in the metestrus and diestrus phases of the cycle (30% on average) and less time in proestrus 
(around 17% of the time) compared to the estrus phase (Figure 5.5). 
 
Table 5.1. The average length and the number of estrous cycles in Foxp3 heterozygous and 
wildtype mice.  
 Wildtype Foxp3 Heterozygous 
Cycle Length (Days)  6.0 ± 0.2 6.0 ± 0.3 
Cycles (number) 4.1 ± 0.1 3.9 ± 0.2 
The average cycle length and number were analysed over 28 days in Foxp3 heterozygous and wildtype 
mice, while a single complete cycle was defined as the day of estrus through to the day of the next 
estrus. 
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Figure 5.4: The effect of Foxp3 heterozygosity on estrous cycling.  
Eight weeks old female Foxp3 heterozygous (n=38) and C57BL6 wildtype mice (n=37) were tracked 
over the course of estrous cycles for 28 days through histological analysis of vaginal smears. A single 
complete cycle was defined as the first day of estrus through to the first day of the next estrus (n=8-




Figure 5.5: Percentage of time spent in each stage of the estrous cycle in Foxp3 heterozygous and 
C57BL6 wildtype mice. 
Daily vaginal smears were analysed by phase contrast microscopy in female mice (n=8-10 per group) 
over 28 days. The percent of viable epithelial cells, cornified epithelial cells, and leukocytes in the 
smears distinguished mice in proestrus, estrus, metestrus, and diestrus. Data are mean + SEM and 
were analysed by an unpaired t-test. 
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5.2.3.   THE EFFECTS OF FOXP3 HETEROZYGOSITY ON MAMMARY 
GLAND MORPHOGENESIS DURING THE OVARIAN CYCLE 
To investigate the effect of Foxp3 heterozygosity on mammary gland morphogenesis over the 
course of the ovarian cycle, one side of the fourth inguinal pair of mammary glands from Foxp3 
heterozygous and wildtype control females were collected at each of the four stages of the cycle 
and whole-mounts were stained with carmine alum. Representative images of mammary gland 
whole-mounts at each stage are shown in Figure 5.6. The number of branch points per 
millimetre length of epithelial ducts was counted using Image J software. 
 
Ductal branching analysis of mammary gland whole-mounts showed that mammary ductal 
branching morphogenesis is similar between the Foxp3 heterozygous and wildtype control 
mice. During the estrus phase, Foxp3 heterozygous mice had 1.9 ± 0.1 branch points/mm (n=10) 
compared to the wildtype mice which had 2.0 ± 0.1 branch points/mm (n=8). Similar results 
were obtained at metestrus whereby Foxp3 heterozygous mice had 1.9 ± 0.1 branch points/mm 
(n=9), compared to the controls which had 2.0 ± 0.1 branch points/mm (n=10). Both groups of 
mice had the highest number of their mammary ductal branch points at the diestrus phase (2.3 
± 0.2 branch points/mm vs. 2.3 ± 0.1 branch points/mm; n=10). The lowest number of ductal 
branch points were observed during the proestrus phase regardless of genotype. However, 
Foxp3 heterozygous mice had a comparable number of ductal branch points at this stage, 
compared to the wildtype mice (1.7 ± 0.1 branch points/mm vs 1.8 ± 0.1 branch points/mm, 
n=9) (Figure 5.7). 
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Figure 5.6: Representative images of mammary gland whole-mounts during the estrous cycle for 
Foxp3 heterozygous and wildtype mice.  
The fourth inguinal mammary gland from Foxp3 heterozygous and wildtype mice, stained with carmine 
alum as whole-mounts at estrus (n=18), metestrus (n=19), diestrus (n=20) and proestrus (n=18). The 
images are representative of mammary glands from wildtype and Foxp3 heterozygous female mice at 
each of the four stages of the cycle. 
 
  
Figure 5.7: The effect of Foxp3 heterozygosity on morphology and branching of mammary glands in 
virgin adult mice during the estrous cycle. 
Mammary gland whole-mounts of Foxp3 heterozygous and wildtype control were stained with 
carmine alum at estrus (n=18), metestrus (n=19), diestrus (n=20) and proestrus (n=18). The number of 
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5.2.4.   MESSENGER RNA EXPRESSION OF FOXP3 IN THE MAMMARY 
GLAND DURING THE ESTROUS CYCLE 
Analysis of Foxp3 utilises a different approach to measure its expression and this requires 
special reagents for real-time PCR. Due to the high cost and the low availability of reagents, 
the mRNA expression of Foxp3 was only assessed at the estrus and diestrus phases of the cycle 
from third pair mammary glands in Foxp3 heterozygous and wildtype mice. To compare 
abundance of Foxp3 in the mammary gland to tissues with known high expression of Foxp3, 
pooled samples of mesenteric, lumbar and axillary lymph nodes (from each mouse) were also 
assessed as Tregs are largely found in the draining lymph nodes (190). The comparative Ct 
method (i.e., 2-(ΔΔCT) method) was used to analyse quantitative real-time PCR data, relative 
to expression of housekeeper gene Rpl13a in each mouse. The results were normalised to the 
average expression of Foxp3 in the estrus phase so that the average of mRNA expression in this 
stage is 1 (n=8-10 per stage). 
 
Although there was high variability within groups and no significant differences, the abundance 
of Foxp3 mRNA tended to be lower in the mammary gland during the diestrus compared to the 
estrus phase of the cycle. Moreover, the expression of Foxp3 mRNA in the lymph nodes tended 
to be higher during the diestrus phase compared to the estrus (non-significant results). There 
was no significant difference between Foxp3 heterozygous and wildtype mice in regards to 
mRNA expression of Foxp3 in the mammary glands and lymph nodes (Figure 5.8). This 
demonstrates a variable pattern in the expression of mammary gland-specific Foxp3 and Tregs 
in the lymph nodes. 
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Figure 5.8: mRNA expression of Foxp3 in the mammary gland (A) and lymph nodes (B) of Foxp3 
heterozygous and wildtype mice at estrus and diestrus stages of the cycle. 
RNA was extracted from the third mammary glands and lymph nodes at estrus and diestrus phases of 
the cycle. Using RT-PCR, the messenger RNA expression of Foxp3 was analysed in the mammary gland. 
The comparative Ct method (i.e., 2-(ΔΔCT) method) was used to analyse the data, relative to 
expression of housekeeper gene RPL13a in each mouse. The results were normalised to the average 
expression of Foxp3 in the estrus stage so that the average of mRNA expression in this stage is 1 (n=8-
10 per stage). 
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5.2.5.   MESSENGER RNA EXPRESSION OF CYTOKINES IN HORMONE-
TREATED HUMAN MAMMARY EPITHELIAL ORGANOIDS 
To investigate the effects of estradiol and progesterone on regulating the expression of FOXP3 
and ZEB1 in mammary epithelial cells, primary human mammary epithelial organoids (n=6) 
were embedded in Matrigel and treated with various combinations of estradiol and progesterone 
for 72 hours. Messenger RNA expression of FOXP3 and ZEB1 were examined from hormone-
treated human epithelial organoids. The comparative Ct method (i.e., 2-(ΔΔCT) method) was 
used to analyse quantitative real-time PCR data, relative to the mean of expression of 
housekeeping genes MPRL19 from the same patient. 
 
The expression of both genes was highly variable amongst patients with no trend, and no 




Figure 5.9: Hormonal regulation of mRNA encoding FOXP3 and ZEB1 in 3D organoid cultures.  
Box plots represent the mean variation in the expression of genes A) FOXP3 and B) ZEB1 from Matrigel-
embedded human epithelial organoids upon treatment with combinations of estradiol (E2) and 
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5.2.6.   MESSENGER RNA EXPRESSION OF CYTOKINES IN HUMAN 
MAMMARY EPITHELIAL CANCER CELL LINES 
To investigate the effects of estradiol and progesterone on FOXP3 production by mammary 
epithelial cells, human mammary epithelial cell lines were treated with estradiol and 
progesterone over different time courses. Messenger RNA expression of FOXP3 and ZEB1 
genes were examined from MCF7, T47D, and ZR751 human mammary epithelial cell lines 
treated with combinations of estradiol and progesterone for i) 24 hours and ii) 72 hours. The 
comparative Ct method (i.e., 2-(ΔΔCT) method) was used to analyse quantitative real-time PCR 
data, relative to expression of housekeeper gene MPRL19 in each treatment group. The results 
were normalised to this gene so that the average of the control samples was 1. 
 
In MCF7 cells treated with hormones for 24 hours, the mRNA expression of the genes encoding 
FOXP3 and ZEB1 was not significantly regulated by hormones. However, there was a tendency 
for the combination of estradiol and progesterone to downregulate FOXP3 expression by 
approximately 40% compared to control-treated cells. Moreover, the expression of mRNA 
encoding ZEB1 was slightly increased upon treatment with either estradiol or progesterone 
(Figure 5.10A and 5.10B). 
 
In T47D cells, treatment with progesterone significantly downregulated the expression of 
mRNA encoding FOXP3 by approximately 40% compared to the controls (p<0.01), while the 
combination of estradiol and progesterone decreased FOXP3 expression by the same extent 
compared to estradiol-treated cells (p<0.05). Although non-significant, estradiol and 
progesterone treatment alone seemed to attenuate the expression of mRNA encoding FOXP3 
gene (Figure 5.10C). On the other hand, the combination of hormone treatment significantly 
increased the expression of mRNA encoding ZEB1 gene by 4-fold compared to the control-
treated cells (p<0.05). Interestingly, there was a tendency for either of the hormones to 
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upregulate the expression of mRNA encoding ZEB1 gene in these cells (non-significant results) 
(Figure 5.10D). 
 
Hormone treatment of ZR751 mammary epithelial cells for 24 hours had no significant effect 
on the expression of mRNA encoding FOXP3 and ZEB1 genes. However, there was a tendency 
for estradiol to increase the expression of these genes in ZR751 cells (Figure 5.10E and 5.10F). 
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Figure 5.10: Messenger RNA expression of FOXP3 and ZEB1 in human mammary epithelial cell lines 
(MCF7, T47D, and ZR751) after 24 hours hormone treatment. 
Graphs represent the variation in the expression of genes FOXP3 and ZEB1 in human mammary 
epithelial cell lines (MCF7, T47D, and ZR751) upon treatment with combinations of estradiol (E2) 
and/or progesterone (P4) for 24 hours (n=3 experiments, each in triplicate). Results were normalised 
to the housekeeper gene MPRL19 so that the average of the control samples was 1. Data are mean + 
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In MCF7 cells treated with hormones for 72 hours, progesterone had significant suppressive 
effects on the expression of mRNA encoding FOXP3 and ZEB1. Treatment with progesterone 
alone significantly downregulated the mRNA expression of FOXP3 and ZEB1 by more than 
80% and 50% respectively (p<0.05). Similar effects were observed when estradiol was 
combined with progesterone; the expression of mRNA encoding FOXP3 and ZEB1 was 
significantly attenuated by approximately 80% and 90% respectively, compared to the control-
treated cells (p<0.05 for FOXP3 and p<0.01 for ZEB1) (Figure 5.11A and 5.11B). 
 
The expression of mRNA encoding FOXP3 in T47D cells treated with progesterone was 
significantly upregulated compared to the cells treated with vehicle, estradiol or a combination 
of hormones (p<0.01 for all groups). Similar results were obtained for ZEB1 mRNA expression 
which was approximately 4-fold higher in progesterone-treated cells, compared to the cells 
treated with either ethanol or estradiol (p<0.05) (Figure 5.11C and 5.11D). 
 
The expression of mRNA encoding FOXP3 in ZR751 cells was not altered by hormone 
treatment. There was a tendency for estradiol alone to increase the expression of ZEB1 
compared to the control-treated cells (non-significant results) (Figure 5.11E and 5.11F). 
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Figure 5.11: Messenger RNA expression of FOXP3 and ZEB1 in human mammary epithelial cell lines 
(MCF7, T47D, and ZR751) after 72 hours hormone treatment. 
Graphs represent the variation in the expression of genes FOXP3 and ZEB1 in human mammary 
epithelial cell lines (MCF7, T47D, and ZR751) upon treatment with combinations of estradiol (E2) 
and/or progesterone (P4) for 72 hours (n=3 experiments, each in triplicate). Results were normalised 
to the housekeeper gene MPRL19 so that the average of the control samples was 1. Data are mean + 
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5.2.7.   FOXP3 OVEREXPRESSION IN HUMAN MAMMARY EPITHELIAL 
ORGANOIDS 
Lentiviral vectors are efficient tools to introduce the gene of interest into dividing and non-
dividing cells. To investigate the consequences of FOXP3 overexpression in human normal 
breast epithelial cells, lentiviral vectors were used to induce stable, long-lasting FOXP3 
expression. In order to obtain sufficient number of cells to conduct the experiment, samples of 
human mammary epithelial organoids were pooled from 10 patients and were transduced with 
lentiviral vectors either carrying FOXP3-GFP or GFP alone. Un-transduced cells were also used 
as control. Cells were embedded in Growth Factor Reduced Matrigel and cultured for five days 
to allow organoids to stabilise and grow, before RNA extraction. This experiment was 
conducted once in duplicate due to the limited number of primary mammary epithelial 
organoids. The transduction efficiency was assessed using confocal microscopy and RT-PCR. 
 
Fluorescence intensity was determined qualitatively relative to the un-transfected control cells 
(No LV). The green fluorescence was clearly visible by fluorescence microscopy in the GFP 
and FOXP3-GFP transduced cells, compared to un-transduced control cells (Figure 5.12A-C). 
FOXP3 mRNA expression was increased (up to 10-fold) in cells transduced with FOXP3-GFP 
lentiviral vectors compared with control cells (Figure 5.12F). When GFP transfection was 
assessed quantitatively using RT-PCR, the expression of mRNA encoding GFP was much 
higher (up to 150-fold) than that of FOXP3-GFP-transduced cells (Figure 5.12E). However, 
these data could not be statistically analysed due to the low sample size. Following stable 
FOXP3 overexpression in human mammary epithelial organoids, an apparent increase was 
observed in the expression of ZEB1 mRNA (approximately 100%), compared to GFP-
transduced and un-transduced cells (Figure 5.13A). The expression of HER2 and CXCL12 was 
reduced by approximately 80% in both groups of lentiviral-transduced cells compared to un-
transduced cells (Figure 5.13B-C). No overt changes were observed in the expression of mRNA 
encoding TGFB1 and the housekeeper gene, PPIA.   
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Figure 5.12: Lentiviral transduction of human mammary epithelial organoids. 
Pooled samples of human mammary epithelial organoids were transduced with lentiviral vectors 
expressing FOXP3 and GFP. Control groups include a no lentiviral treatment (No LV) and lentiviral 
vectors which express GFP alone. Representative images are shown for GFP detection in the cells: A) 
un-transduced B) GFP transduced, and C) FOXP3-GFP transduced. RNA was extracted from the cells 
and mRNA encoding GFP and FOXP3 were measured using RT-PCR (D-E). Data shown are the mean of 
duplicate values (n=1 experiment in duplicate), normalized to the housekeeper gene MPRL19. No 
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Figure 5.13: Lentiviral transduction of human mammary epithelial organoids. 
Pooled samples of human mammary epithelial organoids were transduced with lentiviral vectors 
expressing FOXP3 and GFP. Control groups include a no lentiviral treatment (No LV) and lentiviral 
vectors which express GFP only. Graphs represent the variation in the expression of genes ZEB1, HER2, 
CXCL12, TGFB1, and PPIA in human mammary epithelial organoids transduced with different lentiviral 
transduction group. Data shown are the mean of duplicate values (n=1 experiment in duplicate), 
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5.3.   DISCUSSION 
Unlike most tumour suppressor genes which are autosomal, FOXP3 is X-linked and is subject 
to X chromosome inactivation, meaning that it can be inactivated by a single genetic or 
epigenetic hit (87). Although Foxp3 heterozygous mice appear healthy in the first year of life, 
there is little known about their mammary gland development and function, and how they 
develop cancer when they are older. Studies have suggested that mammary gland development 
may play an essential role in determining future breast cancer risk (188, 191). We hypothesized 
that Foxp3 heterozygosity might impair mammary gland development and affects its 
architecture, a process which may ultimately increase the risk of cancer. However, our results 
suggest that Foxp3 heterozygosity has no effects on mammary gland development during 
puberty and over the course of the estrous cycle. Despite these observations, epithelial-specific 
FOXP3 and its potential downstream cytokine, ZEB1, seemed to be regulated by estradiol and 
progesterone in mammary epithelial cancer cell lines.  
 
5.3.1.   FOXP3 HETEROZYGOSITY DOES NOT AFFECT MAMMARY 
GLAND DEVELOPMENT IN MICE 
Our results indicate that Foxp3 heterozygous mice exhibit overtly normal mammary gland 
ductal architecture, suggesting that Foxp3 heterozygosity has no effects on the mammary gland 
development during puberty and adulthood. The analysis of the estrous cycle regularity in adult 
virgin cycling mice showed that Foxp3 heterozygous mice undergo regular estrous cycling, 
indistinguishable from the wildtype controls, suggesting that the ovarian hormones are 
normally circulated in these mice. The normal phenotypes of mice observed in our study 
suggest that half-dose expression of Foxp3 is sufficient for its normal function, and does not 
impair mammary gland development or the estrous cycle regularity.  
 
Our results suggest that Foxp3 heterozygosity does not impair mammary gland morphogenesis 
or function in young adult mice, suggesting that other factors might be involved in making these 
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mice susceptible to cancer development. One possibility for the rise of breast cancer risk in 
aged Foxp3 heterozygous mice could be due to indirect effects of immune cells in the mammary 
gland, which has not yet been investigated. It is also noteworthy that the mice used in the study 
by Zuo, Wang (94) were in BALB/C genetic background whereas in our study we used Foxp3 
heterozygous mice on the C57BL6 background. Indeed, different strains of mice can show 
variable side branching or alveologensis in the mammary gland (192). It would be informative 
to examine these phenotypes in Foxp3 heterozygous mice on a BALB/C background to observe 
any defects in the mammary epithelial ductal branching. 
 
Loss of the wildtype Foxp3 allele has been suggested to be exclusive to cancer, since skewed 
X-inactivation was only observed in tumour cells, but not the adjacent healthy breast tissue in 
Foxp3 heterozygous mice (94). Whether or not FOXP3 plays a role in mammary gland 
development in humans remains speculative. The pattern of X chromosome inactivation was 
analysed in the peripheral blood of a woman heterozygous for FOXP3 mutation, and it was 
found that there was no significant imbalance between T cells expressing the mutated FOXP3 
allele and normal T cells (90). Although human female carriers of FOXP3 mutation are 
completely healthy and have normal immunological parameters including lymphocyte 
subpopulations (90), it is possible that genetic alterations of FOXP3 work in concert with 
additional genetic hits to increase breast cancer risk. This X-linked gene may be inactivated by 
various events such as mutations, loss of heterozygosity, bi-allelic methylation, and skewed X-
inactivation in breast cancer (193). The mechanisms through which FOXP3 may get altered in 
the normal breast is not clear; however, the ovarian hormones might be involved. It should also 
be noted that there are few differences between human and mouse Foxp3, one of which is the 
presence of three isoforms in humans, while there is only a single Foxp3 isoform present in 
mice (92). The longest form resembles the murine Foxp3, while the other two isoforms are 
unique to humans (194). The PCR primer sets used in our experiments amplify all isoforms; 
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however, it would be intriguing to investigate the mammary epithelial-specific expression of 
different FOXP3 isoforms in the human breast. 
 
5.3.2.   HORMONE REGULATION OF FOXP3 IN MAMMARY EPITHELIAL 
CELLS AND ITS EFFECT ON ZEB1 
Nuclear expression of FOXP3 is much lower in cancer cells than in normal breast epithelia (94). 
Its expression is abnormal and variable in different cancer cell lines, with the highest expression 
in MCF7 cells (94, 195). This is in parallel with our observations which also showed that the 
mRNA expression of FOXP3 is variably regulated by estradiol and progesterone, depending on 
the cancer cell type or the treatment time course.  
 
Considering the role of FOXP3 as a tumour suppressor gene, it is likely that downregulation of 
this gene by hormones may increase the expression of oncogenes such as HER2 or SKP2 (94, 
95) and contribute to breast cancer development. This is supported by a recent study in which 
lower expression of the nuclear FOXP3 protein in primary tumour samples was significantly 
correlated with tumour clinical stage and lymph node metastasis (196). On the other hand, 
upregulation of this gene can be an ideal effect considering the role of FOXP3 as an inducer of 
transcriptional activity of tumour suppressor genes in both normal and malignant breast 
epithelial cells (99). Peripheral FOXP3 has been shown to regulate the expression of several 
DNA damage-associated genes, suggesting that it may suppress tumour cell growth by either 
preventing the repair of DNA damaged cells or promoting their apoptosis (197). If the 
epithelial-specific FOXP3 functions in the same manner, it may inhibit the proliferation of 
DNA-damaged cells in the breast during the menstrual cycle. Several studies have reported the 
higher expression of FOXP3 to be a prognostic factor for breast cancer (198, 199), although a 
few have suggested the opposite role (200, 201). High expression of the FOXP3 protein in 
breast tumours is correlated with the abundance of Tregs, suggesting that a higher immune 
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tolerance occurs in mammary gland tumours. This could affect aggressive tumour growth, 
leading to the shutdown of any effective anti-tumour immune response. 
 
Our RT-PCR results revealed that the correlation of ZEB1 and FOXP3 mRNA expression is 
dependent on the properties of breast cancer cell lines as well as the hormone treatment time 
course. For instance, both FOXP3 and ZEB1 mRNA expression was induced by progesterone 
in T47D cells, whereas these genes were downregulated with estradiol treatment in estrogen-
responsive MCF7 cells. It is likely that hormone treatments might trigger regulatory 
mechanisms between FOXP3 and ZEB1 in the mammary gland, which subsequently aids in the 
transformation of mammary epithelial cells. Whether or not FOXP3 regulates EMT via 
mechanisms involving ZEB1 requires further investigations using EMT assays and more 
detailed cell culture models. 
 
It seems that FOXP3 mRNA expression in the mammary epithelium is variable in different 
breast cancer cell lines. However, due to the conflicting clinical results in the literature, as well 
as in our experiments, the significance of mammary epithelial cell-specific FOXP3 expression, 
and its regulation by ovarian hormones remain unclear. In the immune system, FOXP3 
expression is essential to modulate immune surveillance through Tregs (194). Therefore, 
hormonal alterations of this gene might affect the immune surveillance in the breast. The results 
obtained in this study might be just the ‘tip of the iceberg’ of insights into the crosstalk between 
the ovarian hormones and Foxp3 expression in the human breast and further research is needed. 
 
5.3.3.   FOXP3 OVEREXPRESSION IN HUMAN MAMMARY EPITHELIAL 
ORGANOIDS: 
A recent study showed that overexpression of FOXP3 in breast cancer cell lines has an 
inhibitory effect on cancer cell adhesion and invasion (196). In another study using MDA-MB-
231 breast epithelial cell lines, FOXP3 overexpression was associated with a significant 
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reduction in CXCR4 and HER2, whereas silencing FOXP3 had the opposite effect (98). These 
researchers suggest that FOXP3 regulates CXCR4 expression and that a loss of FOXP3 by 
invasive breast tumours might promote CXCL12-regulated metastasis (98).  
 
In our experiment, both groups of cells were infected with a similar multiplicity of infection 
(MOI) and expressed the reporter GFP at the gene and protein level. The lower expression of 
GFP in FOXP3-GFP-transduced cells is probably due to the presence of a second gene of 
interest (i.e., FOXP3), rather than GFP alone (202). In FOXP3-GFP lentiviral vectors, full-
length FOXP3 is driven by the EF1-alpha promoter, while an encephalomyocarditis virus 
(EMCV) Internal Ribosome Entry Site (IRES), located downstream of FOXP3 gene, enables 
the expression of the GFP reporter. However, GFP lentiviral constructs contain an additional 
GFP gene in place of FOXP3. Therefore, co-expressing two different transgenes linked by an 
IRES element in a single bicistronic lentiviral transcript might have affected the low expression 
of the second gene (i.e. GFP) in FOXP3-GFP-transduced cells. Different mechanisms may 
contribute to the capacity of an IRES to precisely translate the second gene (downstream of the 
IRES), however, in most cases, only the first gene is strongly expressed in a bicistronic vector 
(202, 203). Notwithstanding, the expression of GFP reporter in both groups of cells is clearly 
higher than that of un-transduced cells, confirming that transduction of the organoids was 
efficient in this experiment. 
 
Following stable FOXP3 overexpression in human mammary epithelial organoids, an apparent 
increase was observed in the expression of ZEB1 mRNA, suggesting that ZEB1 is a downstream 
target of FOXP3. To an extent, this effect is consistent with our observations in progesterone-
treated T47D and MCF7 mammary epithelial cell lines whereby regulation of FOXP3 was 
associated with an increase or decrease of ZEB1 in these cell lines, respectively. Also, consistent 
with previous findings in the literature, the mRNA expression of HER2 and CXCL12 genes was 
downregulated following an increase in FOXP3 levels. Unexpectedly, however, a similar effect 
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was observed in the cells transduced with GFP alone, suggesting that such impact in FOXP3-
GFP-transduced organoids is not solely due to FOXP3 overexpression. The reason for this is 
not apparent; however, it might be either due to technical errors in the assays or the effects of 
lentiviral vectors interfering with the expression of these genes. Nonetheless, the mRNA 
expression of the housekeeper gene PPIA was constant across the groups. This suggests that 
the sample variations could have occurred due to other experimental processes such as the cell 
culture or lentiviral transduction. 
 
It must also be noted that due to the limited number of cells, due to limitation in access to 
primary mammary epithelial cells from patients, we pooled the organoids from 10 individuals 
before lentiviral transduction. For the same reason, there were insufficient number of cells 
required to purify and sort the cells based on their GFP expression which is a marker that the 
individual cell has been transduced. Hence, the obtained results are from a mixture of 
transduced and non-transduced cells, making the RT-PCR data less reliable. However, this is 
the first study that has used such novel model of primary human mammary epithelial organoids 
to analyse the role of FOXP3 in the breast. Manipulating the genetic profile of human mammary 
epithelial organoids using lentiviral vectors serves as a promising resource in experimental 
research on the breast epithelium. Using a physiologically relevant model system of genetically-
engineered primary cells can surpass conventional cell line and transgenic mouse models 
regarding cost, speed, and reliability. One approach to be taken in future is to use microarray 
technology or chromatin immunoprecipitation (ChIP) to identify more downstream target genes 
of FOXP3 in the breast epithelia. Also, it would be reasonable to silence FOXP3 gene in the 
organoids and analyse its effects on cytokine production by normal mammary epithelial 
organoids.  
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5.4.   CONCLUSION 
The data presented in this chapter revealed that Foxp3 heterozygosity does not affect mammary 
gland development during puberty and young adulthood in mice. Although FOXP3 is 
hormonally regulated in human mammary epithelial cells in vitro, its heterozygosity does not 
affect the estrous cycle regularity in mice. It is likely that subtle effects of Foxp3 heterozygosity 
on the immune cell compartment and possibly directly on mammary epithelial cells are 
involved in causing aged Foxp3 heterozygous female mice susceptible to mammary cancer 
development over a long period of time. Foxp3 expression confers suppressor functions on 
peripheral CD4+CD25+ Tregs (88). This is required to suppress the function of autoreactive T 
cells and inhibit the development of autoimmunity. Therefore, it is possible that a defect in this 
gene in the mammary epithelium may deregulate the immune homeostasis, leading to immune 
tolerance and increases tumour development. Overall, further investigations are required to 
dissect the underlying mechanisms of how Foxp3 heterozygosity increases breast cancer risk in 









6.1.   INTRODUCTION 
It is widely accepted that mammary gland development is dependent on the dynamic 
interactions between hormonally-responsive mammary epithelium and the immune 
microenvironment in the stroma; these interactions are mediated through activation and 
function of a variety of transcription factors and cytokines. However, it is not clear how 
fluctuations of estrogen and progesterone affect the immune cytokine expression in the 
mammary gland. We attempted to address this question using a variety of different approaches 
to investigate hormonal regulation of cytokine expression by mammary epithelial cells. The 
approaches that were employed were three-dimensional human mammary epithelial organoids, 
cell lines, and mouse mammary glands. Functional three-dimensional primary organoids 
provide a greater understanding of normal breast structure and development and recapitulate 
morphogenetic events regulated by ovarian hormones in the breast (128). Human mammary 
epithelial cell lines have a well-defined hormone receptor profile, and mouse models were used 
to track the molecular changes in the mammary gland associated with the natural fluctuations 
in hormones across the estrous cycle.
 
The general hypothesis of this thesis was that estrogen and progesterone regulate the expression 
of certain immune-related transcription factors and cytokines in the breast epithelial cells. Our 
results showed that transcription factors ELF5 and FOXP3, as well as their downstream 
cytokines, were variably regulated by estradiol and progesterone depending on the hormone 
receptor profile of the mammary epithelial cells. It was also hypothesized that Foxp3 
heterozygosity perturbs mammary gland development in mice; a theory which was negated. 
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The studies outlined in this thesis are the first to investigate the significance of hormone 
regulation of these immune-related cytokines in primary mammary epithelial cells. In this 
chapter, the overall effects of estradiol and progesterone on cytokine expression by mammary 
epithelial cells are discussed. The current knowledge on the cellular and molecular changes in 
the human breast during the menstrual cycle is also reviewed. Further, the limitations of these 
studies to investigate how menstrual cycle-associated hormones affect mammary epithelial cell 
function are outlined. Finally, opportunities for future research to improve our understanding 
of the hormone-regulated cytokine networks are highlighted. 
 
6.2.   CURRENT KNOWLEDGE ON THE CELLULAR AND 
MOLECULAR CHANGES IN THE BREAST DURING THE 
MENSTRUAL CYCLE 
Much of what is known about the cellular and molecular interactions directing mammary gland 
morphogenesis during the ovarian cycle comes from studies involving animals (20, 40, 204, 
205). Using mouse models, Chua, Hodson (20) observed that the abundance and phenotype of 
macrophages fluctuates over the course of the estrous cycle. Following this study, Hodson, 
Chua (40) reported differential percentage of murine macrophages that express cell surface 
proteins NKG2D, CD204, and MHCII during different stages of the ovarian cycle, regulated 
by progesterone and estrogen. NKG2D which was increased during metestrus and diestrus, is a 
receptor that recognises antigens expressed on the surface of DNA-damaged cells. When 
activated, it induces production of pro-inflammatory cytokines, causing inflammation at the site 
of injury. The mammary gland is most resistant to tumour initiation during the development 
phase of the ovarian cycle (206), which may be the result of heightened immune surveillance 
mediated by NKG2D-expressing macrophages. Additionally, the percentage of macrophages 
expressing MHCII and CD204 phenotypes were found to be highest during proestrus which is 
consistent with the established roles of MHCII and CD204 in the recognition and phagocytosis 
of apoptotic cells (40). Based on these findings, it is possible that similar phenotypes of 
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macrophages exist in the human breast which fluctuate with the ovarian hormones and affect 
immune surveillance in this tissue. 
 
Few studies have investigated the gene expression profile in the human breast during the 
menstrual cycle. In 1994, Sabourin, Martin (207) analysed the expression of B-cell lymphoma 
2 (BCL-2) protein in 50 samples of normal breast tissue and found that its expression in lobular 
epithelial cells increases during the follicular phase and decreases sharply at the end of luteal 
phase. BCL-2 prevents apoptotic cell death and plays a critical role in determining the life or 
death of a cell (208). As noted by Ferguson and Anderson (18), mammary epithelial apoptosis 
in normal mammary gland increases at the end of the luteal phase when the circulating 
concentration of estrogen and progesterone decline. Hence, hormonal fluctuations of BCL-2 
during the menstrual cycle is part of a normal process in the mammary gland. However, 
dysregulation of this protein might lead to overabundance of mammary epithelial cells, which 
can be a trigger for hormone-dependent tumorigenesis in the breast (207). More recently, Pardo, 
Lillemoe (209) analysed the DNA expression in premenopausal breast epithelium using next-
generation whole transcriptome sequencing, and found a significant difference in the expression 
of 255 genes between the two phases of the cycle. The majority of these genes were upregulated 
during the luteal phase, and play roles in the cell cycle events such as DNA replication, DNA 
damage response and mitosis. Interestingly, most of these genes were overexpressed in breast 
cancer, suggesting that they play a role in tumorigenesis via increasing the mitotic rate in the 
breast (209).  
 
Other studies revealed that the molecular profile of ECM in healthy human mammary gland 
undergoes cyclical changes during the menstrual cycle in vivo (210, 211). In particular, the 
expression of proteoglycans syndecan-1, syndecan-4, and decorin was found to be reduced 
during the luteal phase (211). Since polymorphisms of these genes are associated with breast 
cancer susceptibility (212, 213), it is likely that their modulation by hormones during the 
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menstrual cycle deregulate the behaviour of stromal cells and trigger tumorigenesis in the 
mammary gland microenvironment. Despite all these attempts, no study has investigated the 
function and phenotypes of immune cells such as macrophages and T cells in the breast over 
the course of menstrual cycle. There is a pressing need for more research on the cellular cell 
signalling in healthy breast tissue under normal physiologic settings. However, several 
considerable challenges have been identified which make it difficult to address these questions. 
 
A major challenge in studies associated with hormone regulation of the mammary gland during 
the menstrual cycle is to determine the exact phase and duration of menstrual cycling in women 
prior to breast surgery. Currently, conventional methods such as counting the days from the 
onset of bleeding, basal body temperature charts, and measuring serum concentrations of 
estrogen and progesterone are used to estimate the different phases of the menstrual cycle. Also, 
technology has offered apps which allow women to track their menstrual cycle using their smart 
phones. However, using a device which can measure the concurrent concentrations of estrogen 
and progesterone on the days of operation and track the changes affecting the breast overall 
architecture, could be of great benefit. On the other hand, the abundance of hormone receptors 
fluctuates during the menstrual cycle (214), making it more difficult to study hormonal effects. 
Besides, different women with heterogeneous genetic background may respond differently to 
the ovarian hormones.  
 
Clearly, a larger sample size with participants encompassing a more defined menstrual status is 
required to adequately explore the effects of these ovarian hormones on the mammary gland 
microenvironment in situ. Using in vitro techniques of primary mammary culture would also 
overcome some of the difficulties associated with the study of hormonal changes in the breast. 
For instance, isolating cells from a human breast sample and treating the cells with different 
hormone combinations would recapitulate hormone environment in the breast, and also enables 
us to perform paired sample statistical analysis in the same patient.  
General Discussion 
~ 144 ~ 
6.3.   HORMONAL REGULATION OF IMMUNE-RELATED 
CYTOKINES IN THE MAMMARY GLAND 
Ovarian hormones are likely to have direct and indirect effects on cytokine production by 
immune cells. For example, progesterone directly promotes the expression of pro-inflammatory 
cytokines such as TNFA, chemokine (C-C motif) ligand 2 (CCL2), and interleukin 1 beta 
(IL1B). On the other hand, estrogen mediates anti-inflammatory effects by inhibiting the 
expression of TNFA, IL1B, and IL6 in human osteosarcoma cell line, through both of its 
receptors, ERA and ERB (215). Therefore, inhibition of hormone receptors can account for a 
potential mechanism for deactivating the cytokines and inhibiting their effects. However, 
indirect effects are also likely to occur, through interactions with mammary epithelial cells and 
the immune microenvironment of the mammary gland. As described before, mammary 
epithelial cells secrete an array of cytokines, many of which are regulated by ovarian hormones 
and are expected to affect local immune cell populations. A similar cytokine network exists in 
the uterus whereby hormonally responsive uterine epithelial cells direct macrophage abundance 
and function through the expression of specific cytokines (216). The findings in this thesis 
suggest that depending on the presence of hormone receptors and downstream signalling 
pathways that affect mammary epithelial cell function, estrogen and progesterone can activate 
or dampen immune-regulatory cytokine networks in the breast.  
 
Figure 6.1 provides a heat map summary of the abundance of mRNA encoding cytokines across 
three different mammary epithelial cancer cell lines, upon treatment with estradiol and 
progesterone. The results obtained from mammary epithelial organoids, mouse mammary 
glands, and mammary epithelial cancer cell lines suggest that hormone-regulated cytokine 
expression can differ remarkably across the different models. In particular, these hormones tend 
to have inhibitory effects on the cytokines produced by normal mammary epithelial organoids, 
while having stimulatory effects on the same cytokines in mouse mammary gland and 
malignant mammary epithelial cell lines. A similar observation, that hormones affect cytokine 
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expression differently depending on the exposure time, could be noted when cell lines were 
hormone-treated over different time courses. For example, progesterone treatment of MCF7 
cells for 24 hours tended to stimulate the expression of inflammatory cytokines, whereas 72 
hours treatment had inhibitory effects, suggesting that short exposure to hormones can lead to 
inflammation, whereas prolonged exposure can dampen the inflammatory response. 
Furthermore, MCF7 and T47D cell lines tend to respond to estradiol and progesterone by 
altering the expressions of mRNA encoding cytokines more so than ZR751 cells, making them 
useful tools for understanding the effects of these hormones on mammary gland development.  
 
It is likely that ovarian hormones over the menstrual cycle maintain a balance between the pro 
and anti-inflammatory cytokine signals using a transcriptional regulatory feedback system to 
mediate the dynamic and complex changes in the breast. Although we could not precisely 
determine the immune signalling pathways in the breast, our studies suggest that the epithelial 
cell-specific transcription factor ELF5 might play a role in mediating the cytokine production 
in breast epithelia. It might act as a modulator of inflammatory signals in the breast by 
dampening the effects of immune cytokines such as S100A8, S100A9 and CXCL12. As 
mentioned earlier, dysregulation of many of these cytokines is found in breast cancer and may 
contribute to increased risk of tumorigenesis. Therefore, an imbalance in hormone fluctuations 
that can be caused by an unbalanced lifestyle, chronic stress, and exposure to synthetic oral 
contraceptives, might influence the function of transcription factors in the mammary gland, 
leading to dysregulation of immune cytokines and subsequently dampening the immune 
surveillance in this tissue. Throughout reproductive years, impaired immune surveillance along 
with increased proliferation of mammary epithelial cells mediated by estrogen and 
progesterone, might cause genomic instability, increase the likelihood of mutations in the breast 
and lead to increased risk of breast cancer in women. 
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Figure 6.1: Heat-map profiles of mRNA expression of cytokines in mammary epithelial cancer cell 
lines upon treatments with estradiol and progesterone.  
The image represents the scale of mRNA expression of cytokines in different mammary epithelial 
cancer cell lines. Orange indicates downregulation of mRNA encoding each cytokine, blue indicates 
upregulation and no change is indicated in grey.  
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6.4.   LIMITATIONS OF THIS STUDY: 
There were some weaknesses and limitations to this study. Firstly, we used heterogeneous 
population of cells including primary normal human cells, cancerous cell lines, and mouse 
mammary glands which are physiologically different from each other and none of which are an 
ideal system to represent the events occurring in vivo in humans. Moreover, we largely 
investigated gene expression in our studies rather than protein expression. Gene expression may 
not be identical to the expression of the corresponding protein, which might be affected by 
different post-transcriptional modifications, leading to mistaken conclusions on the more 
physiologically relevant protein secretions. This was evident in our studies involving genetic 
knockdown of ELF5 in T47D cells whereby the expression of ELF5 was efficiently silenced at 
the mRNA level, but not at the protein level. Also, most of these studies were performed in 
isolated in vitro cell culture settings and in the absence of local microenvironment co-factors 
including those expressed by immune cells, and physiological concentration of estradiol and 
progesterone. It is likely that estrogen and progesterone trigger the mechanisms through which 
immune cells are recruited to the mammary epithelial cells. This was evident in our ex vivo 
studies which showed that hormone treatment of human breast tissue explants result in a higher 
expression of S100A8 protein on stromal macrophages. Nevertheless, it is important to focus 
on such models in order to answer the main question regarding hormonal effects on immune 
cell function in the mammary gland. 
 
Primary organoids are usually impure and contaminated with stromal and non-epithelial cells 
(217). Although the protocol was designed to isolate the epithelial cells from human breast 
tissues, the efficiency and the purity of samples could not be determined due to the limited 
number of cells. It is likely that these organoid samples consist of not only epithelial and 
myoepithelial cells, but stromal components such as fibroblasts, macrophages and adipocytes 
which might have contributed to the effects. To tackle this issue, immunohistochemistry 
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techniques and mammary epithelial cell-specific markers could be used to precisely study on 
the purity of human mammary epithelial organoids. 
 
Although cell lines are usually highly proliferative and easy to culture, there are a number of 
limitations which make them a less favourable option in research. Cell lines have lost the true 
characteristics of the original tissue from which they were derived. Moreover, serial subculture 
of these cells can cause genotypic and phenotypic variations over an extended period of time 
(218). The cell lines used in this experiment are from the same aggregate morphological class, 
however, they originate from different patients, have unique biologic features, and express 
variable levels of hormone receptors; thus show different gene expression patterns upon 
hormone treatments. It should also be noted that although these cell lines were purchased from 
ATCC, their identity was not confirmed by sequencing. Therefore, misidentification of these 
cell lines could be another reason for the variable results reported in this project.   
 
Another limitation associated with this study is that RNA was extracted from whole mammary 
glands, and expression of genes encoding specific cytokines may not solely be specific to 
mammary epithelial cells, and other cell types might be involved in producing such results. 
Using laser capture microdissection could help us address this issue by isolating the mammary 
epithelial cells from the tissues and analysing gene expression specifically in mammary 
epithelial cells. It is also important to note that the serum levels of hormones was not measured 
in these mice; this makes the results less reliable as the exact cycle stage determined by vaginal 
cytology was not confirmed with circulating concentration of estradiol and progesterone. 
 
Given more time for these studies, the sample sizes for primary tissue studies would be 
increased. With the high degree of variation observed in primary cell culture, it is estimated that 
a sample size of 25 breast tissues is needed for a 95% power result and 5% significance level. 
It would also be beneficial to conduct more in depth studies on the time frame of hormone 
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stimulation and the reproducibility of results of organoids, mouse mammary glands and explant 
cultures. The small amounts of primary tissue we obtained limited our ability to robustly test 
timing of hormone treatments, and the reproducibility of results obtained from the same patient 
is currently unknown. However, a larger study should certainly address these questions. We are 
currently collecting normal and cancerous breast tissue biopsies during different stages of the 
menstrual cycle within individual patients. This would be a valuable resource as it allows us to 
analyse hormonal changes as well as gene expression patterns in malignant breast tissues and 
compare them to those from healthy individuals across the menstrual cycle. 
 
6.5.   FUTURE RESEARCH DIRECTIONS 
The experiments reported herein demonstrated the complexity of immune cytokine networking 
in the mammary epithelia which is regulated by estradiol and progesterone. However, the 
precise molecular mechanisms affecting breast cancer risk in the mammary gland during the 
menstrual cycle are still far from clear. There are several aspects of the immune-cytokine 
regulatory networks in the breast that need to be explored. For example, the specific 
mechanisms through which estrogen and progesterone modulate the phenotype and function of 
immune cells such as macrophages and T cells in the breast should be investigated. Moreover, 
transgenic knockout mouse models can be used to investigate the correlation between ovarian 
hormones and specific cytokines in the mammary gland and their influence on tumour initiation. 
It would also be interesting to use human breast xenograft mouse models to analyse the effects 
of exogenous hormones on regulation of molecular networks in the mammary gland. On the 
other hand, lentiviral transduction techniques can be utilised to manipulate human mammary 
epithelial cells and investigate the effects of transcription factors and cytokines in the breast. 
However, it would be more beneficial to use high content screening technology to determine 
entire pathways rather than individual factors mediating the relationship between cyclic 
hormone-induced changes in mammary epithelium and tumour stroma.  
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Furthermore, the effects of Foxp3 heterozygosity on mammary gland morphogenesis will be 
analysed using aged mice. This is a critical step to understand the cellular changes in Foxp3 
heterozygous mice’s mammary gland since these animals are prone to breast cancer 
development when they age. It is also part of our future plan to study other immune-associated 
gene candidates which have the potential to mediate hormonally-regulated cytokine production 
in the mammary gland. Research in our lab has discovered an important role for the complement 
protein C1q in the establishment of breast cancers. C1q plays an essential role in promoting 
macrophage-mediated clearance of dying mammary epithelial cells during the regression phase 
of the ovarian cycle. Mouse models lacking C1q protein are far less susceptible to mammary 
cancers than normal mice, a finding that opens the door for therapeutic intervention. We are 
planning to produce monoclonal antibodies capable of neutralising C1q activity and test the 
therapeutic capacity of these antibodies in a mouse model of mammary cancer. A therapeutic 
antibody that neutralises C1q activity has the potential to prevent breast cancers from becoming 
established. 
 
Overall, the information from this study can benefit the ongoing research regarding the 
development of new approaches to prevent breast cancer in premenopausal women. The 
susceptibility of the human breast to cancer-initiating factors may be altered during specific 
stages of the menstrual cycle (13). Thus, avoidance of exposure to initiating factors such as 
alcohol and radiation such as that in imaging X-rays at specific stages of the cycle can help 
reduce the risk of cancer development. A similar concept could be applied in designing more 
effective screening and treatment programs. For instance, knowing the best time to get a 
mammogram during the menstrual cycle could help increase the accuracy of the results, as 
shown by a recent study suggesting that the sensitivity of mammography in the detection of 
breast cancer increases when women undergo screening during the first week of their menstrual 
cycle (219). Furthermore, gene expression profiling tests are commonly used to diagnose breast 
cancer subtype, and help guide treatment decisions (220-222). However, these tests have been 
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developed and validated predominantly in postmenopausal women, and it remains unclear 
whether these tests are appropriate for use in premenopausal women (222). It is possible that 
breast cancer gene expression and the treatment pathways which stem from its measurement, 
could fundamentally depend on a woman’s menstrual cycle stage at the time of tissue collection. 
In addition, these studies can help us identify key mechanisms in mammary gland development 
during menstrual years, and how these factors may increase cancer risk later in life. 
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6.6.   CONCLUSION 
Estrogen and progesterone regulate the expression of specific immune cytokines in mammary 
epithelial cells, however, the response is highly variable and dependent on a number of factors 
including where the cells originated from (for example whether they are primary cells from an 
individual patient or a cell line), hormone receptor profile, and the time of exposure to the 
hormones. The different expression profiles of cytokines have provided us a framework for 
understanding the complexity of hormone regulatory cytokine signalling in the mammary 
gland. A complex interplay of transcription factors including ELF5 and FOXP3 might mediate 
cytokine expression in mammary epithelium. Figure 6.2 represents a schematic of the changes 
in the cellular components of the mammary gland during menstrual cycling. 
 
Overall, fluctuations in the ovarian hormones estrogen and progesterone, across the course of 
menstrual cycle, might create a pro-tumorigenic environment in the mammary gland that causes 
the mammary gland to be more susceptible to cancer. Although the biological mechanisms 
underlying this pro-tumorigenic microenvironment is still unclear, it may involve dampened 
immune surveillance and/or tumorigenesis driven by the inflammation associated with altered 
cytokine signalling. Also, inflammatory factors may induce DNA damage, leading to genetic 
instability and proliferation of mutated cells (223). Therefore, understanding the cellular and 
molecular mechanisms that govern mammary epithelial cell cytokine expression can help in 
identifying potential new treatments for breast cancer. 
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Figure 6.2: Schematic of the changes in the cellular components of the mammary gland during 
menstrual cycling.  
The follicular phase of the menstrual cycle is characterised by high serum levels of estrogen, lower 
number of mammary epithelial cells, and higher number of Tregs and anti-inflammatory cytokines 
compared to the luteal phase. In contrast, the luteal phase is characterised by high serum levels of 
progesterone and increased numbers of mammary epithelial cells as well as increased abundance of 
macrophages compared to the follicular phase. The phenotype and function of macrophages in the 
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Fluctuations in circulating estrogen and progesterone across the menstrual cycle lead to 
increased breast cancer susceptibility in women; however, the biological basis for this 
increased risk is not well understood. Estrogen and progesterone have important roles in 
normal mammary gland development, where they direct dynamic interactions among the 
hormonally regulated mammary epithelial, stromal, and immune cell compartments. The 
continuous fluctuations of estrogen and progesterone over a woman’s reproductive life-
time affect the turnover of mammary epithelium, stem cells, and the extracellular matrix, 
as well as regulate the phenotype and function of mammary stromal and immune cells, 
including macrophages and regulatory T cells. Collectively, these events may result in 
genome instability, increase the chance of random genetic mutations, dampen immune 
surveillance, and promote tolerance in the mammary gland, and thereby increase the 
risk of breast cancer initiation. This article reviews the current status of our understand-
ing of the molecular and the cellular changes that occur in the mammary gland across 
the menstrual cycle and how continuous menstrual cycling may increase breast cancer 
susceptibility in women.
Keywords: estrogen, progesterone, microenvironment, cytokine, menstrual cycle
iNTRODUCTiON
The mammary gland is an essential reproductive organ, present in females of all mammalian spe-
cies, which produces milk for both nourishment and immunological protection of newborns. It is 
a unique organ, as the vast majority of mammary gland development occurs postnatally, during 
puberty, pregnancy, and the postpartum period (1). Mammary gland development is highly depend-
ent on the actions of hormones, including estrogen and progesterone, and these endocrine factors 
act locally within the tissue through complex interactions with growth factors and cytokines in 
the mammary microenvironment (2, 3). While there has been much interest in the cellular and 
molecular interactions directing mammary gland development during pregnancy and postpartum 
involution, surprisingly little is understood of the biological mechanisms that promote development 
during the menstrual cycle.
A number of risk factors are associated with breast cancer, including family history of breast 
cancer, increasing age, and high breast density (4). There are also a number of significant risk fac-
tors associated with a woman’s reproductive history, one of which is increased number of years 
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of menstrual cycling. A large meta-analysis demonstrated that 
the period of time between onset and cessation of menstrual 
cycling strongly correlates with increased breast cancer risk in 
women (5). For each year younger a girl commences menstrual 
cycling, there is a 5% increase in lifetime risk of breast cancer. 
Similarly, for each year older at the time of menopause, there 
is a 3.5% increased breast cancer risk (5). Studies on naturally 
postmenopausal women also showed increased breast cancer risk 
in those who had experienced greater than 490 menstrual cycles 
in their lifetime as compared to those with fewer or irregular 
cycles (6). This indicates that fluctuations in ovarian hormones 
associated with menstrual cycling affect breast cancer susceptibil-
ity. However, the biological basis for the link between fluctuations 
in ovarian hormones and increased breast cancer risk is not well 
understood.
The mammary gland consists of a number of different cell 
lineages including epithelial, hematopoietic, endothelial, and 
stromal (7). Epithelial cells are organized in a hierarchical man-
ner of mammary stem cells (MaSCs), mammary progenitor cells, 
and committed mammary epithelial cells, including luminal 
and myoepithelial cells. The majority of human carcinomas 
originate from mammary epithelial cells (8). Immune cells, 
extracellular matrix (ECM), fibroblasts, and endothelial cells 
are all abundant in the stroma of the mammary gland (9), and 
their roles are mediated via a complex network of intracellular 
and extracellular signaling pathways. It is widely accepted that 
mutations in mammary epithelial cells are the initial drivers of 
tumorigenesis. However, what is increasingly appreciated are the 
cell-to-cell interactions between epithelia and the surrounding 
stroma that affect DNA mutation rate, survival of DNA-mutated 
cells, and development of malignancy in the breast. Fluctuations 
in estrogen and progesterone across the menstrual cycle affect 
the abundance and function of mammary epithelial cells, stromal 
immune cells, and the ECM, and these changes are likely to be 
associated with biological mechanisms that cause increased 
breast cancer risk associated with menstrual cycling. The focus of 
this review is to collate current knowledge of the molecular and 
cellular events that occur during hormone-mediated menstrual 
cycling that affect epithelial and stromal cells in the mammary 
gland and how these contribute to increased breast cancer risk 
in women.
BiOLOGiCAL CHANGeS iN THe BReAST 
DURiNG THe MeNSTRUAL CYCLe
The phases of the menstrual cycle in women are regulated by 
fluctuations in the pituitary gland hormones, follicle-stimulating 
hormone and luteinizing hormone, and the ovarian hormones, 
estrogen and progesterone (10). Hormonal fluctuations are cycli-
cal in nature and occur continuously, such that each cycle merges 
into the next. There is also variability in cycle length (22–36 days) 
between different women (11). The majority of the literature on 
menstrual cycle-associated changes in women is consistent with 
mouse literature and suggests that the main proliferative phase is 
the mid-luteal phase of the menstrual cycle, during which time 
circulating progesterone and estrogen are both high and epithelial 
alveolar buds begin to form. The high level of mitotic activity in 
this phase suggests progesterone is associated with a proliferative 
action (12). Conversely, the late luteal phase or the menstruation 
phase could be considered as the regression phase of mammary 
gland epithelia (13). During this time, the newly formed alveolar 
buds undergo apoptosis and tissue remodeling occurs such that 
the mammary gland returns to its basic architecture ready for 
another menstrual cycle (1, 14).
Progesterone appears to be a key hormone in regulation of 
mammary gland development and regression during the cycle. 
A number of animal studies have demonstrated a positive corre-
lation between the percentage of alveolar epithelial buds in the 
mammary gland and the concentration of serum progesterone 
during the ovarian cycle (15–17). Indeed, the highest percentage 
of alveolar epithelia were observed during the diestrus phase 
(mouse equivalent of luteal phase), where the concentration 
of serum progesterone is maximal. Although estrogen exerts 
proliferative effects on mammary epithelial ducts directly via 
estrogen receptors (ERs) (18), it also upregulates the expres-
sion of the progesterone receptor (PR) during the luteal phase 
of the cycle (19). Importantly, progesterone withdrawal is also a 
critical regulator of mammary gland function. Newly developed 
alveolar buds require continuous progesterone signaling and 
undergo apoptosis and tissue remodeling which returns the 
mammary gland to a more basic architecture when progester-
one falls (17).
These cycles of hormone-driven development and regression 
are likely to have a significant impact on breast cancer risk, even 
when breast cancer arises after menopause. Nielsen et  al. (20) 
noted that clinically occult in situ breast carcinomas and atypical 
lesions are frequent in young and middle-aged women; they may 
remain in the non-invasive phase for 15–20  years before they 
develop into invasive breast cancers. In other words, hormone-
regulated cellular events that occur during premenopausal years 
may induce persistent changes in the developmental fate of mam-
mary epithelial cells. Alterations in signal transduction pathways, 
growth factors, and cell cycle regulators (21) associated with these 
clinically occult cancers would increase the lifetime risk of breast 
cancer.
DiReCT eFFeCTS OF OvARiAN 
HORMONeS ON TUMORiGeNeSiS
The roles of estrogen and progesterone in mammary gland 
development have been investigated using mouse models, gene 
expression analysis, and normal human breast tissues. Animal 
studies demonstrate the critical role of estrogen in mammary 
tumorigenesis, as cancer initiation and development can be 
significantly reduced using anti-estrogenic drugs or by perform-
ing oophorectomy (22–24). This is supported in human studies 
wherein early ablation of the ovaries results in regression of 
disseminated breast cancer (25). Furthermore, use of exogenous 
estrogen and progesterone analogs, such as hormone replace-
ment therapy or hormonal oral contraceptives are known to 
increase breast cancer risk in women (26). The primary mecha-
nism through which exogenous and endogenous hormones are 
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implicated in carcinogenesis is through promotion of mammary 
epithelial cell proliferation, which increases the chance of random 
genetic errors (26).
During the menstrual cycle, the highest proliferative rate 
of mammary epithelial cells occurs in the mid-luteal phase, 
as shown in premenopausal women who had highest cellular 
expression levels of proliferative marker Ki67 in the luteal phase 
versus highest expression of quiescent marker p27 in the follicu-
lar phase (27). A number of studies suggest that the mammary 
gland is more susceptible to carcinogenesis when there is higher 
proliferative activity in mammary epithelial cells (24, 28). The 
higher Ki67+ and the lower p27+ cell frequencies were positively 
associated with higher breast cancer risk among premenopausal 
women (27). Higher proliferative activity increases the chance of 
random mutations or DNA lesions (29). If the DNA-damaged 
cell is not repaired immediately, it will be used as a template for 
DNA synthesis in the next proliferative phase of the menstrual 
cycle, which would lead to the accumulation of faulty cells in the 
mammary epithelia. Polymorphisms in DNA repair genes such as 
BRCA2 and XRCC1, which maintain the integrity of the genome, 
can account for this genetic instability and the inability to repair 
DNA-damaged cells (30, 31). This genomic instability is favorable 
for premalignant cells to gain the faulty genotypes that enable 
tumor progression (32).
Although the role of progesterone in breast cancer etiology 
is controversial, it has been hypothesized that progesterone is 
the main driver of breast cancer risk during the menstrual cycle 
(33). More recently, Brisken et  al. (34) proposed that repeated 
activation of PR signaling during the luteal phase may promote 
tumorigenesis in the breast. On the other hand, a recent study 
suggested the anti-mitogenic effects of progesterone, by inhibit-
ing the estrogen-mediated growth of ER-positive tumors in 
human breast explants and cell lines (35). Overall, it seems that 
exposure to ovarian hormones affects cell signaling pathways 
and mammary progenitor cell fate. This leads to higher mitotic 
activity, which in turn may result in increased risk of genome 
instability and random genetic errors in DNA replication.
iMPACT OF MeNSTRUAL  
CYCLiNG ON MaSCs
Mammary stem cells reside within the breast tissue and sup-
port mammary gland morphogenesis during different stages of 
development, such as during pregnancy. These cells are capable 
of self-renewal divisions as well as generating various lineages of 
mammary epithelial cells (36, 37). With the recent advances in 
stem cell biology and the technical frameworks for identification 
of these cells, the concept that cancers originate from stem cells 
and that MaSCs are the targets for transformation has become a 
hot topic in understanding breast cancer risk.
It should be noted that only a small percentage of normal 
mammary epithelial cells express ER and PR, and MaSCs 
lack these hormone receptors. Nevertheless, they are highly 
responsive to and are regulated by estrogen and progesterone via 
paracrine signaling from luminal cells involving receptor activa-
tor of nuclear factor-κB ligand (RANKL), WNT, CXCL12, and 
amphiregulin (38–41). Investigating the phenotypes of MaSCs 
in the mammary gland, particularly during the menstrual cycle, 
can be very challenging due to their rarity and the absence of 
specific markers for identification of these cells (42). Although 
there is evidence suggesting that ovarian hormones regulate the 
fate of MaSCs (7), research on the link between estrogen and 
progesterone and these multi-potent cells during menstrual 
cycling is limited.
In 2009, Graham et  al. (43) reported that progesterone 
increases proliferation of normal human mammary epithelial 
cells by activating DNA replication mechanisms and increas-
ing the number of bipotent progenitor cells. However, recent 
studies by Lombardi et al. (44) implicate another hormone in 
this process. Progesterone induces normal mammary epithelial 
cells to secrete pituitary hormone and growth hormone, and 
subsequently growth hormone increases proliferation of stem 
and progenitor cells in the mammary gland (44). The highest 
levels of serum growth hormone occurs in the luteal phase, 
correlating with the high progesterone levels. Joshi et  al. (7) 
observed that the abundance of MaSCs significantly increases 
during the diestrus phase in cycling mice as well as in ova-
riectomized mice treated with the combination of estradiol and 
progesterone.
It is speculated that the high levels of growth hormone and 
progesterone during the luteal phase expand the numbers and 
proliferation rates of undifferentiated stem cells (44). These hor-
mones may alter the phenotypes of mammary progenitor cells 
and increase the likelihood of transformation of undifferentiated 
cells into malignancy (7). Moreover, progesterone affects both 
symmetric and asymmetric cell division of MaSCs by increasing 
the population of basal and mature mammary epithelial cells 
(7). An imbalance between asymmetric and symmetric stem cell 
divisions can occur when there is deregulation in progesterone-
regulated self-renewal pathways, such as WNT and RANKL 
(45, 46). It may be that repetitive menstrual cycling expands 
the number of undifferentiated MaSCs which are more prone 
to oncogenic hits (39, 44), leading to an increased risk of breast 
cancer.
CHANGeS iN THe iMMUNe 
MiCROeNviRONMeNT DURiNG THe 
MeNSTRUAL CYCLe
Mammary gland development and function depends on dynamic 
interactions between hormonally responsive mammary epithelia 
and the immune microenvironment. Immune cells are closely 
associated with mammary epithelial cells (47) and contribute to a 
number of stages of mammary gland development. Macrophages 
affect development and regression of the mammary gland over 
the course of the cycle, and these alternating roles of macrophages 
may affect menstrual cycle-associated breast cancer risk, particu-
larly during the process of mammary gland regression. Another 
type of immune cell that may affect cancer risk in the mammary 
gland during the menstrual cycle is regulatory T cells (Tregs). 
Although immune cells are known to have an active role in the 
development and function of the mammary gland, it is still not 
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clear whether these cells affect menstrual cycle-associated breast 
cancer risk.
If a DNA mutation occurs, there is still a high chance that the 
immune system will recognize and eliminate the premalignant 
cell. Failure of the immune system to eliminate transformed cells 
throughout life can lead to cancer development. Thus, immune 
surveillance is a critical aspect to protect against tumorigenesis 
and evasion of the immune response against transformed cells 
is a hallmark of cancer (48). Studies on breast tumor micro-
environment demonstrate that Tregs, macrophages, and other 
immune cells have critical roles in the immune evasion abilities 
of the tumor in the breast (49). The abundance and function 
of these cells change over the course of the menstrual cycle, 
potentially opening a window of breast cancer risk at specific 
stages of the cycle.
Fluctuations of estrogen and progesterone during the ovar-
ian cycle influence the abundance, phenotype, and function 
of local macrophages in the mammary gland. Macrophages 
promote the proliferation of epithelial cells and formation of 
alveolar buds when circulating estrogen and progesterone con-
centrations are high and promote alveolar bud regression and 
tissue remodeling as circulating progesterone concentration 
declines (16). These processes of development and regression 
are associated with altered macrophage phenotype, which may 
affect the immune microenvironment in the mammary gland 
(17). The impact of hormone-regulated macrophages on breast 
cancer risk is not known, but may affect protection against 
persistence of DNA-mutated cells and tolerance to transformed 
cells, particularly during mammary gland regression, discussed 
in the next section.
Abundance of Tregs in the human blood correlates with serum 
concentration of estrogen; it increases during the follicular phase 
and decreases during the luteal phase (50). Prieto and Rosenstein 
(51) reported that exogenous estradiol promotes proliferation of 
T cell receptor-activated Tregs isolated from the blood of healthy 
individuals and enhances their suppressive function in vitro. On 
the other hand, progesterone regulates differentiation of naïve 
T cells into immune suppressive Foxp3+ Tregs in fetal cord blood 
and promotes immune tolerance (52). It is noteworthy that Tregs 
must be activated before ovarian hormones can enhance their 
suppressive functions (50, 51). Stimuli that activate Tregs during 
the menstrual cycle are not known; however, infections or altered 
cell signaling pathways may play a role.
Both mammary epithelial cells and immune cells secrete 
cytokines and chemokines, which act as intercellular mediators 
in the generation of immune responses. Induction of mam-
mary epithelial differentiation is accompanied by a switch from 
production of Th1 cytokines (such as TNFA, IFNG, and IL12) 
to Th2 cytokines (such as IL13, IL10, and IL4) by mammary 
epithelial cells (53). Interestingly, progesterone has been shown 
to regulate Th1/Th2 phenotypes in the mammary gland (54) 
and is a potent inducer of Th2 cytokines during pregnancy 
(55). Th1 cytokines are more effective in producing antitumor 
immunity and tumor rejection, whereas Th2 cytokines are 
mostly produced by tumors; they induce alternatively activated 
macrophages and are involved in increasing humoral pro-
tumorigenic responses (56, 57).
On the other hand, estradiol is shown to induce pro-
inflammatory cytokine profile during the estrus phase in mice, 
an effect that was strongly mitigated by progesterone during other 
phases of the cycle (58). This inflammatory milieu may lead to 
tumor development and cancer progression. Thus, it seems that 
fluctuations of estrogen and progesterone can direct the cytokine 
profile of immune cells in the mammary gland. Considering 
the immunosuppressive roles of the immune cells in the tumor 
microenvironment, it is possible that these cells may weaken the 
mammary gland’s capability for immune detection at certain 
stages of the menstrual cycle and potentially affect risk of tumo-
rigenesis in the breast.
iNCReASeD CANCeR SUSCePTiBiLiTY 
DURiNG MAMMARY GLAND 
ReGReSSiON
The ductal and alveolar epithelial structures that form in the 
breast during diestrus in anticipation of pregnancy become 
unnecessary when the cycle progresses. These cells must be 
removed as the breast is remodeled during proestrus to a more 
basic architecture. The onset of apoptosis in mammary epithe-
lium that occurs at the end of the luteal phase is tied to declining 
levels of progesterone (59). A number of animal studies have 
compared the sensitivity of the mammary gland to chemical 
carcinogens such as 9,10-dimethyl-1,2-benzanthracene (DMBA) 
or N-methyl-N-nitrosorea (NMU) between different phases of 
the ovarian cycle. Although there are some conflicting results in 
the literature, the majority reported that young rats exposed to 
chemical carcinogens at proestrus had a higher rate of mammary 
tumor incidence (28, 60, 61). This was accompanied by increased 
number of tumors, as well as shorter tumor latency than those 
rats injected during the metestrus or estrus phase. Proestrus is 
the phase in which circulating estrogen is high, and circulating 
progesterone is declining. This suggests that the phase of the 
cycle associated with mammary gland regression may be more 
susceptible to the initiating factors that lead to cancer than other 
phases of the cycle.
Macrophages are central players in the immunologically silent 
removal of apoptotic cells. Hodson et al. (17) reported differential 
percentage of murine macrophages that express cell-surface 
proteins NKG2D, CD204, and MHCII during different stages 
of the ovarian cycle, regulated by progesterone and estrogen. 
Macrophages present during epithelial proliferation and alveolar 
development during diestrus display a greater predominance of 
an immune surveillance phenotype, characterized by the expres-
sion of the NGK2D marker, associated with the recognition of 
DNA-damaged cells (17). At this stage, they are able to remove 
epithelial cells that have experienced replication errors. Toll-like 
receptors, which recognize danger-associated molecular patterns, 
can also participate in this activity. At proestrus, progesterone 
levels have declined, and this is associated with decreased NKG2D 
and an increase in the expression of antigen presentation receptor 
MHCII and scavenger receptor CD204 on macrophages, which 
have roles in phagocytosis and antigen presentation of dying 
epithelial cells (17, 62). Hence, it is suggested that fluctuations 
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of macrophage phenotypes over the course of the ovarian cycle 
may regulate their capability to recognize DNA-damaged cells, 
phagocytose, and present antigen to generate adaptive immune 
responses, which may subsequently affect tumor incidence in the 
mammary gland (17).
Previously, it was thought that macrophages only protect the 
tissues from cancer, by phagocytizing the apoptotic cell debris or 
presenting tumor-associated antigens to T cells. However, it is 
now clear that these cells are also involved in breast tumorigen-
esis, progression, and metastasis, depending on their functional 
phenotype (63, 64). Macrophages are highly plastic cells that are 
capable of both anti-tumorigenic and pro-tumorigenic functions 
(56). Macrophage phenotypes and functions are heterogeneous, 
complex in human pathologies, and are activated by various 
stimuli (65). It is possible that hormonal regulations of these 
immune cells during menstrual cycling direct them toward a 
pro-tumorigenic state in which they can assist in the growth of 
potential tumors in the tissue.
Concomitant with the drop in progesterone is the increase 
in the expression and activation of TGFB1. TGFB1 has pleio-
tropic effects in the environment of the involuting mammary 
gland, first by further retarding epithelial cell proliferation and 
second by inducing epithelial apoptosis and causing a shift to 
alternative differentiation in the macrophages infiltrating the 
breast (62,  66). TGFB1 signaling triggers apoptosis through 
members of the Bcl family, leading to activation of caspase 3 
with eventual nuclear condensation and DNA fragmentation 
(67). This process is accompanied by the release of damage-
associated molecular patterns (DAMPs) or “find me” signals 
for immune phagocytes. Secreted DAMPs include ATP and 
lysophosphatidylcholine (68). In addition to DAMPs, apop-
totic cells express the membrane markers phosphatidylserine 
(PS) and calreticulin (CRT). PS is normally found in the cell 
membrane on the cytoplasmic side and extracellular exposure 
is an early event in apoptosis. Calreticulin is found in the endo-
plasmic reticulum where it functions in protein folding and 
calcium retention in the endoplasmic reticulum (69). Apoptosis 
dysregulates calcium localization, leading to the release of CRT 
from the endoplasmic reticulum and its eventual exposure on 
the membrane surface (70). Membrane localization of these two 
molecules act as a signal of abnormal processes within the host 
cell and are also important in the eventual clearance of the cell 
by phagocytes (71, 72).
As apoptosis progresses, membrane blebbing leads to the 
release of exosomes. The membrane integrity deteriorates and 
if the cell is not cleared it will eventually become necrotic. In 
necrosis, the cell membrane ruptures and allows the release of 
pro-inflammatory cytoplasmic contents, such as Il-1 alpha and 
HMGB1 (73). Necrosis in breast tissue is not a desirable outcome, 
especially since this tissue will be exposed to hormone cycling 
repeatedly with attendant proliferation/apoptosis during the full 
extent of a woman’s reproductive life. Macrophages and other 
epithelial cells remove apoptotic cells from the breast before they 
necrose and provoke harmful inflammation. Necrosis attracts 
a variety of immune cells that interact to produce a vigorous 
response that increases the possibility of autoimmunity and 
carcinogenic DNA damage (74).
There is a multiplicity of mechanisms for the removal of 
apoptotic cells, both in terms of the target and the phagocyte. 
This allows for an enhanced flexibility in the host immune sys-
tem and a greater likelihood an apoptotic event will be cleared 
and not allowed to necrose. And the key component discussed 
above involves PS only and does not take into account other 
mechanisms involving lectins, thrombospondin, or ICAM-3 
(68). However, the dynamic and changing immune require-
ments in the breast throughout the menstrual cycle may result in 
mutated cells persisting from one cycle into the next, increasing 
the chance of tolerance of pre-cancerous cells and accumulation 
of further mutations that ultimately result in increased risk of 
cancer.
OTHeR POTeNTiAL CANCeR PATHwAYS
The RANKL belongs to the tumor necrosis factor superfamily and 
acts as a paracrine modulator of progesterone action in the adult 
mouse mammary gland (75). RANKL also plays critical roles in 
progesterone-induced expansion of MaSCs and is implicated in 
increased breast cancer risk associated with high exposure to this 
hormone (76). The mRNA and protein expression of RANKL 
in mammary epithelium is upregulated during the luteal phase 
in normal breast tissues from women at standard risk of breast 
cancer as well as in malignant breast tissue, suggesting a role for 
RANKL in breast cancer initiation (40, 77). Moreover, Brisken 
(78) hypothesized, based on mouse model studies that repeated 
activation of RANKL by progesterone during the luteal phase 
promotes breast carcinogenesis. In short, RANKL is considered 
as a potential target in breast cancer treatment and prevention in 
premenopausal women (79).
Using next-generation whole transcriptome sequencing on 
20 samples of normal human breast epithelium, Pardo et al. (40) 
examined the effects of hormonal fluctuations during menstrual 
cycle on gene expression. There were significant differences in 
the expression of 255 genes between the two phases of the men-
strual cycle, most of which had higher expression in the luteal 
phase compared to the follicular phase. Genes elevated during 
the luteal phase include FOXM1, MYC, BCRA1, and WNT4, and 
are mainly involved in the cell cycle events, such as DNA replica-
tion, DNA damage response, and mitosis. Interestingly, steroid 5 
alpha reductase 1 (SRD5A1) gene, which has a role in catalyzing 
the conversion of progesterone to 5 alpha-pregnenes mitogens 
in situ (80), was highly expressed during the luteal phase. This 
finding suggests that the fate of progesterone metabolism is 
affected during the menstrual cycle. Most of the cell cycle genes, 
which had higher expression in the luteal phase in this study 
are overexpressed in breast cancer samples (40). Hence, it is 
likely that the rise of progesterone during the luteal phase drives 
mitosis, which may increase the likelihood of genome instability 
and mutations in the breast and subsequently increase the risk 
of tumorigenesis.
In 1992, Ferguson and his colleagues noted that molecular 
profile of ECM in the human breast changes during the men-
strual cycle in vivo (81). Alterations in the molecular profile of 
ECM would alter cell signaling and deregulate the behavior of 
stromal cells, which may lead to generation of a tumorigenic 
FiGURe 1 | (A) The concentration of estrogen (green) and progesterone (red) fluctuates during the phases of the menstrual cycle and is associated with 
morphological changes in the cellular components of the mammary gland; shown here in carmine alum-stained mouse mammary gland whole-mount preparations 
(B) [adapted from Ref. (17) with permission]. (C) The follicular phase of the menstrual cycle is characterized by increase in the number of Tregs and proteoglycans 
compared to the luteal phase. In contrast, the luteal phase is characterized by increased numbers of mammary epithelial cells as well as increased abundance of 
macrophages compared to the follicular phase. The phenotype of macrophages in the mammary gland also changes throughout the cycle.
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microenvironment (82). More recently, it was observed that 
gene expression of proteoglycans syndecan-1, syndecan-4, and 
decorin was reduced during the luteal phase in healthy breast 
tissues of parous women (83). Single nucleotide polymorphisms 
in syndeacan-1 are associated with breast cancer susceptibility 
(84, 85). The expression of both Syndeacan-1 and 4 is significantly 
correlated with human carcinoma cell proliferation (86). Reduced 
expression of decorin has also been observed in breast cancer 
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tissues compared with normal tissues (87). It is suggested that 
lower expression of decorin weakens the ECM and is correlated 
with rapid progression, higher recurrence, and poor survival 
rate in breast cancer patients (87, 88). Proteoglycans regulate 
the activity of extracellular regulatory proteins in the ECM and 
interact with growth factors, cytokines, and chemokines (89). 
The direct effects of exogenous hormones on proteoglycans are 
not well studied. However, considering the role of proteoglycans 
in breast carcinomas, it is likely that hormonal regulation of 
these ECM components during the menstrual cycle affects cell 
signaling and triggers cancer pathways in the mammary gland 
microenvironment.
In situ microdialysis on normal human breast tissues revealed 
that the extracellular levels of vascular endothelial growth factor 
(VEGF), which is a potent stimulatory factor in angiogenesis, 
doubled during the luteal phase (90). Angiogenesis and high 
levels of growth factors are important factors for transforma-
tion of normal cells into malignancy (91, 92). Moreover, VEGF 
mRNA expression increases in breast cancer and is induced with 
estrogen and progestins in human breast cancer cell lines (93, 
94). The higher levels of VEGF during the luteal phase suggest 
that there is a proangiogenic microenvironment at this time. 
This reflects the normal capacity of hormone-induced mammary 
gland to stimulate vascular growth. However, as breast cancer is 
an angiogenic-dependent disease (94), this proangiogenic profile 
might provide the essential fuel (i.e., blood supply) for the growth 
of potential tumor cells.
New DiReCTiONS FOR BReAST CANCeR 
DiAGNOSiS AND PReveNTiON iN 
PReMeNOPAUSAL wOMeN
Understanding the biological changes that occur over the 
course of the menstrual cycle could lead to the development 
of new approaches to prevent breast cancer in premenopausal 
women. Studies in rodent species, discussed above, suggest that 
susceptibility to initiating factors that lead to cancer might be 
elevated during specific stages of the cycle. Alcohol consump-
tion increases breast cancer risk, potentially through increasing 
circulating estrogen and enhancing estrogen responsiveness, as 
well as increasing production of reactive oxygen species leading 
to DNA damage (95, 96). Another risk factor for breast cancer is 
exposure to radiation. Medical imaging techniques that employ 
low-dose ionizing radiation, such as computed tomography, 
x-rays, molecular breast imaging, and mammography, can affect 
cancer risk (97, 98). As the susceptibility of the breast to these 
carcinogenic exposures might be altered by menstrual cycle stage 
in premenopausal women, avoidance of exposure to alcohol and 
ionizing radiation at specific stages of the cycle has the potential 
to reduce breast cancer risk.
A better understanding of how immune cell abundance 
and function fluctuates across the menstrual cycle may 
provide us with improved potential to harness the immune 
system to treat and prevent breast cancer. Immunotherapy 
and immunoprevention of cancer can involve immunization 
with a vaccine, passive transfer of tumor-specific antibodies, 
or adoptive transfer of immune cells that kill tumor cells. 
Changes in the types of macrophages in the breast, the cytokine 
microenvironment, and the phenotype of tumor-infiltrating 
lymphocytes across the cycle could affect the efficacy of both 
adaptive and humoral immune responses that recognize and 
eliminate tumorigenic cells (99, 100). Further studies on the 
effect of hormonal fluctuations on immune function could help 
us address such questions as how to improve immune surveil-
lance and break the immunological tolerance induced during 
specific stages of the menstrual cycle.
In addition to potential for breast cancer prevention and 
treatment, research on the effect of menstrual cycle stage on 
gene expression in the breast is critical in improving the utility of 
PCR-based diagnostic and prognostic tests for breast cancer. The 
relative expression of panels of genes, employed in tests such as 
Oncotype DX and Prosigna, classifies tumor subtype and predicts 
risk of disease recurrence, in order to guide treatment decision-
making (101, 102). However, such tests were developed and vali-
dated largely in postmenopausal women, and the utility of these 
tests in premenopausal women might be affected by fluctuating 
estrogen and progesterone at different stages of the menstrual 
cycle (103). Overall, a clearer understanding of the molecular, 
cellular, and immunological changes that occur in the breast 
during the menstrual cycle could be fundamental for improving 
personalized and preventive programs in breast cancer.
CONCLUSiON
Women who undergo early menarche and/or late menopause 
experience higher exposure to estrogen and progesterone, and 
a higher number of cyclical fluctuations of these hormone dur-
ing their life time. Together with the direct effects of estrogen 
and progesterone on cancer initiation, there are a series of 
coordinated events during the menstrual cycle which are regu-
lated by these ovarian hormones which have been implicated 
in increased breast cancer risk. Figure 1 represents a summary 
of the changes in the cellular components of the mammary 
gland during menstrual cycling. The circle of proliferation and 
regression that occurs every month with each menstrual cycle 
affects the fate of MaSCs, which might increase the chance of 
random genetic errors and tumor initiation. An imbalance 
between mammary epithelial cell proliferation and apoptosis 
may provide the ideal conditions for the growth of potential 
tumor cells. In addition, deregulation of stromal components, 
such as ECM, macrophages, and Tregs, may alter the gene 
signaling pathways and tumor suppressor genes in the human 
breast, which might become persistent in some women. In addi-
tion, hormone-regulated immune cells can influence a micro-
environment (e.g., by secreting cytokines and chemokines) in 
which immune surveillance is dampened and the breast is at 
increased risk of oncogenic initiation. Over time, the recurrent 
rise and fall in circulating estrogen and progesterone would 
provide the conditions for altering cell fate, increasing the risk 
of genome instability, and random mutations. It is a significant 
challenge to dissect mechanisms of menstrual cycle-associated 
breast cancer risk; however, the benefit will be that of a greater 
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understanding of breast cancer susceptibility in women and the 
potential for discovery of new cancer biomarkers, indicators 
of prognosis, and therapeutic strategies to treat and prevent 
breast cancer.
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APPENDIX B: 
Table I: PCR primers used to quantify cytokine mRNA expression in human breast 
organoids, human breast epithelial cell lines, and mouse mammary glands.  
  
Gene Primer Sequence 
FoxP3 (Human) 5’GGCACTCCTCCAGGACAG 
3’GCTGATCATGGCTGGGCTCT 
FoxP3 (Mouse) 5’TACTTCAAGTTCCACAACATGCGACC 
3’CGCACAAAGCACTTGTGCAGACTCAG 
TGFB1 (Human) 5’AAATTGAGGGCTTTCGCCTTA 
3’TGAACCCGTTGATGTCCACTT 
TGFB1 (Mouse) 5’GAGAAGAACTGCTGTGTGCG 
3’GTGTCCAGGCTCCAAATATAGG 
ELF5 (Human) 5’ATG AAAAGTTGAGCAGAGCCCTGAG 
3’TGCCACCCGTGTGCATTT 
ELF5 (Mouse) 5’GTGGCATCAAGAGTCAAGACTGTC 
3’CTCAGCTTCTCGTACGTCATCCTG 
MPRl19 (Human) 5’TGCCAGTGGAAAAATCAGCCA 
3’CAAAGCAAATCTCGACACCTTG 
RPL13a (Mouse) 5’GAGGTCGGGTGGAAGTACCA 
5’TGCATCTTGGCCTTTTCCTT 
FKBP51 (Human) 5’GGGTCACTAATGAAAAAGGAACAGA 
3’CTCTTCCCTCCTTGGCGTG 
FKBP51 (Mouse) 5’GTACAACAAAGCCGTGGAGTG 
3’GCCCTGTTCTGAGGATTGACT 
TNFA (Human) 5’GCCCGACTATCTCGACTTTGC  
3’GGAGGCGTTTGGGAAGGTT 
TNFA (Mouse) 5’GGCAGGTTCTGTCCCTTTCAC 
3’TTCTGTGCTCATGGTGTCTTTTCT 
STAT5 (Human) 5’TTACTGAAGATCAAGCTGGGG 
3’TCATTGTACAGAATGTGCCGG 
STAT5 (Mouse) 5’CGCTGGACTCCATGCTTCTC 
3’GACGTGGGCTCCTTACACTGA 
STAT3 (Human) 5’GAGGACTGAGCATCGAGCA 
3’CATGTGATCTGACACCCTGAA 
STAT3 (Mouse) 5’GCACCTTGGATTGAGAGTCA 
3’CCCAAGAGATTATGAAACACCA 
S100A8 (Human) 5’ATCAGGAAAAAGGGTGCAGACGTC 
3’TTTTTGTGGGCTGCCACG 
S100A8 (Mouse) 5’AGTGTCCTCAGTTTGTGCAG 
3’ACTCCTTGTGGCTGTCTTTG 
S100A9 (Human) 5’GTGCGAAAAGATCTGCAAAATTT 
3’GGTCCTCCATGATGTGTTCTATGA 
S100A9 (Mouse) 5’GTTGATCTTTGCCTGTCATGAG 
3’AGCCATTCCCTTTAGACTTGG 
ZEB1 (Human) 5’ TTCCGAGCGGCCAAGTC 
3’ TGGGAGATACCAAACCAACTG 
ZEB1 (Mouse) 5’GCACCTGAAGAGGACCAGAG 
3’GCCATCTGGTGTTCCATTTT 
IL12 (Human) 5’CCTTGCACTTCTGAAGAGATTGA 
3’ACAGGGCCATCATAAAAGAGGT 
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IL12 (Mouse) 5’AAGCTCTGCATCCTGCTTCAC 
3’GATAGCCCATCACCCTGTTGA 
CXCL12 (Human) 5’ACCAGTCAGCCTGAGCTACC 
3’GCTCTGGCGATGTGGCTCTC 
CXCL12 (Mouse) 5’CAGAGCCAACGTCAAGCA 
3’AGGTACTCTTGGATCCAC 
HER2 (Human) 5’ CTGAACTGGTGTATGCAGATTGC 
3’ TTCCGAGCGGCCAAGTC 
EGFP (Human) 5’AAGCTGACCCTGAAGTTCATCTGC 
3’CTTGTAGTTGCCGTCGTCCTTGAA 
PGR (Human) 5’TGCCTTACCATGTGGCAGATCCC 
3’ACTGGGTTTGACTTCGTAGCCCT 
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APPENDIX C: 
Table II: Primary antibodies used in Western Blots  (WB) and Immunohistochemistry (IHC). 
 
Antigen Isotype  Conjugate Species 
Reactivity 
Application Manufacturer Catalogue 
number 
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APPENDIX D: 
 
Figure I: Analysis of FoxP3 primer specificity in mice cDNA samples. 
5µl of each PCR product was electrophoresed on 1.5% agarose gel in 1X TAE buffer following 40 PCR 
cycles. Lane 1: DNA ladder size marker (1kb plus), lane 2&3: FoxP3 amplified in WT mouse mammary 
gland, lanes 4&5: FoxP3 amplified in FoxP3 heterozygous mouse’s mammary gland, lane 6: FoxP3 
amplified in WT mouse lymph nodes, lane 7: FoxP3 amplified in FoxP3 heterozygous mouse lymph 







ladder Mammary Gland Lymph Nodes
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